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Abstract 
 
Once an immune response is initiated, a combination of several mechanisms coordinates 
and directs the homing of T cells to their target tissue. Co-stimulatory receptors 
expressed on the surface of T lymphocytes are known to actively regulate T cell motility 
and thus are crucial for regulating T cell migration. The B7 co-stimulatory receptor family 
members CD28 and CTLA-4 are well known to positively and negatively regulate effector T 
cell motility respectively. However, their effect on motility and subsequently migration 
has not been specifically studied in regulatory T cells (Tregs).  
Tregs are a CD4+ T cell subset fundamental for maintaining immune homeostasis and 
their role in controlling autoimmunity has been well established through a variety of 
experimental animal models. Tregs differ from conventional T cells in their expression of 
CTLA-4. While conventional T cells express CTLA-4 only after activation, Tregs are known 
to express this negative co-stimulatory receptor constitutively. Additionally, Tregs display 
a distinct metabolic phenotype to that of conventional T cells. This thesis examines the 
impact of both co-stimulatory receptors on Treg migration while taking in account the 
consequences of the concomitant delivery of signals from both. The data in this study 
suggests that glycolysis, rather than lipid oxidation induced by CD28 promotes Treg 
migration through glycolytic enzymes including glucokinase, whose expression in T cells 
was previously unknown. In contrast, CTLA-4 inhibits CD28 induced Treg migration via 
inhibition of these glycolytic enzymes. The therapeutic implications of these results in the 
context of disease and transplantation are discussed.  
CD31, an IgG like molecule, is expressed on a number of leukocytes including 
lymphocytes. In T cells, CD31 inhibits activation by recruiting phosphatases through its 
cytoplasmic ITIM domains and has thus been described as a co-inhibitory receptor. The 
role of this co-receptor in the regulation of T cell migration is investigated in the last part 
of this thesis. Our observations suggest that CD31 selectively signals in activated T cells to 
regulate their migration in response to inflammatory chemokines, revealing an additional 
role of this receptor in regulating T cell-mediated inflammation.  
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Abbreviations 
 
1MT 1-methyltryptophan 
2-DG 2-Deoxy-D-glucose  
2-ME 2-mercaptoethanol 
6-NBDG 6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-Deoxyglucose  
Ag Antigen 
AICD Activation-induced cell death 
AMPK AMP-activated protein kinase  
APCs Antigen presenting cells  
bmDCs Bone marrow-derived Dendritic Cells  
BTLA B and T lymphocyte attenuator  
CIITA Class II transactivator 
CASK Calmodulin associated serine/threonine kinase 
CBL-B Casitas-B-lineage lymphoma protein B 
CFSE Carboxyfluorescein succinimidyl ester 
CIA Collagen-induced arthritis 
CLA Cutaneous lymphocyte antigen 
CLIP Class II-associated invariant chain peptide 
CNS Central nervous system  
CPT1a Carnitine palmitoyltransferase 1a  
cSMAC Central supramolecular activation cluster  
CTACK Cutaneous T cell activating chemokine  
CTLA-4 Cytotoxic T lymphocyte associated antigen 4 
DCs Dendritic cells 
DDAO-SE  Dodecyldimethylamine oxide-succinimidyl ester 
dLN Draining lymph node 
DMEM  Dulbecco's modified eagles medium 
DOCK2 Dedicator of cytokinesis 2 
EAE Experimental autoimmune encephalomyelitis  
ECAR Extracellular acidification rate  
ECs Endothelial cells 
EDTA Ethylenediaminetetraacetic acid  
ER Endoplasmic reticulum 
ERG Ether- à –go-go related gene 
ERKs Extracellular-signal-regulated kinases  
ERRα Estrogen related receptor-alpha  
ETX Etomoxir 
FAO Fatty acid oxidation 
Foxp3 Forkhead box P3 
GAD Glutamic acid decarboxylase  
GAGs Glycosoaminoglycans  
GALT  Gut-associated lymphoid tissue 
GCK Glucokinase 
GCs Germinal centres 
GEFs Guanine nucleotide exchange factors  
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GlyCAM-1 Glycosaminoglycan cell adhesion molecule 1 
GPCRs G protein-coupled receptors  
GTPase Guanosine triphosphatase 
HEVs High endothelial venules 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase  
HVEM Herpesvirus entry mediator 
ICAM-1 Intercellular adhesion molecule 1 
ICAM-2 Intercellular adhesion molecule 2 
ICOS Inducible T-cell costimulator 
IDO Indoleamine 2,3-dioxygenase 
IFN-γ Interferon gamma  
Ig-CAMs Ig superfamily  
IgSE Immunoglobulin superfamily 
IL-2 Interleukin-2  
IRF-3 Interferon regulatory factor 3  
ITAMs Immunoreceptor tyrosine-based activation motifs  
ITIMs Immunoreceptor tyrosine-based Inhibitory motifs  
ITK Interleukin-2 (IL-2)–inducible Tec kinase  
iTREG Inducible regulatory T cells 
Jak Janus Tyrosine Kinase 
JAMs Junctional adhesion molecules  
JNK Jun N-terminal kinase  
LAT Linker for activation 
LBRC Lateral border recycling compartment  
LDH Lactate dehydrogenase  
LFA-1 Lymphocyte function associated antigen 1 
LKB1 Liver kinase B1  
Mac-1 Macrophage-1 antigen 
MAdCAM-1 Mucosal addressin cell adhesion molecule 1  
MDC Macrophage-derived chemokine 
MET Metformin 
MHC Major histocompatabality complex 
MLNs Mesenteric lymph nodes  
MLR Mixed lymphocyte reaction  
MS Multiple sclerosis 
mTOR Mammalian target of rapamycin  
mTORC1 Mammalian target of rapamycin complex 1  
mTORC2 Mammalian target of rapamycin complex 2  
ndLN Non draining lymph node 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells  
NK cells Natural killer cells 
nTREG Naturally ocurring regulatory T cells 
OCR Oxygen consumption rate  
OXPHOS Oxidative phosphorylation  
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered solution 
PCNA Proliferating nuclear cell antigen 
PD-1 Programmed cell death protein 1 
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PDH Pyurvate dehydrogenase  
PDHK PDH Kinase  
PDK1 Phosphoinositide-dependent kinase 1 
PDZ Postsynaptic density-95/ discs large/zona occludens-1 
PECAM-1 Platelet endothelial cell adhesion molecule 1 
PI Phosphoinositol  
PI(3,4)P2  Phosphoinositol 3,4-bisphosphate 
PI(3,4,5)P3  Phosphoinositol 3,4,5-triphosphate 
PI(4)P  Phosphoinositol 4-bisphosphate 
PI(4,5)P2  Phosphoinositol 4,5-bisphosphate 
PI3K Phosphoinositide 3-kinase  
PKB Protein kinase B 
PKC Protein kinase C  
PKCθ Protein kinase C θ 
PLC Phospholipase C 
pLN Peripheral lymph node 
PMA Phorbol myristate acetate  
PNAd Peripheral lymph node addressin  
PP2A  Protein phosphatase 2A 
PSGL-1 P-Selectin ligand, P-selectin glycoprotein ligand 1  
PTEN  Phosphatase and tensin homologue deleted on chromosome 10 
PTPases Protein tyrosine phosphatases  
Rac1 Ras-related C3 botulinum toxin substrate 1 
RAG Recombination-activating gene  
Rap1 Ras-proximate-1 or Ras-related protein 1 
Rapa Rapamycin 
RAPL  Ras association domain-containing protein 5  
RHEB Ras Homolog Enriched In Brain 
RIAM Rap1 effector Rap1–GTP-interacting adapter molecule  
S1PR Sphingosine 1 phosphate receptor 
SDF-1 Stromal cell-derived factor 1  
SFK Src family of tyrosine kinases  
SHIP SH2 domain-containing inositol 5’-phosphatase  
SHP-1  Src-homology 2 domain (SH2)-containing phosphatse-1 
SHP-2  Src-homology 2 domain (SH2)-containing phosphatse-2 
SLP76 SH2-domain-containing leukocyte protein of 76 kDa  
SPL Spleen 
SRC Spare respiratory capacity  
SREPB-2  Sterol-regulatory element binding protein-2  
STAT Signal transducer and activator of transcription 
TAP-1 Transporter for antigen presentation 1 
TARC  Thymus and activation regulated chemokine  
TCA Tricarboxylic acid  
TCM T central memory cells 
TCR T cell receptor 
TECK Thymus expressed chemokine  
TEFF T effector cells 
TEM Trans-endothelial migration 
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TEM T effector memory cells 
TGF-β Transforming growth factor beta 
Tiam1 T cell lymphoma invasion and metastasis 1  
TNFα Tumour necrosis factor alpha 
TREG T regulatory cells 
TSC1 Tuberous sclerosis complex 1 
VCAM Vascular cell adhesion molecule  
VLA-4 Very late induced antigen 4 
WASp Wiskott-Aldrich syndrome protein  
WT Wildtype 
ZAP-70 Zeta-chain-associated protein kinase 70 
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Chapter 1 Introduction 
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1.1 T cell migration: an overview 
 
After their development and exit from the thymus, naïve T cells constantly recirculate through 
blood and lymphoid tissues where they recognise cognate antigen displayed by antigen 
presenting cells and undergo activation. Once activated, T cells differentiate into memory T cells 
and effector T cells (von Andrian and Mackay 2000). The effector T cells primarily localise to sites 
of inflammation while differentiated memory cells re-circulate between the peripheral and 
lymphoid tissues so as to prepare for secondary responses (Chalasani et al. 2002; Masopust et al. 
2001; Weninger et al. 2001). 
These migratory events rely upon the T cells exiting the bloodstream and lymphatic system 
through vascular endothelium by means of tightly regulated molecular interactions summarised in 
the multistep paradigm of lymphocyte migration (Springer 1994). Specifically, the lymphocytes 
must first tether and roll on the vascular endothelium mediated through the action of selectins 
and integrins. Chemokines bound to the luminal side of the vascular endothelium of postcapillary 
venules increase integrin affinity causing a firm arrest of the lymphocytes on the endothelium. 
Finally, lymphocytes cross the endothelial barrier through a complex process involving multiple 
molecular interactions known as trans-endothelial migration (TEM) or diapedesis.  A similar 
stepwise process is also observed in the extravasation of other leukocytes such as neutrophils and 
monocytes. 
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1.1.1 Multistep paradigm of lymphocyte migration 
 
1.1.1.1 Rolling 
In the first step, lymphocytes traversing through the vascular endothelial lumen constantly roll 
across the endothelial walls by means of low affinity interactions of adhesion molecules. This 
slows the lymphocytes allowing interactions with the endothelial cells (ECs)(Garrood et al. 2006). 
Most important of these adhesion molecules are a group of specialised transmembrane 
glycoproteins known as selectins. Three selectins identified in humans and mice are L-selectin, P-
selectin and E-selectin. 
L-selectin (also known as CD62L) is constitutively expressed my most circulating leukocytes and is 
downregulated in lymphocytes following activation. Expressed on the tips of microvilli, this 
selectin plays a crucial role in the rolling and tethering of T cells at sites of inflammation (Bruehl et 
al. 1996; Stein et al. 1999). Loss of L-selectin as seen in L-selectin knockout mice, results in 
impaired rolling of lymphocytes in inflamed postcapillary venules and subsequently reduced 
infiltration through endothelium in these mice (Arbones et al. 1994; Tedder et al. 1995). L-selectin 
is also necessary for T cells to re-circulate to the secondary lymphoid organs (Bradley et al. 1994). 
Conversely, T cells from mice expressing reduced levels of L-selectin display increased rolling 
velocity in vivo (Galkina et al. 2007). L-selectin also binds to the P-Selectin ligand, P-selectin 
glycoprotein ligand 1 (PSGL-1) (Tu et al. 1996). PSGL-1 expressed by circulating leukocytes can 
bind the L-selectin of a previously tethered leukocyte, forming a positive feedback whereby an 
adherent leukocyte recruits more leukocytes exponentially (Walcheck et al. 1996). Ligands for L-
selectin can be found in both inflammatory and lymphoid tissues. These are primarily glycosylated 
proteins which include glycosaminoglycan cell adhesion molecule 1 (GlyCAM-1), mucosal 
addressin cell adhesion molecule 1 (MAdCAM-1), CD34, Sgp200, podocalyxin and endomucin (S. 
D. Rosen 2004).  
P-selectin (also known as CD62P) is expressed primarily on platelets and ECs of inflamed tissues. It 
is circulated to the plasma membrane from intracellular Weibel-Palade bodies in ECs (or α-
granules in platelets) through stimulation by histamine and thrombin (Patel et al. 2002) within 
minutes thus mediating the early recruitment of platelets to tissue injury sites. The major ligand 
for P-selectin, PSGL-1 is expressed by circulating myeloid cells and T cells (Ley and Kansas 2004).  
E-selectin (also known as CD62E) is also expressed on inflamed endothelium. Unlike P-selectin, E-
selectin is regulated by increased transcription in response to inflammatory stimuli (Bevilacqua et 
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al. 1987). In humans, the major ligand for E-selectin is the cutaneous lymphocyte antigen (CLA), 
expressed by a majority of T cells at sites of chronic cutaneous inflammation (Berg et al. 1991). In 
mice, E-selectin binding of PSGL-1mediates Th1 lymphocyte migration (Hirata et al. 2000). 
While selectins are the best characterised mediators of lymphocyte rolling, other molecules are 
also know to carry out this function. CD44, a transmembrane glycoprotein expressed in an 
activated form on subgroups of activated lymphocytes (reviewed inPonta et al. 2003) can mediate 
selectin independent rolling on inflamed tissue (DeGrendele et al. 1997). Its ligand hyaluronic acid 
is a polysaccharide component of the extracellular matrix, expression of which can be upregulated 
by pro inflammatory signals (Mohamadzadeh et al. 1998). Interactions of α4 integrins and β2 
integrins expressed by lymphocytes with their endothelial ligands can also play a role in rolling 
(Alon et al. 1995; U. Jung et al. 1998; Kadono et al. 2002). 
 
1.1.1.2 Activation and firm arrest  
 
While rolling allows for weak contact between the leukocytes and endothelial surface, if no 
further stimuli are provided to the leukocytes, they detach and return back to circulation. 
However, in the presence of luminally expressed activating molecules, they progress to firm 
adhesion (reviewed in Garrood et al. 2006). Thus, the next step in leukocyte extravasation relies 
on providing activating stimuli to the leukocytes by a group of small polypeptides known as 
chemokines.  
Chemokines or chemoattractant cytokines have molecular weights between 8-12 kDA and can be 
grouped into four groups based on the number and position of the 4 conserved cysteine residues 
near the N-terminus (reviewed in Griffith et al. 2014; B. Moser et al. 2004). Chemokines with 
adjacent cysteines are CC chemokines, and are the most abundant. Chemokines with an amino 
acid between the two cysteines CXC and with only one conserved cysteine XC  along with 
chemokines containing three inter cysteine amino acids CX3C form the other groups. Receptors 
for these chemokines expressed by leukocytes are 7 transmembrane G protein coupled receptors 
(GPCRs) which may bind to one chemokine specifically or bind different chemokines exhibiting 
considerable overlap. Binding of chemokines to their receptors results in enhanced leukocyte 
adhesiveness, allowing for the next migration step –firm adhesion - to proceed. Chemokines can 
also be classified into inflammatory or homeostatic based on the functions they carry out 
(reviewed in Ebert et al. 2005; Griffith et al. 2014). Inflammatory chemokines may be produced by 
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a number of cell types in response to inflammation to allow recruitment of leukocytes to 
inflammatory sites (redundant, non-tissue-specific). On the other hand, homeostatic chemokines 
control cellular traffic in the secondary lymphoid organs and contribute to the immune 
surveillance of the peripheral tissues (tissue-specific, non-redundant)(B. Moser et al. 2004). They 
also control cellular migration in the bone marrow. 
Apically expressed chemokines, which allow attachment and signalling, need not necessarily be 
produced by the endothelial cell expressing it. Chemokines secreted elsewhere can be uptaken by 
transcytosis and anchored to the endothelium by glycosoaminoglycans (GAGs), synthesised by the 
endothelium (Middleton et al. 2002). The variety of chemokines in different tissues and the 
expression of multiple chemokine receptors by subgroups of leukocytes have been known to be 
responsible for the bulk of the homing pattern seen in the recruitment of leukocytes (reviewed in 
Griffith et al. 2014). Within the tissue extravasation process, chemokines also guide the 
lymphocytes through the layers underlying the endothelium.    
An extensive list of chemokine receptors, cellular expression type and associated function are 
described in the Table 1 below adapted from (Griffith et al. 2014). 
    Introduction 
24 
 
 
 
Table 1   Chemokine receptors that are involved in cellular recruitment 
This table adapted from (Griffith et al. 2014) gives an up to date list of chemokine receptors that 
have been discovered to regulate cellular trafficking including their cellular expression and 
associated function.   
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Chemokine receptor Structure and Activation 
All Chemokine receptors are 7 trans-membrane receptors with seven helical membrane spanning 
regions that are connected by extra-membranous loops (Allen et al. 2007). These N terminus and 
three extracellular loops are exposed to outer surface of the cell. While the C terminus and three 
intracellular loops face the cytoplasm. The signalling initiated through these receptors upon ligand 
binding is due, at least in part, to the presence of motifs within these cytoplasm facing loops. The 
DRY motif (Asp-Arg-Tyr) in the second intracellular loop is one such motif which is missing in the 
scavenger chemokine receptors (Rovati et al. 2007).These ‘scavenging’ or atypical chemokine 
receptors do not signal and are important for shaping chemokine gradients and dampening 
inflammation by scavenging chemokines in a GTPase independent manner. The N terminus is 
important for ligand binding. 
Chemokine receptors are GPCRs where the (αβγ) heterotrimeric G proteins bind to the 
intracellular loops (Cabrera-Vera et al. 2003; Pierce et al. 2002). The Gα subunit interacts directly 
with GPCR intracellular loops and with the Gβ subunit, which in turn binds with the Gγ subunit. 
The Gα protein subunit contains the GTPase domain involved in the hydrolysis of GTP. In the 
inactive state, the Gα subunit remains bound to GDP. Upon ligand binding, a conformational 
change activates the heterotrimeric G protein inside the cell, causing dislocation of GDP from the 
Gα subunit and replacement by GTP. The Gα-GTP then dissociates from the receptor and Gβγ 
heterodimers, and both complexes activate downstream effector signalling molecules. Over-
stimulation through continued stimuli can lead to receptor desensitisation and internalisation by 
agonist-dependent phosphorylation of the C terminus of the GPCR. This receptor phosphorylation 
subsequently promotes binding of proteins known as arrestins, which block further interaction 
with G proteins and initiates receptor internalisation through clathrin coated pits and lipid 
rafts/caveolae (Lefkowitz and Whalen 2004; Neel et al. 2005). 
Upon chemokine binding, the N terminus of the receptor binds the N terminus of the chemokine 
in an extended fashion, orienting the chemokine into the helical bundle. Additionally, the other 
extracellular loops also bind to the globular body of the chemokine orienting the N terminus of 
the chemokine into the transmembrane helices. 
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1.1.1.3 Firm Adhesion 
 
Once the chemokines provide activating signals via their receptors expressed on the lymphocytes, 
conformational changes brought about in the integrins allows for rapid increase in affinity leading 
to firm adhesion to the endothelial surface (Explained in detail later). These integrins are 
glycosylated protein heterodimers composed of a large alpha chain that pairs non-covalently with 
a smaller beta chain (reviewed in Danen and Sonnenberg 2003; van der Flier and Sonnenberg 
2001). Integrins bind to components of the extracellular matrix or their ligands on the endothelial 
surface resulting in this firm adhesion. In T cells, two integrins are particularly important for 
extravasation. These are the very late induced antigen 4 (VLA-4, α4β1 ) and Lymphocyte function 
associated antigen 1 (LFA 1).  
LFA-1 binds to its two ligands (ICAM-1) and (ICAM-2) expressed on ECs. These ligands are Ig-like 
type 1 transmembrane glycoproteins with short cytoplasmic tails, single transmembrane regions 
and larger extracellular domains. Both ligands through their interactions with LFA-1 play 
important roles in the migration of T cells. While expression of ICAM-1 can be significantly 
increased following inflammatory stimuli such as IL-1 and TNFα (Gahmberg et al. 1997), ICAM-2 
remains constitutively expressed on vascular and lymphatic endothelium with indifference to 
inflammatory stimuli (de Fougerolles et al. 1991; Geijtenbeek et al. 2000). Thus, ICAM-1 is 
important for the migration of T cells to the inflamed non lymphoid tissue. Antibody mediated 
blockade of ICAM-1 and not ICAM-2 was shown to reduce migration of T cells to inflamed skin in 
vivo (J. C. Lehmann et al. 2003). In the case of trafficking to lymph nodes, there is significant 
redundancy between these two ICAM molecules as antibody mediated blockade of either had 
little effect on migration to peripheral lymph nodes, while antibody mediated blockade of both 
dramatically reduced homing of T cells to the lymph nodes (J. C. Lehmann et al. 2003). 
Like ICAM-1, the expression of vascular cell adhesion molecule (VCAM-1), the ligand for VLA-4 is 
greatly induced on endothelium upon stimulation through inflammatory mediators (Henninger et 
al. 1997). VCAM-1 has also been reported to support rolling, mediated through VLA-4, leading to 
firm adhesion without the need of chemokine stimulation (Alon et al. 1995). In addition, VLA-4 
also binds another integrin α4β7 expressed by subgroups of T cells (Carter and Wicks 2001). 
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1.1.1.4 Integrin Activation 
 
The arrest of tethered or rolling leukocytes on the target endothelium is almost entirely mediated 
by members of the integrin superfamily and their endothelial immunoglobulin superfamily (IgSF) 
ligands (reviewed in Ley et al. 2007; A. D. Luster et al. 2005). Interestingly, the majority of 
leukocytes maintain these integrins in largely inactive states (exceptions include T and B cell 
blasts, and some myeloid cells that constitutively express high or intermediate integrin affinity) 
and require their modulation for high-affinity and flow shear-resistant adhesiveness towards their 
specific endothelial ligands (Laudanna and Alon 2006). Previous studies conducted in both in vitro 
and in vivo have revealed that this increased integrin adhesiveness and microclustering occurs 
within a fraction of seconds following contact with endothelial ligands (Grabovsky et al. 2000; 
Shamri et al. 2005). As mentioned above, chemokine or chemoattractant binding to their G 
protein-coupled receptors (GPCRs) on the leukocyte surface initiates the high integrin avidity to 
ligand within sub-seconds at restricted leukocyte-endothelial contact points (Laudanna 2005). It is 
unclear whether this ‘inside out’ signalling via chemokines is locally transmitted at the endothelial 
contact zone or if the rolling leukocyte accumulates successive chemokine signals to surpass an 
activation threshold.  
From a structural viewpoint, inside out signalling induces conformational changes in the integrins 
from their inactive bent clasped heterodimeric structure (reviewed in Ley et al. 2007) towards 
their unclasped heterodimeric form with extended ectodomains exhibiting intermediate to high 
affinity towards their ligands (Arnaout et al. 2005). In light of the short time frame involved in this 
process, integrins may exist in preformed associations with different cytoskeletal adaptors and 
membrane proteins such as tetraspanins, CD47, CD98 and CD44. However, chemokine-induced 
inside out signalling only partially accounts for the conformational changes that ensure firm 
arrest. Recent data suggests that bidirectional integrin signals induce the necessary 
rearrangements of the α and β subunits of the integrin cytoplasmic tails as well as changes in the 
extracellular domain that follow binding of extracellular ligands (reviewed in Abram and Lowell 
2009). This associated ’outside in’ signalling involves early coupling of tyrosine kinases, 
particularly those of the Src and Syk families. Rapid activation of these enzymes has been 
reported in lymphocytes, myeloid cells and platelets following β1, β2 and β3 integrin engagement 
(Arias-Salgado et al. 2003). Deficiency of Syk kinase was described to block β1, β2 and β3 integrin 
signalling events in neutrophils and macrophages (Mocsai et al. 2002). In Jurkat T cells, the 
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deficiency of the Zap-70 kinase (member of the Syk family of tyrosine kinases) has been shown to 
abrogate signalling events from the β1 integrin (Epler et al. 2000).  
A key protein that interacts with the α chain of integrins during the inside out signalling is the 
guanosine triphosphatase (GTPase) Rap1 (reviewed in Kinashi 2005). Expression of dominant 
negative Rap1 has been reported to inhibit TCR-mediated LFA-1 activation in Jurkat T cells (K. 
Katagiri et al. 2000), while overexpression of the Rap1-specific GAP, SPA1, inhibits rapid ICAM-
dependent adhesion of primary T cells to vascular endothelium (Shimonaka et al. 2003). Rap1 
acting through Ras association domain-containing protein 5 or RAPL has also been reported to 
alter integrin clustering (Koko Katagiri et al. 2003). A second mechanism that contributes to 
integrin activation mediated by Rap1 is through the facilitation of talin binding to the intracellular 
domain of the β-integrin subunit. The talin protein is a major integrin activating adaptor in 
leukocytes and platelets (Critchley 2009; S. Tadokoro et al. 2003). This talin binding is mediated by 
the Rap1 effector Rap1–GTP-interacting adapter molecule (RIAM) (Watanabe et al. 2008). The 
binding of talin to the β integrin subunit also results in the opening of the extracellular integrin 
headpiece to promote high-affinity-ligand binding. Conditional knockdown of talin in platelets of 
mice showed poor activation of integrins and increased resistance to arterial thrombosis 
mediated by platelet β1 and β3 integrins (Nieswandt et al. 2007; Petrich et al. 2007).  Another 
family of proteins called Kindlins can also interact with integrin β1 and β3. Kindlin-1 and 2 are 
ubiquitously expressed whereas Kindlin-3 is restricted to hematopoietic cells (reviewed in Abram 
and Lowell 2009). Kindlin-3-deficient mice die due to severe bleeding as a result of platelet 
dysfunction resulting from defective inside out signalling via β3 integrins (M. Moser et al. 2008), 
while, Kindlin-2 deficient embryonic stem cells in mice exhibit decreased adhesion on a variety of 
ligands (Montanez et al. 2008).  
Thus ‘inside out’  and ‘outside in’ signalling induces both conformational changes to the integrin 
structure increasing affinity and also causes enhanced integrin clustering (increased avidity).This 
occurs at the apical surface of the endothelium leading to firm adhesion of the lymphocytes to the 
ECs.      
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1.1.1.5 Trans-endothelial migration (diapedesis) 
 
Once a lymphocyte has committed to trans-endothelial migration (TEM), the firmly-adhered cell 
changes shape and begins to display two distinct edges on the endothelium. These are the leading 
edge and the trailing edge (uropod) of the cell (del Pozo et al. 1995). This polarised state of the 
cell is the result of changes in the distribution of actin filaments initiated through signalling 
pathways resulting from the interaction of the lymphocyte with the endothelium. The leading 
edge is characterised by a high density of chemokine receptors and integrins highlighting its role 
in chemotaxis while the trailing edge or uropod is important for contact between polarised 
lymphocytes through the action of selectins (reviewed in Sanchez-Madrid and del Pozo 1999). In 
addition, cholesterol-rich structures known as lipid rafts that facilitate signalling are thought to be 
fundamental in establishing cell polarity (reviewed in Simons and Toomre 2000; Villalba et al. 
2001), as cholesterol depletion abolished the formation of both the leading edge and the uropod 
in the study by (Gomez-Mouton et al. 2001).   
Although migration through the endothelial cell itself (transcellular route)(Carman and Springer 
2008; Feng et al. 1998) has been described, the majority of the lymphocyte migration occurs 
through the junctions between adjacent ECs (paracellular route). These junctions are formed 
through the interaction of dedicated adhesion molecules including junctional adhesion molecules 
(JAMs), platelet endothelial cell adhesion molecule (PECAM-1)/CD31, CD99, vascular endothelial 
(VE) cadherin, occludins and claudins (reviewed in W. A. Muller 2003). CD31 through homophillic 
interactions with CD31 expressed on T cells plays a crucial role in TEM (Described in detail below). 
Similar to CD31, CD99 also plays a role in TEM through homophillic interactions between 
endothelial cell junctions and T cells. 
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CD31 
 
Platelet endothelial cell adhesion molecule 1 or PECAM-1 (CD31), a 130kD type I transmembrane 
cell adhesion molecules from the Ig superfamily (Ig-CAMs), is a key adhesion molecule involved in 
leukocyte trans-endothelial migration (P. J. Newman et al. 1990). This molecule is expressed on a 
number of hematopoietic and immune cells including platelets, neutrophils, monocytes, 
megakaryocytes, natural killer cells, T cell, B cells and on ECs where it is expressed on the borders 
of adjacent cells (reviewed in Jackson 2003; P. J. Newman 1997).  
Structurally, CD31 is composed of 6 extracellular domains, a transmembrane portion, and a 
cytoplasmic tail. The 6 extracellular Ig-like domains are differentially glycosylated involving N-
linked and O-linked glycosylation sites (Xie and Muller 1993). CD31 can interact through 
homophilic (or homotypic) fashion via its 1st domain (reviewed in Newman and Newman 2003; 
Privratsky et al. 2010). In addition, a number of putative heterotypic ligands for CD31 have also 
been identified. These include the ADP-ribose cyclase (CD38) (via domain 2) (Deaglio et al. 1998), 
the neutrophil expressed CD177 (domain 6) (Sachs et al. 2007) and the integrin αvβ3 (domains 1 
and 2) (Piali et al. 1995). Within the cytoplasmic tail, CD31 contains residues that serve for 
palmitoylation, phosphorylation and docking of cytosolic signalling molecules (Newman and 
Newman 2003). Importantly, CD31 bears two Immunoreceptor Tyrosine-based Inhibitory Motifs 
(ITIMs) that encompass Tyr663 and Tyr686 which when phosphorylated have been observed to 
recruit Src homology 2 (SH2) domain-containing proteins. SH2 domain containing proteins that 
have been previously identified to be recruited include SHP-2 (Newman and Newman 2003), SHP-
1 (Henshall et al. 2001; Hua et al. 1998) Henshall et al. 2001), SH2 domain-containing inositol 5’-
phosphatase (SHIP) (Pumphrey et al. 1999), phospholipase Cγ1 (PLCγ1) (Henshall et al. 2001) and 
members of the Src family of tyrosine kinases (SFK) (Lu et al. 1997; Masuda et al. 1997; Osawa et 
al. 1997) . Another residue in the cytoplasmic domain subjected to post-translational modification 
is Cys595, which, when palmitoylated, can target CD31 to membrane microdomains enabling it to 
act as a regulator of cell signalling and apoptosis (Sardjono et al. 2006). An overview of the 
structure of CD31 is depicted in the Figure 1 below adapted from (Privratsky et al. 2010). 
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Figure 1    Structure of CD31 
The diagram indicates CD31 cytoplasmic signalling domains, including the ITIMS that recruit the 
SH2 domain containing phosphatases when phosphorylated, as well as the extracellulular domains 
that are important for binding ligands. Figure adapted from (Privratsky et al. 2010). 
 
The role of PECAM-1 (CD31) in TEM 
 
Historically, CD31 remains a multifaceted molecule implicated in both pro-inflammatory and anti-
inflammatory roles.  Its pro-inflammatory aspect results from its ability to facilitate leukocyte 
trans-endothelial migration. The first studies to investigate this functional aspect utilised CD31 
specific antibodies to report blocking of leukocyte transmigration across endothelial monolayers 
in vitro (W. A. Muller et al. 1993) and leukocyte accumulation at inflammatory sites in vivo 
(Vaporciyan et al. 1993). Following these initial reports, several other studies have established 
pro-inflammatory roles for CD31 primarily through its ability to support leukocyte emigration 
from vasculature to inflammatory sites. These studies are summarised in the Table 2 adapted 
from (Privratsky et al. 2010). Evidence implicating CD31 in leukocyte transmigration through 
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venular walls was first directly visualised using the technique of intravital microscopy in the 
studies by (Wakelin et al. 1996)and (Thompson et al. 2001) indicating inhibition of leukocyte TEM 
following treatment with CD31 blocking antibodies. Importantly, besides demonstrating that 
CD31 mediated leukocyte migration through ECs, CD31 can also mediate leukocyte migration 
through the perivascular basement membrane (Thompson et al. 2001). 
Mechanistically, CD31 is known to facilitate TEM through its effects on both ECs and leukocytes 
during early and late stages of the leukocyte migration cascade.  
 
Leukocyte CD31 in TEM 
 
CD31 engagement on the leukocytes can initiate signalling events resulting in the activation of 
integrins. For example, β1- and β2-integrins in T cell subsets (Tanaka et al. 1992), β1-integrins in 
macrophages (Vernon-Wilson et al. 2006; Vernon-Wilson et al. 2007), β2-integrins in natural killer 
(NK) cells (Berman et al. 1996) and the αMβ2 (Mac-1, CD11b/CD18) integrin in monocytes and 
neutrophils (Berman and Muller 1995) have all been described to become activated downstream, 
following CD31 stimulation on these cell types. In neutrophils, homophilic CD31 engagements 
were reported to trigger upregulation of integrin α6β1 – a receptor for laminin, a major 
component of the basal lamina (Dangerfield et al. 2002). Thus one of the main functions of 
leukocyte CD31 is to activate integrins following homophilic engagement resulting in efficient 
emigration through the endothelium and the sub-endothelial matrix. An exact mechanism 
through which CD31 engagement achieves integrin activation remains poorly understood. 
However, there is evidence to suggest the involvement of the Ras family GTPase, Rap1 in this 
process. Rap1 initiates cytoskeletal rearrangement and its activation has been observed in Jurkat 
T cells that were exposed to antibody mediated CD31 ligation (Reedquist et al. 2000). In addition, 
CD31 molecules exist on the cell surface in dynamic equilibrium between primers, dimers and 
oligomers, and this oligomerised state has been described as best suited for CD31 to serve as a 
positive regulator of integrin activation (T. Zhao and Newman 2001). There is also evidence that 
CD31 on leukocytes can modulate cell membrane potential which can enhance integrin mediated 
adhesion. For example, in phagocytes, CD31 inhibited membrane repolarization mediated by the 
ether- à –go-go related gene (ERG) ,a voltage gated potassium channel which enhances β1-
integrin-mediated firm adhesion (Vernon-Wilson et al. 2007). 
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Endothelial CD31 in TEM 
 
On the other hand endothelial CD31 through its homophilic or heterophilic interactions with 
leukocytes can also facilitate leukocyte TEM. Besides simply facilitating adhesion, a series of 
elegant studies have identified CD31 as a main constituent of the recycling compartment on ECs, 
termed the lateral border recycling compartment (LBRC). The LBRC is a surface-connected 
membrane network located at the borders between adjacent ECs (Mamdouh et al. 2003).This 
network contains CD31, CD99, and junctional adhesion molecule (JAM)-A, and is recycled and 
targeted to the region of the cell where paracellular or transcellular migration is occurring 
(Mamdouh et al. 2003; Mamdouh et al. 2009). The study by (Mamdouh et al. 2003) indicated that 
CD31 interactions between EC and leukocytes are important for triggering targeted CD31 and 
LBRC-recycling, which are required for leukocyte transmigration. Later studies by the same group 
showed that both CD31 dependent or independent leukocyte TEM was dependent on LBRC 
recycling mediated by endothelial microtubules and kinesin family molecular motors (Mamdouh 
et al. 2008). Interestingly, the Y663 but not the Y686 ITIM-mediated recruitment of SHP-2 was 
essential for these functions. Indeed, blockade of CD31 via antibody on monocytes prevented 
endothelial CD31 targeting to the zone around the monocyte, thus, preventing TEM with little 
consequence to monocyte-endothelial cell adhesion (Dasgupta et al. 2009). It is unclear whether 
CD31 mediated downstream signalling in the ECs is important for leukocyte TEM. The study by 
(O'Brien et al. 2003) reported that leukocyte transmigration was independent of endothelial CD31 
signalling using ITIM-mediated recruitment of SHP-2. Nonetheless, recruitment of CD31 to the 
LBRC and LBRC recycling via the cytoplasmic tail remain crucial events for leukocyte TEM. 
 
Junctional adhesion molecules (JAMs) 
 
JAMs are expressed on both ECs and T cells. As with CD31 and CD99, they are capable of 
homophilic interactions as well. The JAMs also act as integrin ligands binding both LFA-1 and VLA-
4 on T cells (Ostermann et al. 2002).  JAM A is concentrated at endothelial borders. While it 
normally engages in homophilic adhesion, under inflammatory conditions it can bind LFA-1 on T 
cells and is thus important in TEM (W. A. Muller 2003; Ostermann et al. 2002). Antibody mediated 
blockade of JAM A on human ECs was shown to reduce TEM in vitro (Ostermann et al. 2002).In in 
vivo studies, antibody-mediated blockade of JAM A resulted in reduced trans-endothelial 
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migration (Woodfin et al. 2009). JAM C can engage in homophilic adhesion or heterophilic 
adhesion with JAM B or CD11b/CD18 (Mac-1) (Chavakis et al. 2004; Johnson-Leger et al. 2002). 
JAM C is also known to interact with the integrin Mac-1 expressed on monocytes and neutrophils 
and thus, plays a role in their TEM (Chavakis et al. 2004). Human JAM-C is also expressed by 
platelets, monocytes, natural killer cells, dendritic cells, B cells and a subset of T cells (reviewed in 
Weber et al. 2007). However, JAM C has not been detected on mouse leukocytes. 
While the exact mechanism through which JAM-A promotes leukocyte extravasation remains to 
be identified, it is likely to involve the association of this molecule with key mediators of 
cytoskeletal remodelling (reviewed in Weber et al. 2007). Localised at the intercellular contacts of 
ECs and epithelial cells, JAMs participate in the assembly and maintenance of junctions, signalling 
to cytoskeleton-associated proteins and recruiting cell polarity proteins to the junctions via their 
PDZ-binding-domain motif. JAM-A is apically positioned at tight junctions and interacts with Rap-
1, calmodulin associated serine/threonine kinase (CASK), an atypical protein kinase C (PKC) 
complex and PSD-95/Disc Large/zona occludens protein-1 (ZO-1; PDZ)-containing proteins, all of 
which can act as scaffolds for larger complexes (Bazzoni et al. 2000; Ebnet et al. 2000). Blocking 
JAM-A has shown to reduce neutrophil or monocyte extravasation in inflammatory meningitis, 
peritonitis, skin or cremaster microcirculation, ischemia-reperfusion of heart and liver (reviewed 
in Weber et al. 2007). 
 
CD99 
 
CD99 is a heavily O-glycosylated 32-kD type I transmembrane protein that is present on 
thymocytes, T cells and many other hematopoietic cell types. It is also concentrated at the 
intercellular borders of confluent human ECs. Homophilic interactions between leukocyte and 
endothelial CD99 are known to play a crucial role in transmigration (W. A. Muller 2003). However, 
CD99 appears to have a role in distal stages of diapedesis, after the point at which CD31 has 
played its critical role. In the study by (Schenkel et al. 2002), leukocytes treated with antibody-
mediated CD31 blockade were still inhibited from treatment with anti-CD99 after the anti-CD31 
blockade had been removed. Contrariwise, leukocytes treated with anti-CD99 could no longer be 
inhibited from transmigration by anti-CD31 treatment after the anti-CD99 block had been 
removed. In this study, antibody-mediated blockade of CD99 arrested monocytes at appoint 
where they were partially through the junction. Similar observations were also reported in 
neutrophils by (Lou et al. 2007). Blocking of CD31 and CD99 has an additive effect on the 
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inhibition of migration, suggesting that both molecules likely regulate distinct aspects of 
diapedesis (Schenkel et al. 2002). 
While CD31 and CD99 do not play a role in the step preceding transmigration (firm adhesion), 
VCAM-1, ICAM-1 and JAMs are thought to have a roles in both tight adhesion and transmigration 
stages. Clustering of VCAM-1 and ICAM-1 on the ECs has been observed as the leukocyte 
approaches the ECs border (Barreiro et al. 2002; Carman and Springer 2004). Once adherent, 
ICAM-1 is enriched under the leukocyte as it migrates and continues to surround it as it 
transmigrates. The actin cytoskeleton is involved in this process; specifically, the Src-dependent 
phosphorylation of the actin-binding molecule cortactin is required for ICAM-1 clustering (Yang et 
al. 2006). Furthermore, ICAM-1 clustering further induces phosphorylation of cortactin inducing 
even more clustering (Durieu-Trautmann et al. 1994). Similarly, VCAM-1 clustering and 
enrichment under leukocytes has also been reported (Barreiro et al. 2002).  
The intracellular signalling following adhesion allows for the opening of the endothelial barriers 
and also results in the breakage and formation of the leukocyte-endothelial bonds. This further 
induces retraction of the uropod and protrusion of the leading edge. The leading edge protrusion 
towards and through the junctional barriers is mediated through means of its polarised 
chemokine receptors. Within the leukocytes, dramatic reorganization of membrane domains and 
the cytoskeleton enables a polarised morphology with an actin-rich lamellipodium at the front 
and a uropod at the rear (reviewed in Sanchez-Madrid and Serrador 2009). The formation of these 
structures are controlled by members of the Rho GTPase family of proteins, including RhoA, 
Rac1/2 and Cdc42 (reviewed in Heasman and Ridley 2010). Recently, a study has established that 
Rho A-depleted cells lack both lamellipodia and uropods, and instead have narrow protrusions 
extending from a rounded cell body (Heasman et al. 2010).  
Thus multiple processes are integrated to achieve effective migration across an endothelial 
barrier. It has been suggested that considerable overlap between the different steps of the multi-
step model of leukocyte extravasation also exists and that there is substantial cooperation 
between adhesion molecules at all stages (W. A. Muller 2003). After crossing the endothelial 
barrier, the lymphocyte must cross the perivascular basement membrane. The mechanisms 
involved in this process remain incompletely defined, however, studies have identified that this is 
achieved through the interaction of integrins on lymphocytes with proteins on the basement 
membrane known as laminins (Hohenester and Yurchenco 2013; Kenne et al. 2006). 
 
    Introduction 
36 
 
1.1.2 Homing of T cells   
The selectivity associated with the recruitment of specific subgroups of T cells to distinct locations 
within the body suggest that T cells do not migrate in a random fashion but are guided to their 
destinations through the actions of key molecules. While naïve T cells constantly recirculate from 
blood back to the lymphoid organs, upon activation they acquire specific receptors termed 
‘homing receptors’ enabling them access to the non-lymphoid tissue (reviewed in Mora and von 
Andrian 2006). On the other hand, vascular endothelium selectively displays tissue specific ligands 
for these homing receptors known as vascular addressins, further increasing the specificity of T 
cell recruitment. Chemokine receptor ligands expressed selectively by endothelium in certain 
tissues adds an additional another layer of specificity to the recruitment. 
 
1.1.2.1 Homing of naïve T cells to peripheral lymphoid organs (PLNs) 
 
Naïve T cells traffic into the peripheral lymphoid organs through specialised vessels known as high 
endothelial venules (HEV) (Mackay et al. 1990; Vestweber 2003; Weninger et al. 2003). Located 
with the T cell zones of the lymph nodes, they are lined by specialised ECs that display addressins. 
The peripheral lymph node addressin (PNAd) is highly expressed on the HEVs of the PLNs and 
mesenteric lymph node of the gut and binds the L-selectin displayed by naïve T cells (Streeter et 
al. 1988). In humans PNAd is a complex made up of podocalyxin and endomucin and GLyCAM-1 
thus mediating binding through selectins. These HEVs also display the chemokine ligands CCL19 
and CCL21 which bind the chemokine receptor CCR7 abundantly expressed on naïve T cells and 
subsets of memory T cells (Baekkevold et al. 2001). Thus the naïve T cells utilise the 
aforementioned migration steps to enter the PLNs. Briefly, the interaction of L-selectin with the 
addressin on the HEVs induce tethering and rolling (reviewed in Ebert et al. 2005). The chemokine 
receptor CCR7 signalling through its ligands displayed on the HEVs induces the inside out 
signalling causing the high affinity LFA-1 binding to ICAM-1 displayed on the endothelium, 
resulting in arrest of the cell. The T cell then exits through the endothelial junctions and enters the 
T cell zone where chemokines are present.  
Another chemokine receptor, described to contribute to lymph node homing is the CXCR4 
receptor which binds stromal cell-derived factor 1 (SDF-1, CXCL12) (Campbell et al. 2003). In the 
absence of CCR7 ligation by CCL19/21, some cells were still observed to be able to migrate to the 
lymph nodes and this was abolished in CXCR4 deficient mice in the study by (Okada et al. 2002). 
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An additional pathway involved in the entry as well as the exit of T cells to the lymph nodes is the 
sphingosine 1 phosphate (S1P) receptor signalling pathway (Chi and Flavell 2005; Rosen and 
Goetzl 2005). Sphingosine 1 phosphate is a phospholipid expressed at low concentrations in the 
lymphoid tissue and at high concentrations in the lymph and blood itself. This concentration 
gradient is maintained through the action of the enzyme S1P lyase expressed ubiquitously in the 
tissues (Schwab et al. 2005). The phospholipid binds to its receptor S1PR causing internalisation 
thereby reducing its expression. As a naïve T cells circulate in the blood, the high concentrations 
of S1P reduce their receptor expression and prevent entry into the tissues (reviewed in Vera 
Reitsema 2014). Once the naïve T cell enters the lymph node, the low concentration induces S1P 
receptor (S1PR) upregulation. However, the receptor upregulation can take several hours allowing 
enough time for antigen presentation to occur, following which the activated effector cells are 
subjected back to an increasing S1P concentration gradient allowing for the exit of the cell via the 
efferent lymphatics. Blockade of S1PR using the drug FTY720 prevents T cell egress from the 
lymph nodes thus acting as an immunosuppressive agent (reviewed in Cyster 2005; Matloubian et 
al. 2004). In addition, it has been reported that naïve T cells from S1PR-deficient mice adoptively 
transferred into wildtype (WT) mice were able to populate the lymph nodes but were unable to 
exit (Matloubian et al. 2004). 
 
1.1.2.2 Homing of T cells to peripheral non lymphoid and inflamed tissues 
 
Upon antigen activation, naïve T cells proliferate and differentiate into short lived effector T cells 
(TEFF) and into a small fraction of long lived memory T cells. The memory T cells can be further 
grouped into central memory (TCM) and effector memory T cells (TEM) (reviwed in Sallusto et al. 
2004; Sallusto and Lanzavecchia 2009). The former express L-selectin, CCR7 and thus, are able to 
traffic in a manner similar to that of naïve T cells. However, they also acquire the necessary 
homing receptors enabling access to sites of chronic inflammation (Ley and Kansas 2004). TCM cells 
do not have immediate effector functions but are responsible for secondary recall responses thus 
providing antigenic memory (Manjunath et al. 2001). The TEM cells lack expression of L-selectin 
and CCR7 and instead acquire tissue specific integrins thus becoming able to traffic back to the 
extra-lymphoid sites where an immediate effector response is required (Sallusto et al. 1999; von 
Andrian and Mackay 2000). TEM cells do not traffic to resting lymph nodes and are mainly found in 
the blood, spleen and peripheral tissues and have immediate effector functions (Masopust et al. 
2001).  TEFF  cells represent the major fraction of differentiated T cells that undergo apoptosis soon 
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after the primary response (contraction phase) (Sprent and Webb 1995). Thus TEFF and TEM form 
the ‘effector arm’ of the T cell responses. A diagram summarising the migratory properties of 
naïve,TCM, TEFF and TEM is given in Figure 2below adapted from (Ward and Marelli-Berg 2009). 
 
 
 
Figure 2    Molecular interactions required for homing of different subsets of T cells to 
their respective sites. 
Naïve T cells predominately traffic to the secondary lymphoid tissues such as the peripheral lymph 
nodes (PLNs), PP and MLNs in the gut. Memory T cells predominately travel to the non-lymphoid 
tissue such as the skin, the lamina propria of the gut, and the central nervous system. The figure is 
adapted from (Ward and Marelli-Berg 2009). 
 
 
As the T cells become activated, they begin to express the ligands for E-selectin and P-selectin. 
They also upregulate the expression of LFA-1, VLA-4 and specific chemokine receptors enabling 
them access to the inflamed sites where an effector response is to begin. On the other end, the 
endothelium at the site of infection, in response to inflammatory signals such as cytokines 
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upregulate E-selectin, P-selectin and ligands for integrins expressed on activated T cells such as 
ICAM-1 and VCAM-1 (reviewed in W. A. Muller 2003). Inflammatory chemokines produced from 
the endothelium, tissue specific macrophages and other cells induce motility and transmigration 
of the activated T cells to enter the site of infection. 
The chemokine receptor CXCR3 is expressed on activated T cells plays a key role in the effector 
responses (Bonecchi et al. 1998). CXCR3 binds to CXCL10 expressed by ECs, monocytes and 
fibroblasts in response to interferon gamma (IFN-γ) produced in inflammation(A. D. Luster and 
Ravetch 1987b). Several other chemokine receptors have been implicated in selectively recruit 
subsets of effector/memory T cells to different inflamed tissues (See Table 1).  
Within the secondary lymphoid tissues, differentiating TEFF cells can acquire specific homing 
receptors and chemokine receptors thus enabling specific subsets, best suited to respond to 
certain tissues, to selectively migrate to those tissues. Clear examples of this are observed in the 
migration of effector T cells to the gut and skin. Effector T cells migrating to the skin express the E-
selectin ligand cutaneous lymphocyte antigen (CLA) (Berg et al. 1991). They also express 
chemokine receptors CCR4 and CCR10 which bind chemokines CCL17 (also known as thymus and 
activation regulated chemokine TARC )(J. J. Campbell et al. 1999; Reiss et al. 2001) and CCL27 (the 
cutaneous T cell activating chemokine CTACK) expressed in inflamed skin (Morales et al. 1999; 
Reiss et al. 2001). Effector T cells that migrate to the gut are known to express integrin α4β7 which 
binds MAdCAM-1 expressed on gut endothelium (Berlin et al. 1993; Lefrancois et al. 1999).These 
cells also express chemokine receptor CCR9 which binds CCL25 (also known as thymus expressed 
chemokine TECK) (Stenstad et al. 2006), a chemokine expressed in the inflamed bowel. Indeed, 
antibody blockade of either CCR9 or TECK has been described to significantly reduce T cell 
migration to the small intestine (Hosoe et al. 2004; Rivera-Nieves et al. 2006). 
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1.1.2.3 Mechanisms of T cell homing induction 
 
As mentioned above, activation of naïve T cells by antigen presentation can differentiate T cells to 
specific subsets capable of selective recruitment to tissues. This implies that signals delivered to 
the naïve T cells during antigen presentation may also induce homing properties. Thus, it is 
reasonable to suggest that the lymphoid microenvironment, including the resident APCs such as 
the DCs influence the gain of selective homing properties for tissues. 
T cells activated in the cutaneous associated lymphoid tissue express high levels of CLA while 
those activated in intestinal lymphoid tissue acquire integrin α4β7 expression. Indeed, dendritic 
cells from the GALT such as those found in the mesenteric lymph nodes and Peyers patches 
induce high expression of α4β7 and CCR9 on T cell while reducing CCR4 in vitro (Johansson-
Lindbom et al. 2003; Mora et al. 2003; Mora et al. 2005). Additionally, these T cells migrated more 
towards the chemokine CCL25 and had reduced expression of L-selectin (Johansson-Lindbom et 
al. 2003; Mora et al. 2003). The mechanism involved was later described to occur through the 
action of the Vitamin A metabolite retinoic acid on a subset of dendritic cells found primarily in 
the MLNs and Peyers patches (Iwata et al. 2004). Interestingly, Vitamin A deficient mice have 
reduced α4β7 expressing T cells as well as depletion of T cells from the lamina propria of the gut 
(Iwata et al. 2004; Mora et al. 2005).  
Similarly, T cells stimulated with DCs from the peripheral lymph nodes exhibited higher levels of 
fucosyltransferase-VII (FucT-VII), the enzyme required for post translation modification of PSGL-1, 
as well as high levels of P and E selectins in the study by (Mora et al. 2005). In addition, they 
displayed high levels of CCR4 and migrated more efficiently to the skin when adoptively 
transferred. Another mechanism postulated to explain this phenomenon was through the action 
of the vitamin D3 metabolite, 1,25(OH)2D3. DCs isolated from the skin draining lymph nodes are 
demonstrated to convert vitamin D3 to 1,25(OH)2D3 which would then act on T cells imprinting a 
skin homing phenotype (Sigmundsdottir et al. 2007). 
It is important to bear in mind that T cell homing phenotypes are reversible. For example, 
activated T cells from the Peyer’s patches re-stimulated with peripheral lymph node DCs are able 
to express PSGL-1 (Mora et al. 2005). Similarly peripheral lymph node T cells re-stimulated with 
Peyer’s patches DCs can also acquire α4β7 expression.  
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1.1.3 Regulation of T cell Migration 
1.1.3.1 Molecular mediators involved in the regulation of T cell motility 
 
Role of Rho family GTPases in T cell migration 
In naïve T cells, the Rac GEF (guanine-nucleotide exchange factor) DOCK (dedicator of cytokinesis) 
2 initiates the early wave of chemokine induced F actin formation. (Fukui et al. 2001), have 
previously demonstrated that DOCK-2 deficient T lymphocytes exhibit reduced chemokine 
induced F-actin formation, cell polarity and in vitro migration. Furthermore, DOCK2 deficient T 
cells were observed to have reduced interstitial motility within the lymphoid tissue (César 
Nombela-Arrieta et al. 2007). DOCK2 is also required for the chemokine-induced T cell adhesion 
under shear stress mediated by the integrin α4β1 (García-Bernal et al. 2006). 
Another Rac GEF Tiam1 (T-cell lymphoma invasion and metastasis 1) has been demonstrated to 
be involved during chemokine-induced T-cell migration and associates with members of the Par 
(partitioning defective) polarity complex that include Par3 and PKC (protein kinase C)-ζ. The 
complex segregates at the leading edge of the cells and is important in establishing the anterior 
posterior axis (Gérard et al. 2007; Ludford-Menting et al. 2005). 
Vav, another Rac GEF is also known to be involved in activation of integrins and adherence of T 
cells. Overexpression of Vav mutants, as demonstrated by (Vicente-Manzanares et al. 2005) 
diminished lymphocyte polarisation, actin polymerisation and migration responses to the 
chemokine CXCL12. However, opposing these results, Vav-1 deficient cells exhibited normal 
migration in the study performed by (Vicente-Manzanares et al. 2005).This could reflect the 
compensation of other Vav isoforms.  
Rho-dependent signalling is also thought to be a key component of T cell migration and adhesion 
in response to several chemokines in mature T-cells and thymocytes (Cronshaw et al. 2004; Z. Li et 
al. 2005). In thymocytes, Rho-A activation was necessary for integrin activation induced by Rap1 
and Rac (Vielkind et al. 2005). In addition, Rho-A controls the LFA-1 high-affinity state triggering 
by chemokines along with the lateral mobility induced by chemokines (Giagulli et al. 2004). 
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1.1.3.2 The role of PI3 Kinase in T cell migration 
A large body of evidence has implicated Phosphoinositide 3-kinase (PI3K) signalling as a major 
mediator of cell motility and migration of leukocytes. In T cells, PI3K-dependent signals are 
induced by chemokine receptor, TCR and co-stimulatory receptor activation known to contribute 
to several aspects of T lymphocyte differentiation and homing as well as reorganization of actin 
and other components of the general migratory machinery (reviewed in Ward and Marelli-Berg 
2009).  
The class IA PI3 kinases are made up of a regulatory subunit and an associated catalytic subunit 
(reviewed in Ward 2006). Five regulatory subunits, encoded by three genes are known to exist in 
the class I PI3 kinases. The PI3K3r1 gene encodes p85α, p55α and p50α, the PI3Kr2 encodes p85β 
and the PI3Kr3 encodes p55γ regulatory subunits respectively. These subunits can bind to three 
catalytic isoforms p110α, p110β and p110δ and recruit the complex to the plasma membrane 
upon receptor ligation and phosphorylation. In T cells p85α and p50α are most abundant. A single 
class 1B catalytic isoform, p110γ can pair with either a p84 or p101 regulatory subunit and can be 
activated downstream of G protein coupled receptors (GPCRs). The class I PI3 kinases 
phosphorylate their substrates phosphoinositol (PI), PI(4)P (phosphoinositol 4-bisphosphate) and 
PI(4,5)P2 (phosphoinositol 4,5-bisphosphate) and PI(3,4)P2 (phosphoinositol 3,4-bisphosphate) 
into the resulting product PI(3,4,5)P3 (phosphoinositol 3,4,5-triphosphate). The resulting 
PI(3,4,5)P3 phospholipids bind to signalling proteins bearing a lipid binding domain such as PH 
(pleckstrin homology) and Phox homology domains. In resting T cells, the levels of PI(3,4,5)P are 
low but readily increase following activation (reviewed in Crabbe et al. 2007; Deane and Fruman 
2004; Vanhaesebroeck et al. 2005). Phosphatases PTEN (phosphatase and tensin homologue 
deleted on chromosome 10) and SHIP (SH2 containing inositol phosphatase) dephosphorylate 
these PI(3,4,5)P3 back to PI(3,4)P2 thereby acting as negative regulators of PI3 kinase activity (S. J. 
Harris et al. 2008). Upon stimulation, pleckstrin homology domain–containing proteins such as 
Akt, phosphoinositide-dependent kinase 1 (PDK1), and phospholipase C (PLC) recognise and bind 
to newly generated and enriched PIP3, resulting in its transient membrane relocalization and 
consequent activation (Xue and Hemmings 2013). 
Using genetic and pharmacological means, the contribution of individual classes of PI3 kinase to T 
cell migration has been extensively studied (Ward and Marelli-Berg 2009). These investigations 
have revealed class I PI3K isoforms P110γ and P110δ to be the dominant isoforms involved in T 
cell migration. In in vitro studies, p110γ deficient CD4 and CD8 T cell migration to chemokines 
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CXCL12, CCL19 and CCL21 is decreased significantly as compared to T cells from WT mice (Reif et 
al. 2004). However, in other studies using experimental systems that more accurately represent 
the physiological conditions of migrating cells, PI3Kγ inhibitors have had little effect on T cell 
migration (Martin et al. 2008). This may be a result occurring through off target activity of the 
PI3K selective inhibitors. Using multiphoton microscopy, studies have observed pan PI3K 
inhibitors to have no effect on the migration of T cells within the T cell zones of the secondary 
lymphoid organs (Asperti-Boursin et al. 2007; Worbs et al. 2007). It is important to note that in 
this regard several other PI3K independent signalling mechanisms could regulate migration. Rac 
guanine nucleotide exchange factors (GEFs) including DOCK2, Tiam1 and Vav have been 
implicated in T cell adhesion and migratory events (Ward and Marelli-Berg 2009) as described 
earlier. With respect to migration of activated T lymphocytes, the P110δ isoform is believed to be 
the dominant isoform coupled to the TCR and CD28. These aspects are further examined in the 
subsequent sections. 
Besides these functions, PI3K-Akt signalling has an impact on the regulation of nutrient uptake 
and metabolism via downstream engagement of the mammalian target of rapamycin (mTOR) 
kinase complex. This complex co-ordinates nutrient sensing pathways to that of metabolism. 
Details regarding the PI3K-akt-mTOR axis are discussed later in the section 1.3.4.1.  
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1.1.3.3 Regulation of Migration by the T cell Receptor 
 
While the acquisition of homing receptors and chemokine receptors confers a level of specificity 
to migrating T cells, additional mechanisms must exist to maximise the efficiency of specific 
memory T cell recruitment to antigen-rich large tissues. For example, the human gut can be as 
long as 6 metres in adult humans. A gut homing T cell would need additional methods through 
which it can find and localise to specific antigen-rich sites within the gut. One mechanism believed 
to provide this additional specificity is through the action of antigen presentation by the 
endothelium and its subsequent recognition by the TCRs of T cells interacting with the 
endothelium as a consequence of inflammation. 
 
T cell recruitment by antigen-presenting endothelium 
 
In humans, ECs express both Class I and Class II Major Histocompatibility Complex molecules. In 
mice, the ECs display only Class I molecules but can rapidly upregulate class II MHC molecules in 
response to stimulation via IFN-γ (Choi et al. 2004; Haraldsen et al. 1998; Savage et al. 1995). The 
extent of expression is described to vary amongst different tissues with non-lymphoid vascular 
ECs having the highest expression (reviewed in Choi et al. 2004). Along with the expression of 
MHC molecules, ECs are also known to be able to present antigen to T cells (Bagai et al. 2005; 
Greening et al. 2003; Haraldsen et al. 1998; Murray et al. 1994). Furthermore, a study in mice 
concluded that vascular ECs could cross present antigen to CD8 T cells – a property believed to be 
restricted to dendritic cells - and this process was mediated by transporter for antigen 
presentation (TAP1)- and Proteasome-dependent pathways (Bagai et al. 2005).  
For T cells to become activated, two key signals are required for a full activation response. The 
first is mediated by TCR engagement by the cognate antigenic peptide displayed on the MHC 
molecule. The second signal occurs via co-stimulatory molecules such as CD80 (B7-1) and CD86 
(B7-2) which can engage CD28 receptors on the T cells. The absence of a secondary signal can lead 
to state of unresponsiveness known as anergy (Schwartz 1996). Besides CD28, other molecules 
such as inducible co-stimulatory molecules such as ICOS and OX40 which bind to their ligands are 
also known to provide co-stimulatory signals for T cells (reviewed in Choi et al. 2004).  In humans, 
ECs lack expression of both CD80 and CD86 while in mice, ECs display low levels of CD80 (Marelli-
Berg et al. 2001b; Marelli-Berg and Jarmin 2004a). Co-stimulatory molecules such as the ICOS-L 
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and PD-1 are expressed constitutively on human ECs and are believed to prevent anergy induction 
upon antigen presentation by the endothelium (reviewed in Rudd and Schneider 2003). 
As ECs are capable of displaying antigen to T cells, it raises the question as to whether such 
antigen presentation could result in proliferation and further activation. It is therefore postulated 
that the functional consequence of antigen presentation differs in light of the context it occurs in. 
Dendritic cells presenting antigen to T cells induce a TCR activated ‘stop signal’ which causes loss 
of migratory ability and polarisation to the APC resulting in proliferation (Dustin et al. 1997). In 
contrast endothelial cell antigen presentation to T cells does not result in proliferation in the 
absence of cytokines (Lodge and Haisch 1993; Pardi and Bender 1991). Interestingly, EC antigen 
presentation was observed to increase migration (Marelli-Berg and Jarmin 2004a) while 
presentation by epithelial cells resulted in anergy and loss of migratory ability (Marelli-Berg et al. 
2001b). Loading of ECs with cognate antigen was observed to reduce migration of cross presented 
CD8 T cells in vitro suggesting that avidity of the signal may be important on determining the 
functional consequence of antigen presentation (Marelli-Berg et al. 2001a). 
Thus antigen recognition by ECs can directly enhance T cell transendothelial migration without 
inducing anergy leading to the hypothesis that antigens are presented by the endothelium of 
infiltrating vessels. Several in vivo studies have given evidence in support of this hypothesis. In an 
experimental autoimmune encephalomyelitis (EAE) model, expression of MHC Class II molecules 
by the vascular endothelium in the central nervous system (CNS) was demonstrated to be crucial 
for T cell infiltration to the CNS (Sobel et al. 1984).  
In another in vivo model of autoimmune diabetes in non-obese diabetic (NOD) mice, insulin 
specific CD8 T cell recruitment was abrogated in IFN-γ deficient NOD mice due to impaired 
autoantigen presentation by the MHC Class I and Class II molecules (Savinov et al. 2001). This 
effect could be reversed by systemic application of IFN-γ. In a separate study, islet specific homing 
by insulin specific CD8 T cells was impaired due to deficient insulin secretion, highlighting the 
cross presentation of local antigens by the endothelium (Savinov et al. 2003). 
A mouse model incorporating male minor histocompatability antigen HY- specific CD4 T cells 
showed selective recruitment of these CD4 T cells in the inflamed peritoneum of male but not in 
that of female mice (Marelli-Berg et al. 2004b). Visualisation of the vascular bed of the 
peritoneum showed cognate recognition of antigen by the endothelium resulted in no difference 
in rolling or adhesion but a significant increase in diapedesis. 
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In the human system, antigen presentation by ECs was revealed to increase the motility of antigen 
specific memory CD4 T cells through endothelial monolayers in vitro (Marelli-Berg et al. 1999b). In 
addition, CD8 T cell clones were shown to migrate more efficiently through murine endothelial 
monolayers treated with murine IFN-γ than through endothelial monolayers that were not 
treated (Marelli-Berg et al. 2004b). In a separate study, IFN-γ treated glutamic acid decarboxylase 
(GAD) pulsed ECs were identified to increase the migration of GAD specific T cells in vitro 
(Greening et al. 2003). Here, antibody blockade of MHC inhibited the migration. 
Collectively, these studies indicate that antigen-presenting endothelium facilitates the 
recruitment of antigen specific memory T cells to antigen-rich inflammatory sites.  
 
IFN-γ signalling and MHC upregulation  
 
IFN-γ is a type II interferon secreted by a variety of lymphoid cells that include CD4+ T cells, CD8+ 
T cells, NK cells and B cells. Also, APCs such as monocytes/macrophages and DCs are known to 
secrete IFN- γ locally, which is crucial for early host defences against pathogens. Deficiency in IFN-
γ signalling has been correlated to reduced natural resistance against bacterial, viral and parasitic 
infections in mice. IFN- γ production is controlled by cytokines such as IL-12 and IL-18. In contrast, 
IFN- γ is negatively regulated by cytokines such as IL-4, IL-10, TGF-β, and by glucocorticoids.  
The functional receptor for IFN- γ is a heterodimer composed of two ligand binding α chains 
(IFNGR1) and two signal transducing β chains (IFNGR2) (Bach et al. 1997).The IFN- γ receptor 
chains lack any intrinsic kinase/phosphatase activity and thus, associates with signalling 
machinery for signal transduction (Schroder et al. 2004). Binding of the IFN- γ to the IFN- γ 
receptor α chains enables receptor activation. The intracellular domains of the IFN- γ receptor 
bear binding motifs for the Janus tyrosine kinases (Jak)1/2 and the latent cytosolic factor, signal 
transducer and activator of transcription (STAT)1. The membrane proximal Jak binding motif LPKS 
in humans is located at residues 266-269, while, the STAT1 binding YDKPH motif are positioned at 
residues 440-444 (Schroder et al. 2004). In humans, the receptor-ligand internalisation is 
mediated through the isoleucine-leucine sequence at residues 270 and 271. 
 The Jak-STAT signalling pathway involves receptor recruitment and activation of members of 
both Janus family of kinases and the STAT family of transcriptional activators that control 
transcription of a variety of previously identified target genes. Upon ligand binding, Jak2 
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undergoes auto-phosphorylation and activation which then trans-phosphorylates Jak1 (Briscoe et 
al. 1996). This activated Jak1 then phosphorylates the tyrosine residue at the YDKPH domain 
enabling recruitment of latent STAT1 via its SH2 domain (Greenlund et al. 1995; Heim et al. 1995). 
The receptor recruited STAT1 pair (one on each α chain) becomes phosphorylated which in turn 
induces disassociation of the STAT1 homodimer and translocation to the nucleus. The SH2 
domains that are necessary for dimerization also enable the STAT1 pair to bind to the promoter 
regions of IFN-γ activation site elements to initiate/suppress transcription of IFN-γ-regulated 
genes. Consequently, STAT1 deficient mice exhibit increased susceptibility to microbial and viral 
infections (Durbin et al. 1996; Meraz et al. 1996).  
In contrast, negative regulation of the IFN-γ signalling is mediated through means of ligand-
receptor internalisation. This ligand-receptor complex enters the endosomal pathway, where the 
complex disassociates (Farrar and Schreiber 1993; Schreiber and Farrar 1993). Eventually, the 
uncoupled and dephosphorylated receptor is recycled to the cell surface while the ligand is 
degraded. Additionally, specific feedback inhibitors such as SOCS-1 inhibit IFN-γ signalling by 
binding to the Jak1/2 and interfering with the tyrosine kinase activity (Alexander et al. 1999). 
Receptor and Jak dephosphorylation can also be mediated via PTPs such as SHP-1 and SHP-2 
(Haque et al. 1997; You et al. 1999).  
IFN-γ signalling mediated upregulation multiple functions in the Class I MHC antigen presentation 
pathway to increase the quantity and diversity of peptides presented on the cell surface (In 
context of Class I MHC) (Schroder et al. 2004). Stimulation via IFN-γ induces a replacement in the 
proteasome protein subunits which increases the quantity, quality and repertoire of peptides for 
Class I MHC loading. The proteasome enzymatic subunits are β1, β2, and β5 of unstimulated cells 
are replaced with the LMP-2 MECL-1 and LMP-7 subunits upon IFN-γ signalling (Schroder et al. 
2004). These enzymatic subunits serve to increase levels and diversity of epitopes presented for 
CD8 T cell recognition in the context of Class I MHC. Furthermore, IFN-γ signalling induces PA28 
activator, which increases the peptide generation by associating with the proteasome and altering 
proteasome proteolytic cleavage (Groettrup et al. 1996). Additionally, IFN-γ signalling induces 
TAP-1 protein that transports peptides from the cytosol to the endoplasmic reticulum (ER) lumen 
(York and Rock 1996). The TAP protein also transiently associates with the Class I MHC to aid in 
efficient peptide loading (Grandea et al. 1995; York and Rock 1996). IFN-γ signalling also 
upregulates other molecules such as the tapasin and GP96 chaperones which aid in the efficient 
peptide: Class I MHC complex (Anonymous 1994; Suto and Srivastava 1995). 
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The IFN-γ signalling mediated upregulation of peptide: Class II MHC molecules occurs by 
promoting expression of several molecules including the invariant (Ii) chain, cathepsins B, H and L 
(Lafuse et al. 1995; Lah et al. 1995) and lysosomal proteases involved in the production of 
antigenic peptides for Class II MHC loading. The transmembrane Ii chain chaperone aids in 
trafficking of Class II MHC molecules from ER to the MHC II endosomal compartment 
(MIIC)(Cresswell 1994; Wolf and Ploegh 1995). Furthermore, An Ii-derived peptide, class II-
associated invariant chain peptide (CLIP) binds to the Class II MHC peptide-binding groove 
preventing inappropriate binding (Cresswell 1994; Wolf and Ploegh 1995). Regulators of peptide 
accessibility, such as DMA and DMB, remove CLIP from peptide binding grooves thus, enabling the 
groove to be accessible for peptide loading (Kern et al. 1995). Moreover, IFN-γ signalling 
upregulates Class II transactivator (CIITA) which acts as a switch for rapid upregulation of class II 
MHC molecule constituents such as the Ii chain and DM molecules (Boss 1997).  
 
Molecular mediators of antigen-dependent regulation of T cell motility 
 
Besides Class I PI3 Kinases, previous studies have identified a number of key molecular mediators 
that regulate migration in response to TCR signalling. These include the GEF Vav1 and the Rho 
GTPase Rac (Ward and Marelli-Berg 2009). Vav1−/− T cells display severe migratory defects in 
vitro and have impaired recruitment to antigen-rich tissue resulting from inability to engage 
sustained TCR signalling (David et al. 2009; Garcia-Bernal et al. 2005). T cells deficient in the Rac 
isoform Rac 2 also exhibit defects in TCR-induced signalling and proliferation as well as reduced 
chemotaxis to chemokines (Faroudi et al. 2010). On the other hand, increased Rac1 activity 
following TCR engagement leads to the loss of stable migratory polarity while T cells expressing 
constitutively active Rac1 produce multiple lamellae, lack a distinguishable uropod and exhibit 
impaired migration in vitro (Cernuda-Morollón et al. 2010). Thus, Rac1 signalling is necessary for 
regulating T cell migration by inhibiting the migratory polarity formation. This process is necessary 
for the TCR induced ‘stop signals’ that facilitate interaction with antigen presenting cells and 
retention at inflammatory sites.  
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1.1.3.4 Regulation of Migration via co-stimulatory receptors 
 
An overview of CD28 co-stimulation 
 
As previously mentioned, naïve T cells require two signals for their activation. This two signal 
model of T cell activation, first derived from the work proposed by (Bretscher and Cohn 1970), 
hypothesises that the first signal is provided through the engagement of a specific antigen in the 
context of an MHC molecule by the TCR on the T cell. The second signal, a nonspecific one, is 
provided by the engagement of certain group of receptors by a number of distinct molecular 
interactions that occur between a T cell and APC. The best characterised of these receptors is the 
CD28 co-stimulatory receptor which binds to its ligands B7-1 and B7-2 on the APC (reviewed in 
Rudd and Schneider 2003). Activation of naïve T cells without CD28 signals leads to state of long 
lasting hyporesponsive state known as T cell clonal anergy, or cell death (Schwartz 1996). In 
humans, CD28 is expressed constitutively on all naïve and activated CD4 T cells and approximately 
50% of CD8 T cells (Topp et al. 2003). Individuals of older age or with chronic infections are seen 
to have higher number of CD28 –ve T cells, suggesting loss of CD28 correlates with immune 
senescence (Posnett et al. 1999). Although, a distinct subset of immunosuppressive CD8+ T cells 
that are CD28 -ve have been identified in mice (Ben-David et al. 2007), CD28 is expressed on all T 
cells and is not down regulated with age or chronic disease (reviewed in Strioga et al. 2011).  
CD28 has been described as a positive co-stimulator of immune responses due to its effect on the 
activation of T cells. Co-ligation of CD28 with the T cell receptor reduces the threshold for 
activation by reducing the number of TCR stimulations necessary for activation and by decreasing 
the duration of TCR engagement (reviewed in Alegre et al. 2001a; Brunner-Weinzierl et al. 2004; 
Salomon and Bluestone 2001). In addition, CD28 ligation was observed to favour survival rather 
than apoptosis following TCR stimulation by the upregulation of pro-survival anti-apoptotic 
protein BCL-XL (Parry et al. 2003). Among other functions, co-ligation of CD28 is known to 
upregulate the secretion of cytokines, most importantly IL-2, a pro survival cytokine (Kane et al. 
2001). This was found to be mediated by both increased transcription of the IL-2 gene as well as 
increased stabilization of IL-2 mRNA (Parry et al. 2003). CD28 also enhances glucose metabolism 
by increasing expression of the glucose transporter Glut1 (Jacobs et al. 2008). Thus, several 
different pathways are integrated by CD28 receptor signalling to result in increased T cell 
activation and survival thus strengthening its identity as a positive co-stimulatory molecule.  
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The CD28 signalling pathway is only a part in a complex network of structurally related signalling 
pathways. Other members of the B7 family of co-stimulatory receptors include cytotoxic T 
lymphocyte associated antigen 4 (CTLA-4/CD152), the inducible co stimulatory receptor (ICOS), 
programmed death receptor 1 (PD-1) and B and T lymphocyte attenuator (BTLA)  (reviewed in 
Greenwald et al. 2005; Sharpe and Freeman 2002).These bind to their ligands B7-1/B7-2, ICOSL 
(B7h), PDL-1/PDL-2 and HVEM respectively, expressed on antigen presenting cells. While CD28 is 
constitutively expressed, the expression of the other CD28 family members by T cells is rapidly 
and transiently upregulated after activation. 
 
CD28 and Migration 
 
The CD28 co-stimulatory receptor is well known to induce signalling pathways that mediate 
adhesion and cytoskeleton rearrangements. These signalling pathways are crucial in mediating T 
cell motility and thus, CD28 has emerged as a positive regulator of T cell migration. 
Crosslinking of CD28 on human CD4 T cells induced a rapid upregulation of integrin mediated 
adhesion to fibronectin, ICAM-1 and VCAM-1 which was described to be dependent on the 
activity of the Protein kinase C (PKC) (Shimizu et al. 1992). Furthermore, CD28 was described to 
rapidly increase LFA-1-ICAM-1 interactions between T cells and B7-1 transfected melanoma cells, 
a process shown to be dependent on PKC activation (Turcovski-Corrales et al. 1995). More 
evidence suggesting a role in adhesion was provided by another study showing increased β1 
integrin-mediated adhesion of a myelomonocytic cell line following CD28 activation (Zell et al. 
1996). CD28 mediated tyrosine phosphorylation of the adaptor molecule Casitas-B-lineage 
lymphoma protein (CBL)-B at its cytoplasmic Src homology 2 (SH2) domain resulting in 
recruitment and activation of PI3-kinase was observed to be the driving molecular mechanism of 
this phenomenon (Krawczyk et al. 2005; Zell et al. 1998). Interestingly, this pathway was noted to 
be distinct from the direct association of PI3K with the SH2 binding domain motif (Wooten et al. 
1999). CD28 also plays an important role in cytoskeletal rearrangements in T cells. CD28 triggering 
induced upregulation of F actin through the activity of the Ras homologue GTpases Rac1 and 
Cdc42 (Kaga et al. 1998; Salazar-Fontana et al. 2003). In a separate study, Cdc42 activation 
following CD28 engagement was described to occur through the action of Src kinases 
independently of ZAP 70 (Zeta-chain-associated protein kinase 70) activation through TCR 
engagement (Salazar-Fontana et al. 2003). In the study by (Michel et al. 2000), CD28 was 
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observed to activate Vav1 independently of the TCR.  In addition, CD28 engagement induced actin 
polymerisation through interaction with the Wiskott-Aldrich syndrome protein (WASp) via PI3-
Kinase (Badour et al. 2007). WASp protein is also known to couple TCR signals with cytoskeletal 
rearrangements (Watanabe et al. 2013). 
In vivo experimental models of autoimmune diseases were crucial for establishing a role of CD28 
in the regulation of T cell migration. Using these models, loss of CD28 signalling was shown to lead 
to inefficient localisation of T cells following priming. In a model of EAE, CD28 deficient mice 
showed significantly delayed type hypersensitivity and reduced disease severity while CD28 
deficient T cells continued to exhibit vigorous responses to myelin derived antigens ex vivo (Girvin 
et al. 2000). Interestingly, in the absence of CD28 ligands the adoptive transfer of 
encephalitogenic T cells localised to meningeal but not to parenchymal sites of the CNS (Chang et 
al. 1999). In a separate study utilizing an EAE model in female NOD mice, antibody blockade of the 
CD28 ligands CD80 and CD86 abrogated tissue infiltration, inflammation and demyelination 
(Chang et al. 1999; Girvin et al. 2000). 
CD28 can also affect the migration of primed T cells to the germinal centers (GC) of secondary 
lymphoid organs in order to sustain B cell responses. In one study, CD28 dependant upregulation 
of OX40 was observed to be crucial for the upregulation of the chemokine receptor CXCR5 
(necessary for migration to B cell zones) (Walker 1999). In addition, CD28-deficient mice failed to 
develop GCs in the Peyer’s patches, spleen, or other peripheral lymph nodes. 
Direct evidence implicating CD28 in the regulation of primed T cell migration to antigenic tissue 
was provided by a study utilizing transgenic mice bearing a point mutation at the PI3K binding 
motif (YMNF) of the cytoplasmic tail of the CD28 receptor (CD28Y170F) (Mirenda et al. 2007). T cells 
from these CD28Y170F mice bear a CD28 receptor unable to recruit class I PI3Kinases but still 
maintain normal clonal expansion and IL-2 production (Okkenhaug et al. 2001). In the study by 
(Mirenda et al. 2007), OT II (ovalbumin specific, MHC class II restricted TCR transgenic) and OT-
II/CD28Y170F double transgenic mice were generated and their T cells were described to proliferate 
equally following immunization with ovalbumin. However, only OT II T cells were able to localise 
to ovalbumin-expressing peritoneal cavity and tissue suggesting that PI3K recruitment via the 
YMNF motif was crucial for recruitment of T cells to antigenic sites.  
It has also been observed that dominant CD28 signalling can override the regulation of memory T 
cell trafficking by the TCR and homing receptors and lead to unregulated T cell trafficking to non-
lymphoid tissue (Mirenda et al. 2007). Optimal antibody activation of CD28 in HY-specific H2-Db-
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restricted CD8+ T resulted in the unregulated infiltration of various organs such as the gut, liver, 
kidney spleen and heart in syngeneic female mice. This effect occurred specifically in memory 
rather than naïve T cells and the effect was abrogated in memory CD28Y170F HY-specific CD8+ T 
cells (Mirenda et al. 2007). 
Conversely, this enhanced homing of T cells to multiple organs involved a vast number of memory 
T cells and not naïve T cells and may explain the effects seen in patients treated with a humanised 
CD28 super-agonist (TGN1412) in the TeGenero Trial at Northwick Park. Here, healthy human 
volunteers, after receiving this CD28 super-agonist, were reported to suffer from multiple organ 
failure and a ‘cytokine storm’ which is believed to have occurred due to uncontrolled infiltration 
of memory T cells into non-lymphoid tissue causing damage to the tissue through the release of 
pro-inflammatory cytokines TNFα, IL-2, IL-10 and IFN−γ (Suntharalingam et al. 2006). Given that in 
humans 50% of T cells are of a memory phenotype compared to that of laboratory mice which 
have a relatively large naïve T cell repertoire, it is plausible that the superagonist may have 
triggered unregulated non lymphoid tissue infiltration by memory T cells that would not be seen 
in mice kept in sterile conditions (Eastwood et al. 2010) (reviewed in Marelli-Berg et al. 2007). 
 
In this context, it is important to note that it is highly likely that co-stimulation mediated 
regulation of migration results from interaction with antigen presenting cells rather than ECs that 
are also know to display antigens in response to inflammatory stimuli (reviewed in Marelli-Berg et 
al. 2007). Evidence supporting this includes the observation that human ECs do not express B7 co-
receptors while, murine ECs only express low levels of B7-1 (Marelli-Berg et al. 1999a; Marelli-
Berg et al. 2000). Furthermore murine ECs do not upregulate B7-1/2 expression in response to 
cytokine mediated stimulation (Marelli-Berg et al. 2000). Similarly, immature dendritic cells also 
express very low levels of B7 molecules.  
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CTLA-4: an overview. 
 
Cytotoxic T-Lymphocyte Antigen 4(CTLA-4), also known as CD152, is a negative regulator of the 
immune responses. CTLA-4 bears significant structural similarities and shares approximately 30% 
homology with CD28. It also shares binding specificity to the CD28 ligands CD80 and CD86 and 
actively competes for its ligands (Walker and Sansom 2011).  However, the binding affinity of 
CTLA-4 to its ligands is 20-50 fold higher and exhibits different kinetics in vitro. The regulation of 
the negative signals provided by CTLA-4 is believed to be a consequence of its tightly regulated 
and timely expression.  
While CD28 is constitutively expressed by T cells, surface expression of CTLA-4 on T cells, 
excluding regulatory T cells, only occurs after activation (Brunet et al. 1987; Freeman et al. 1992; 
Linsley et al. 1992). In resting T cells, little CTLA-4 is expressed on the surface with the majority 
mainly located within intracellular vesicles (Alegre et al. 1996a; Linsley et al. 1996). This occurs by 
virtue of its interaction with the u2 subunit of the clathrin adaptor protein complex AP2 (Chuang 
et al. 1997; Y. Zhang and Allison 1997). TCR engagement rapidly induces trafficking of CTLA-4 from 
the intracellular vesicles to the cell surface with maximal expression reported to occur between 
48-72 hours post-activation (M. L. Alegre et al. 1996b; Linsley et al. 1996). However, CTLA-4 
endocytosis processes are still seen to occur even at the stage of maximal surface expression. 
Thus, the expression of CTLA-4 by activated T cells is transient, as this molecule is rapidly 
internalised by endocytosis. 
The contribution of CTLA-4 signal to the regulation of T cell migration was first reported by studies 
in CTLA-4 knockout mice. These mice rapidly developed lymphoproliferative disease with 
multiorgan lymphocytic infiltration, tissue destruction, severe myocarditis, pancreatitis, and died 
by 3-4 weeks of age. (Tivol et al. 1995; Waterhouse et al. 1995)  
 
CTLA-4 function  
Unlike CD28, much less is known about how CTLA-4 functions as a negative modulator of immune 
responses. Several models have been proposed to explain its mode of action (reviewed in Rudd 
2008; Walker and Sansom 2011). These models can be further divided into those in which CTLA-4 
ligation affects the T cell that expresses it (cell-intrinsic models) and those in which CTLA-4 carries 
out its effects through other cells (cell extrinsic models) 
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Cell intrinsic mechanisms 
 
CTLA-4 has a similar ligand specificity as CD28 for its ligands CD80 and CD86, however CTLA-4 
binds with a 50 -100 fold greater avidity to them. Thus, one model hypothesises that the CTLA-4 
functions by simply outcompeting CD28 for its ligands. Evidence in favour of this hypothesis was 
given in the study by (Masteller et al. 2000). In their study, a truncated variant of the CTLA-4 gene 
lacking its cytoplasmic domain, necessary for signalling, was described as ‘sufficient’ in retarding 
the disease onset in CTLA-4-/- mice (Masteller et al. 2000). High expression of this gene variant in 
CTLA-4-/- deficient mice did result in lymphodenopathy but little tissue infiltration. As such, the 
mice survived to adulthood and were able to reproduce. This suggested that the binding 
ectodomain of CTLA-4 could compete with the CD28 molecule thereby preventing positive co-
stimulation and subsequently proliferation of the T cells. It also suggested that the cytoplasmic 
domains were necessary for preventing the massive tissue infiltration observed in CTLA-4 
deficient mice. However, these observations were complicated by the fact that CD28 signalling 
was required for the onset of the disease in CTLA-4-/- mice (Tivol 1997). Conversely, blockade of 
CD28 by means of an antibody or through expression of an inhibitory variant of the CD28 gene 
could prevent the disease in CTLA-4-/- mice (Tai et al. 2007). Furthermore, since conventional T 
cells only express CTLA-4 after activation, it is unlikely that this mechanism would restrain the 
priming of naïve cells (Walker and Sansom 2011).  
Another mechanism through which CTLA-4 functions in T cells was described by imaging studies 
analysing the formation of lipid rafts that act as platforms for signalling in T cells. While CD28 
signalling was shown to promote lipid raft formation following TCR stimulation, CTLA-4 had an 
opposite effect (Chikuma et al. 2003; Martin et al. 2001; Rudd et al. 2002). Thus this model 
hypothesises that CTLA-4 functions by simply decreasing the formation of these lipid rafts in naïve 
T cells which hold key components required for TCR signalling. However, this model suffers a 
caveat in that the CTLA-4 effect on secondary responses are much less pronounced than that 
observed in naïve T cells even though the total CTLA-4 in naïve T cells is likely to be much lower. 
A similar model showed that CTLA-4 ligation inhibits the formation of microclusters (Schneider et 
al. 2007). Following TCR ligation, TCR molecules arrange themselves into packed structures at the 
point of engagement. These ‘microclusters’ assemble the necessary signalling proteins and 
tyrosine kinases within seconds of TCR ligation (Yokosuka 2005). These include the kinase 
ζ‑chain‑associated protein kinase of 70 kDa (ZAP70) and adaptors, such as the Linker for 
activation (LAT) and SH2‑domain‑containing leukocyte protein of 76 kDa (SLP76) (Bunnell 2006; 
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Yokosuka 2005). In (Schneider et al. 2007)‘s study, co-ligation of TCR and CTLA-4 blocked the 
formation of ZAP70 containing microclusters in T cells. The resulting impairment of microcluster 
formation was thought to dampen the TCR signals necessary for T cell proliferation. Another study 
by (Yokosuka 2010), gave a spatiotemporal basis for CTLA-4 mediated negative signalling at the 
central supramolecular activation cluster (cSMAC) of the immunological synapse. In this study, 
CTLA-4 directly competed with CD28 for its ligands at the cSMAC, ultimately resulting in the 
exclusion of CD28 from the cSMAC. This study provides further evidence for competition between 
CD28 and CTLA-4. In addition, their observations indicated that CTLA-4 inhibited the translocation 
of Protein kinase C θ (PKCθ) and a scaffolding protein CARMA1 necessary for CD28 mediated 
positive co-stimulation at the cSMAC, thus, providing further negative regulation.   
Another model hypothesises that CTLA-4 exerts is negative regulation by engagement of negative 
signalling molecules that regulate TCR signalling. CTLA4 is thought to bind the protein tyrosine 
phosphatases (PTPases) SHP2 (sRC homology 2 (SH2)‑domain‑containing PTPase 2) (K. M. Lee 
1998) , PP2A (protein phosphatase 2A) (Chuang 2000) and SYP (also called PTPN11) (Marengere 
1996).These phosphatases are known to inhibit T cell activation by dephosphorylating key 
signalling molecules downstream of the TCR. Evidence in favour of this was given in the studies by 
(Martin et al. 2001; Schneider 2002). Here, antibody-induced co-ligation of CTLA-4 with the TCR 
reduced phosphorylation of CD3ζ and the linker for activation of T cells (LAT) along with reduction 
in phosphorylation levels of the extracellular-signal-regulated kinases (ERKs). While LAT proteins 
bind other activating proteins downstream, ERKs are required for the production of IL-2. Indeed, 
CTLA-4 deficient cells show reduced ERK activity. However, this model too has some downfalls. 
Firstly, CTLA-4 does not bear binding sites for the SHP2 molecules suggesting an indirect 
connection (H. Schneider and Rudd 2000). In addition, SHP2 has also been described to be a 
positive regulator of ERKs (Frearson and Alexander 1998). Secondly, while PP2A clearly inhibits 
cell growth by acting on Protein Kinase B (PKB/ Akt), a kinase with multiple functions within the 
cell, there is low level of CTLA-4 binding to PP2A relative to its great abundance in the cells and 
several reports have also identified CD28 to bind PP2A (Chambers and Allison 1999). The 
relationship between PP2A and these co-stimulatory molecules remains to be investigated. 
Nonetheless, it is plausible that phosphatases such as PP2A and SHP2 may be utilised by CTLA-4 to 
provide negative regulation to the T cells. In a separate study, ligation of CTLA-4 led to the 
upregulation of E3 ligase Casitas B‑lineage lymphoma B (CBL‑B), an E3 ligase of the ubiquitylation 
pathway that has been linked to autoimmunity (Bachmaier 2000; Chiang 2000). CBL-B deficient 
mice develop autoimmunity but fail however to develop the lethal disease exhibited in CTLA-4 
deficient mice (Bachmaier 2000). 
    Introduction 
56 
 
Finally, CTLA-4 has been proposed to function by inducing the reversal of the TCR induced stop 
signal (reviewed inRudd 2008). TCR triggering initiates a reduction or slowing of T cell motility. 
This ‘stop signal’ was observed to be necessary to form stable contacts with APCs, thus, allowing 
for the formation of the stable immunological synapses between the T cells and APCs (Dustin et 
al. 1997). (Schneider 2006) demonstrated that triggering of CTLA-4 reverses this stop signal both 
in vivo and in vitro. Furthermore, CTLA-4 deficient cells were described to have reduced motility 
and more stable contacts when treated with peptide pulsed antigen presenting cells in vitro. This 
model also suggests that the increase in motility following CTLA-4 triggering could be explained 
through increased activation and clustering of LFA1 via means of recruitment of the GTPase RAP1 
by CTLA-4 (Dillon et al. 2005). Although high affinity LFA-1 interaction with its ligand inter cellular 
adhesion molecule (ICAM-1) is required for cell immobilization, it is also required for increased 
cell motility. Indeed, CTLA-4 deficient T cells showed impaired adhesion to ICAM-1 in vitro 
(Schneider et al. 2005). Thus, this model hypothesises that CTLA-4 functions by reversing TCR 
mediated stop signals which reduce the dwell times of T cell with APCs ultimately raising the 
threshold for activation. 
 
Cell extrinsic mechanisms 
 
Initial studies investigating the role of the B7 pathways in T cells showed that CTLA-4 blinding to 
CD80 and CD86, expressed by antigen presenting cells greatly reduced the activation of the T cells 
(Krummel and Allison 1995).  
One mechanism believed to explain the extrinsic function of CTLA-4 is through the activation of 
the enzyme Indoleamine 2,3-dioxygenase (IDO). The interaction of CTLA-4Ig to CD80 and CD86 
expressed on antigen presenting dendritic cells stimulates them to express IDO (Fallarino 2003; 
Grohmann 2002). IDO catabolises the amino acid tryptophan into kynurenine, a tryptophan 
catabolite toxic to T cells neighbouring the dendritic cells thereby suppressing immune activation 
and preventing further activation of effector T cells (Munn 1999). Evidence to support this was 
given in the study where an IDO inhibitor 1- methyltryptophan (1MT) prevented the CTLA-4Ig 
induced survival of pancreatic islet allografts (U. Grohmann et al. 2002). However, this function of 
CTLA-4 still is another controversial topic. This is due to the fact that IDO-deficient mice lack the 
phenotype seen in CTLA-4 deficient mice. Additionally, 1MT was also observed to modify DC 
function independently of IDO (Agaugue et al. 2006).  
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Preliminary studies observing CTLA-4 expressing T cell interaction with APCs showed that CTLA-4 
engagement with CD80/86 on the APC resulted in the downregulation of these molecules without 
any effect on other co stimulatory molecules ligands such as CD40 or even MHC Class II (Oderup 
et al. 2006; Schildknecht 2010). Interestingly this effect was not inhibited through the action of 
the IDO inhibitor 1MT (Oderup et al. 2006).  
Recent studies have indicated that CTLA-4 can physically remove its natural ligands on APCs 
following binding thereby reducing positive co-stimulation by CD28 (Soskic et al. 2014; Walker 
and Sansom 2015). Elegant Imaging studies revealed that following binding to its natural ligands, 
these are removed from the APC and CTLA-4:B7 complexes undergo rapid endocytosis and are 
degraded within lysosomes. (Hou et al. 2015a; Qureshi et al. 2011) In essence, this model 
represents an extension of the direct competition model between CD28 and CTLA-4, whereby 
CTLA-4 not only competes with CD28 for its ligands but also reduces their availability to CD28.  
One of the simplest models believed to account for CTLA-4 function hypothesises that ligation of 
CTLA-4 expressed on regulatory T cells switches on their suppressive ability. In the study by 
(Barnes et al. 2013), the B7 ligands CD80 and CD86 were capable of inducing Foxp3+ Treg 
populations in vitro and in and in an in vivo T cell transfer model of colitis. Additionally, the 
authors observed enhanced expression of Foxp3, a key nuclear transcription factor for regulatory 
T cell function, following the B7 ligand treatment. Regulatory T cells (Tregs) express CTLA-4 
constitutively and are able to suppress the activation of conventional T cells (described in 1.2.2). 
The role of CTLA-4 in Treg cells will be discussed in section 1.2.2.1. 
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CTLA-4 and migration 
 
Whether the CTLA-4 co stimulatory molecule functions to mediate pro or inhibitory migratory 
signals remains as yet controversial. It is likely that CTLA-4 may regulate migration of T cells in 
conjunction with signals from the TCR or even through means of inhibiting pro migratory signals 
induced by CD28 stimulation. 
As mentioned previously, CTLA-4 triggering induces clustering of LFA-1 integrin in vitro through 
the activation of the small GTPase Rap1 (Dillon et al. 2005; Katagiri 2000). In addition, CTLA-4 
ligation was noted to enhance motility of T cells on ICAM-1 coated plates and thus is believed to 
share similar adhesion and motility regulating signalling pathways and effects as CD28 (Schneider 
et al. 2005). 
However, in vivo studies have showed that CTLA-4 ligation induces signals that are antagonistic to 
CD28 induced pro-migratory signals at least during T cell migration to non-lymphoid tissue 
(reviewed in Marelli-Berg et al. 2007). CTLA-4 is thought to negate the CD28 signals that positively 
regulate T cell extravasation through endothelial barriers at the site of antigen localisation. This 
was clearly demonstrated in the studies showing that intra-peritoneally injected, CTLA-4 ligated, 
CD8+ HY-specific restricted C6 T cells clones were prevented from entering the peritoneal 
membrane (Mirenda et al. 2007). Interestingly, this negative regulation of endothelial 
extravasation of T cells by CTLA-4 occurred in a strictly “cognate recognition of antigen”-
dependant i.e in conjunction with antigen-receptor triggering. 
Finally, it was proposed that CTLA-4 may provide its inhibitory effects on migration of T cells by 
reversing CD3/CD28-mediated phosphorylation via the selective recruitment of phosphatases 
such as SHP-1 and SHP-2. The cytoplasmic domain of CTLA-4 has been reported to interact with 
the tyrosine phosphatase SHP-2 and the serine/threonine phosphatase PP2A.  
In one in vivo study, migration of Th1 differentiated CD4+ T cells to sites of inflammation was 
increased via enhanced chemotaxis towards chemokines ligands of CCR5 and CCR7 when CTLA-4 
signals were given together with CD28 and TCR signals (Knieke et al. 2009). In the same study, 
CTLA-4 signals appeared to increase activation of the PI3K-Akt pathway induced by the CCR5 
ligand CCL4. 
In summary, the overall effect of CTLA-4 signals on PI3Kinase activation and T cell motility remains 
controversial. 
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The interplay between CD28 and CTLA-4 signals in the regulation of T cell migration 
 
Both CD28 and CTLA-4 are known to impact signalling downstream of the TCR. However, a 
thorough analysis of the competition between signals from the two opposing co-receptors as well 
as the selective use of signalling pathways that affect migration are yet to be defined. Recently, a 
study by (Jain et al. 2013), demonstrated that CD28 and the interleukin-2 (IL-2)–inducible Tec 
kinase (ITK) regulate the trafficking of autoreactive T cells. PI3K signalling enables ITK recruitment 
to both the T cell receptor (TCR) and CD28 upon stimulation. Phosphorylation of ITK activates 
phospholipase C-γ1, leading to calcium (Ca2+) mobilization and actin polarization to the site of 
TCR stimulation. In addition, ITK has also been observed to become activated through β1 integrins 
and is involved in Cdc42- and Rac-mediated chemokine-induced migration (Takesono et al. 2004). 
In this study, concurrent ablation of CD28 and ITK enabled self-reactive Ctla4−/− T cells to 
accumulate in secondary lymphoid organs without blocking spontaneous T cell activation. 
Additionally, the authors (Jain et al. 2013) demonstrated that the Itk−/−Ctla4−/− mice remain 
healthy, mount antiviral immune responses and exhibit a long lifespan, even though excessive 
spontaneous T cell activation and proliferation in lymphoid organs is observed.   
Similarly, other signalling pathways that are engaged by these co-stimulatory receptors, and 
display common points of interaction, may account for their roles in regulation of migration of T 
cells. Yet, these pathways remain to be investigated. 
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CD31 as a negative co-stimulator of T cells 
 
Previously we have described CD31 as a crucial mediator of TEM facilitating recruitment of 
leukocytes to inflammatory sites. As mentioned before, CD31 is a multifaceted Ig-like molecule 
that has been described to have both pro-inflammatory and anti-inflammatory functions. While 
the pro-inflammatory role largely accounts from its ability to facilitate TEM of leukocytes towards 
inflamed tissues, its anti-inflammatory roles are thought to occur via two mechanisms.  
Firstly, CD31 is important for the maintenance of the vascular barrier integrity (Privratsky et al. 
2011). This function of CD31 was first described by (Ferrero et al. 1995) who showed that 
treatment with a blocking antibody specific for CD31 increased the permeability of endothelial 
monolayers in vitro.  In another study, CD31 deficient mice exhibited increased inflammatory cell 
infiltration into the brain parenchyma in a model of EAE, and this phenotype was correlated with 
enhanced barrier function of CD31- expressing endothelial monolayers (Graesser et al. 2002).  
Secondly, and more importantly for this study, several reports have highlighted CD31 as a crucial 
immuno-regulatory receptor acting to suppress leukocyte activation and cytokine secretion. A 
summary of all these reports, adapted from (Privratsky et al. 2010) are highlighted in the Table 2 
given below. We shall, however, describe the immunomodulatory role of CD31 in detail in the 
next section. 
 
 
    Introduction 
61 
 
 
Table 2    Anti-inflammatory functions of CD31 
This table lists various studies where CD31 expression has had an anti-inflammatory effect either 
delaying or reducing disease severity in disease models. It also indicates studies where CD31 
crosslinking or ligation has shown to incite anti-inflammatory functions. This table is adapted from 
(Privratsky et al. 2010) 
 
Signalling Function of CD31 
 
CD31 medites its intracellular signalling via the two ITIM motifs in the cytoplasmic tail (Newman 
and Newman 2003). Upon homophilic or heterohpilic engagement of CD31 or through the action 
on other stimuli (TCR triggering), the tyrosine residues at postions 663 and 686 within these ITIM 
domains become phosphorylated. However, CD31 is generally not found to be tyrosine 
phosphorylated in cells maintained in a resting state. Since CD31 does not bear an intrinsic 
kinase activity, the exact kinases involved in this process have been the subject of intense 
investigation.The Src family of kinases is thought to be the dominant kinase family involved in 
this process (Cao et al. 1998; Cicmil et al. 2000). However, studies have identified Src-
independent tyrosine phosphorylation of CD31 via the Csk and Syk family of protein kinases 
(Cao et al. 1998; Sagawa et al. 1997). Once phosphorylated, these ITIM motifs allow for the 
recruitment of  Src homology 2 (SH2) domain–containing signaling proteins which can then 
initiate signalling pathways further downstream. 
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CD31 inhibitory receptor signalling extends to several cell types such as mast cells, macrophages 
and dendritic cells and lymphocytes. In a study by (Wong et al. 2002), CD31 signals suppressed 
mast cell activation, which prevented systemic and local IGE-dependent anaphylactic reactions 
when animals were challenged with allergic stimuli. In macrophages, ligation of CD31 by the 
CD38-Fc fusion protein was identified to negatively regulate TLR-4 signalling likely through 
ITIM/SHP-2 interactions (Rui et al. 2007). Recently, in DCs, activating the CD31/SH2 domain-
containing tyrosine phosphatase-signalling pathway with an agonist was described by (Clement et 
al. 2014) to reduce DC maturation. This rendered them more tolerogenic towards recall antigens 
in both in vitro and in vivo. 
 
CD31-mediated inhibition of Leukocyte activation    
 
CD31-mediated inhibition of T cell activation was first identified in the study by (Newton-Nash 
and Newman 1999) where CD31 was described to attenuate TCR-induced mobilization of calcium 
from intracellular stores. Recently, a study by (Ma et al. 2010) provided direct evidence that CD31 
regulates T cell activation in vivo through partial inhibition of proximal TCR signalling, specifically 
Zap-70 phosphorylation. In B cells, the reduction of calcium mobilization following CD31 
crosslinking was shown to be mediated by recruitment of SHP-2 phosphatase via the cytoplasmic 
ITIM domains of CD31 (D. K. Newman et al. 2001). Together, these studies indicate that CD31 can 
inhibit activation of T and B cells by recruiting (SH2) domain-containing tyrosine protein 
phosphatases that dephosphorylate key mediators in the proximal TCR/BCR signalling thereby 
increasing the overall threshold for activation. Figure 3 adapted from  (Marelli-Berg et al. 2013) 
depicts an overview of CD31-mediated inhibition of T cell activation.  In support of this notion, 
CD31 deficient mice exhibit aberrant proliferation and activation of B cells, which correlates with 
the development of autoimmune disease in older mice (Wilkinson et al. 2002).  
Even though the studies mentioned above suggests that the CD31 negatively inhibits T cell 
activation, CD31-deficient mice do not display autoimmune symptoms under steady state 
conditions and instead, exhibit a very mild phenotype with a normal number of T cells (G. S. 
Duncan et al. 1999a). However, under conditions of inflammatory stress, lack of CD31 affects the 
extent of T-cell mediated inflammation in mice. Given below is a table adapted from (Marelli-Berg 
et al. 2013) that describes various models of disease that have been studied in CD31-deficient 
mice and the effect of CD31 deficiency on the outcome of the disease.  
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The absence of any autoimmune symptoms in CD31 deficient mice during steady state conditions 
(i.e. absence of any inflammation/immune response) may be a consequence of an additional role 
of CD31 in maintaining cell survival in leukocytes. In (Ma et al. 2010)’s study, CD31-deficient mice 
exhibited accelerated and pronounced allograft and tumour rejection. However, their study also 
revealed that, following the enhanced expansion, CD31 deficient T cells displayed increased 
activation-induced cell death (AICD). This result was credited to CD31 signalling-mediated 
activation of the extracellular-signal-regulated kinase (Erk), which associates with pro-survival 
pathways independently of TCR signalling. In a separate study by (Ross et al. 2011), using a model 
of salmonella infection, CD31-deficient mice displayed delayed clearance of pathogens, in spite of 
increased T cell activation. The authors claimed that increased proliferation and activation by the 
CD31-deficient CD4 T cells did not increase pathogen clearance as reduced survival following 
proliferation resulted in slower accumulation of activated cells, which are essential for pathogen 
removal. Thus CD31 signalling not only increases the threshold for T cell activation, but, also 
increases T cell survival.     
 
Table 3    CD31-Deficiency in disease models 
The table given above describes various studies that indicate the effect of CD31 deficiency in a 
disease models and is adapted from (Marelli-Berg et al. 2013) 
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Figure 3    CD31-mediated inhibition of T cell activation and induction of Erk 
This figure indicates how CD31 increases the threshold for T cell activation. The recruitment of 
(SH2) domain-containing tyrosine protein phosphatases that dephosphorylate key proximal TCR 
kinases inhibits activation and regulates proliferation. CD31 signalling also induces Erk 
phosphorylation that protects against TCR induced AICD. Figure adapted from(Marelli-Berg et al. 
2013). 
 
CD31-mediated inhibition of cytokine production    
 
Although incompletely understood, several reports have highlighted the role of CD31 in regulating 
cytokine production. Studies by (Maas et al. 2005) and (Carrithers et al. 2005) showed that CD31 
suppressed the production of pro-inflammatory cytokines following exposure to endotoxin. 
Another study by (Tada et al. 2003), reported enhanced production of the pro-inflammatory 
cytokine IFN-γ by the CD31 deficient lymphocytes in response to collagen in a CIA model. In 
another report, CD31 suppressed cytokine production in a model of non-alcoholic steatohepatitis 
(Goel et al. 2007). In DCs, loss of CD31 from the surface following maturation has been associated 
with their increased production of inflammatory cytokines (Clement et al. 2014). The exact 
mechanism through which CD31 regulates cytokine production remains elusive. However, (Rui et 
al. 2007) have reported the involvement of the inhibition of c-Jun N-terminal kinase (JNK), nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) and interferon regulatory factor 3 
(IRF-3) signalling pathways by CD31 signalling in macrophages.  
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CD31 and T cell migration 
 
In recent years, studies have tried to elucidate the role of CD31 in leukocyte recruitment. In vitro 
studies that used antibody-mediated blockade of CD31 were the first to show the importance of 
CD31 in TEM of T cells. Studies by (Manes et al. 2010; Manes and Pober 2011) revealed that anti–
CD31 antibody blocking abrogated TCR-dependent migration of human effector memory CD4 T 
cells induced by APCs. 
Previous in vivo studies were unable to determine the impact of CD31 signalling selectively on T 
cell migration as they did not distinguish the effect of the CD31-deficiency in T cells and the 
endothelium separately (reviewed in Marelli-Berg et al. 2013). Recently, conclusive evidence to 
suggest a role for CD31 in T cell trafficking was provided by the study by (Ma et al. 2012). In their 
study, CD31-deficiency resulted in impaired trafficking of naïve T cells to the secondary lymphoid 
tissue. Here, CD31-/- naïve T cells adoptively transferred into CD31-expressing (CD31+/+) WT mice 
displayed reduced migration into the secondary lymphoid tissues as compared to CD31-
expressing naïve T cells. However, CD31-deficient mice display normal colonization of secondary 
lymphoid structure. Thus, it is likely that this effect is masked through compensatory mechanisms 
from other molecules involved in TEM (reviewed in Nourshargh and Marelli-Berg 2005). 
In addition, this study demonstrated that CD31-deficiency impaired constitutive trafficking of 
effector T cells and inflammation-induced extravasation into antigen-rich tissue sites. Here, 
effector memory HY (male antigen)-specific T cells, from female CD31-deficient mice, were 
adoptively transferred into male mice. The authors demonstrate that, under non-inflammatory 
conditions, CD31-deficient HY-specific T cells show significantly impaired ability to access non 
lymphoid, non-antigenic tissue of the CD31 competent male mice when compared against WT HY-
specific T cells. Interestingly, when the HY-specific T cells from WT female mice were adoptively 
transferred to CD31-deficient male recipients, similar results were also observed by the authors. 
This suggests that CD31 interactions between T cell and endothelium are essential for the 
constant re-circulation of effector memory T cells into non-lymphoid tissue. When the 
experiments were repeated under inflammatory conditions, induced by IFN-γ injection to the 
peritoneum, HY-specific T cells from CD31-deficient female mice were demonstrated to have 
impaired migration to antigen rich peritoneum of WT male mice. However, when HY-specific T 
cells from WT female mice were adoptively transferred into CD31-deficient or WT male recipients 
treated with IFN-γ, recruitment of HY-specific T cells from CD31 deficient to the peritoneum was 
significantly increased. Thus, antigen-specific memory T cell extravasation under inflammatory 
    Introduction 
66 
 
conditions was enhanced by the selective lack of CD31 on the endothelium. This is in line with 
earlier observations that indicate enhanced disease severity in experimental models of 
autoimmune disease in CD31-deficient mice (reviewed in Marelli-Berg et al. 2013; Privratsky et al. 
2010).      
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1.2 Regulatory T cells  
 
A hallmark feature of the immune system is the ability to effectively recognise and mount an 
immune response against a foreign pathogen or antigen while maintaining a state of acceptance 
to antigens that are expressed natively. This state of acceptance, also described as ‘tolerance’ is 
clearly observed in transplantation settings where the immune system of the recipient fails to 
initiate immune responses against antigens present in the syngeneic donor grafts while readily 
rejecting mis-matched donor grafts following a strong immune reaction to its allo-antigens.  
Under steady state conditions, failure of the immune system to distinguish between self and non-
self can be linked to the development and onset of progressing autoimmune diseases. Originally 
thought to be only dependent on negative selection in the thymus (central tolerance, tolerance is 
now recognised as a dynamic aspect of the mature immune system (peripheral tolerance), where 
many auto/self-reactive T cells (T cells expressing TCRs for self-antigens) are present in a normal T 
cell repertoire (Yan and Mamula 2002). These self-reactive T cells are kept at bay through the 
action of a number of mechanisms.  
Regulatory T cells are crucial in the maintenance of peripheral tolerance. Historically, regulatory T 
cells were identified as T suppressor cells due to their ability to suppress the activation of other T 
cells and subsequently the immune response (reviewed in Sakaguchi et al. 2007). The ability of 
these cells to maintain tolerance is best exemplified by the severe systemic autoimmunity and 
lymphoproliferative disease observed in FoxP3-deficient (Scurfy) mice and in humans carrying 
mutations in the FOXP3 gene, the expression of which is crucial for Treg function. Besides 
preventing autoimmunity, Tregs play a key role in regulating immunity against infections of viral, 
bacterial and parasitic origin (reviewed in Q. Tang and Bluestone 2008b). Thus these cells retain a 
dual role in not just regulating protective anti-tumour and anti-pathogen immunity, but also in 
preventing inflammatory disease by restraining aberrant responses to innocuous antigens. 
Regulatory T cells are a small subset of CD4+ T cells that exist within the body as a heterogeneous 
population exhibiting different surface receptors depending on their localisation and functional 
state. Regulatory T cells can be broadly classified into two categories: naturally occurring 
regulatory T cells (nTregs) which develop in the thymus and inducible regulatory T cells (iTregs) 
that develop in the periphery (reviewed in Curotto de Lafaille and Lafaille ; Sakaguchi et al. 2008; 
Sakaguchi et al. 2010). nTregs mature from thymocytes expressing T cell receptors with weak 
affinity to self-antigens that escape the process of thymic selection. Inducible Tregs develop from 
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conventional naïve CD4+ T cells following stimulation under tolerogenic conditions. These 
conditions may include, but are not limited to, the action of TGF- β and IL-10. While nTregs and 
iTregs share expression of a number of markers and surface receptors, the stability of the FOXP3 
gene expression was observed to be quite distinct between the two populations. In a mouse 
model of transplantation, a comparison of the efficacy in preventing rejection in transplants 
showed nTregs to perform substantially better. iTregs generated in vitro lost Foxp3 expression, 
their ability to maintain tolerance and regained some of their effector function facilitating graft 
rejection (Tonkin et al. 2008). Following this, a gene microarray analysis of the genome of nTregs 
and iTregs revealed differences in the methylated and unmethylated states of key genes 
associated with the stable expression of the FOXP3 gene (Waight et al. 2015).  
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1.2.1 Treg generation and differentiation 
 
1.2.1.1 TCR in Treg development 
 
Tregs develop in the thymus from the pool of double positive (DP) cells and TCR engagement with 
self-peptide-MHC Class II complex and CD28-B7 interactions are crucial for this process (Maloy 
and Powrie 2001). Mice with transgenic TCRs for foreign or non-thymically expressed proteins 
such as chicken ovalbumin or myelin basic protein bred onto RAG deficient backgrounds bear very 
few or no Tregs. While on a RAG sufficient background, TCR specific for self-peptides allow for the 
generation of Tregs (Apostolou et al. 2002; Itoh et al. 1999; Olivares-Villagomez et al. 2000). 
Interestingly, mice expressing cognate antigen in TCR-transgenic mice develop a higher 
proportion and number of Tregs (Jordan et al. 2001; H.-M. Lee et al. 2012). Thus, TCR recognition 
of self-peptides is essential for the thymic generation of nTregs. 
Tregs develop in the thymus with a TCR repertoire that overlaps with that of autoreactive T cells 
in Foxp3-deficient mice. It is widely believed that naturally occurring Tregs develop with TCRs with 
avidity to self-peptide MHC II which is intermediate between positive selection (weak avidity) and 
negative selection (strong avidity) (Hsieh et al. 2012).Evidence in support of this hypothesis was 
provided by a study where retroviral expression of high frequency of TCRα from genes from Tregs 
and not from Teffs into a TCR transgenic RAG deficient background conferred the ability to rapidly 
expand upon transfer into a lymphopenic host (Lathrop et al. 2008).  
1.2.1.2 CD28 and Treg development 
 
CD28 co-stimulation is also required for the development of thymic Tregs. CD28-/- and B7-1 / 2 
deficient mice show marked reduction in Treg numbers (Salomon et al. 2000). During thymic 
selection, CD28 provides co-stimulation for TCR-mediated negative selection of self-reactive 
double positive thymocytes. CD28 signalling not only induces IL-2 production, but also delivers a 
cell-intrinsic signal required for TCR-mediated Foxp3 expression (X. Tai et al. 2005b). CD28-
induced Lck signals and the downstream activation of NF-B transcription factor family member c-
Rel have also been linked to Treg differentiation (Tai et al. 2005a; Vang et al. 2010). During the 
stages of thymic development, CD28 signals operate independently of TCR signals by sustaining 
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the development of Treg precursors and preventing their negative selection (Lio and Hsieh 2008a; 
Lio et al. 2010). 
In the periphery, CD28 signals are crucial for Treg homeostasis (Bour-Jordan and Bluestone 2009). 
In vivo studies indicate CD28 signals as necessary for the survival and self-renewal of adoptively 
transferred Treg cells (Tang et al. 2003). Evidence to support this was observed when blockade of 
CD28 with CTLA-4Ig exacerbated autoimmune diabetes in NOD mice associated with a loss in 
Tregs (Salomon et al. 2000). In addition, B7-1- and B7-2-deficient mice on a NOD background also 
developed exacerbated autoimmune diabetes associated with reduced peripheral Tregs (Salomon 
et al. 2000). Further studies investigated the role of CD28 signalling in Tregs by selective genetic 
ablation of CD28 in the Foxp3+ CD4+ subset (Zhang et al. 2013). These mice displayed 
autoimmunity characterised by skin inflammation and decreased thymic Tregs. The authors 
observed reduced proliferation and survival of CD28-deficient Tregs that were located in the 
periphery. Thus, CD28 plays key roles in both Treg thymic generation as well as in Treg post-
maturational proliferation and survival. 
Similar to nTregs, induction of Tregs from conventional CD4+CD25- T cells also requires CD28 co-
stimulation as was indicated by the study by (Guo et al. 2008). As in mice, effective proliferation 
of human Tregs requires CD28 co-stimulation that cannot be substituted by IL-2 (Hombach et al. 
2007).   
 
1.2.1.3 CTLA-4 in Treg development 
 
As discussed before, CTLA-4 expression on Tregs, unlike in Teffs, is constitutive. Furthermore, Treg 
activation also induces upregulation of CTLA-4 expression with rapid translocation to the cell 
surface (Mead et al. 2005). Like many aspects of CTLA-4 activity, its role in thymic selection of 
nTregs  also remains controversial. As mentioned previously, CTLA-4 deficient mice develop 
lymphoproliferative disease and die within weeks due to multi-organ infiltration and tissue 
destruction mediated by self-reactive T cells (Chambers et al. 1997; Tivol et al. 1995; Waterhouse 
et al. 1995). Studies carried out to investigate the molecular mechanisms involved revealed that 
CTLA-4 along with other signals play a definitive role during thymic selection by setting the 
threshold for the selection of TCRs, the absence of which allows the selection of TCRs of low 
affinity (Verhagen et al. 2013). Here, the authors demonstrated that the CTLA-4 expressed within 
the corticomedullary region of the thymus acts during negative selection by tuning the TCR 
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repertoire of the self-reactive conventional T cells and those of Tregs. Using a TCR transgenic 
mouse model specific for the myelin basic protein peptide, loss of CTLA-4 was observed to result 
in the selection of endogenous TCRa chains of altered peptides thus widening the diversity of the 
Tconv cells and skewing the repertoire of developing thymocytes towards that of regulatory T 
cells. Thus, CTLA-4 not only affects the thymic generation of FoxP3+ Treg cells but also, Tconv 
cells.  
In another independent study, no differences in thymic output of Tregs were reported between 
WT and CTLA-4-deficient mice within 15-17 days after birth (J. Verhagen et al. 2009). In this study, 
an OVA peptide specific, TCR transgenic mouse model revealed increased frequencies of Tregs in 
the periphery due to enhanced proliferation of CTLA-4-deficient Tregs responding to self-antigens. 
Furthermore, antibody-mediated blockade of CTLA-4 was described to augment Treg proliferation 
(Kavanagh et al. 2008; A. L. Tang et al. 2008). These findings also explain why CTLA-4 deficient 
mice have higher frequency of Foxp3-expressing Tregs even though CTLA-4 functions by 
counteracting CD28 signals, crucial for thymic generation of Tregs. 
 
1.2.1.4 IL-2 and Treg development  
 
In addition to the expression of the nuclear transcription factor Foxp3, Tregs are also known to 
express high levels of the high affinity IL-2 receptor CD25 (Sakaguchi et al. 1995). In mice, CD25 
along with Foxp3 expression is used to identify Treg populations. IL-2 is crucial for the generation 
of Treg populations in both the thymus and the periphery (Bayer et al. 2007; Cheng et al. 2013). 
Thus, it is not surprising that IL-2 deficient mice develop lethal multi-organ autoimmunity and 
lymphoproliferation which can be prevented by the adoptive transfer of WT T cells or the 
reconstitution of the CD25+ T cell fraction (Malek et al. 2002). During positive selection in the 
thymus, TCR signalling induces the upregulation of CD25. This upregulation is maintained by IL-2 
signalling to generate the CD4+CD25+ cells containing the Treg precursors (Lio and Hsieh 2008b). 
Following CD25 signalling, STAT5-dependent signalling leads to induction of Foxp3 expression and 
Treg maturation (Burchill et al. 2007; Yao et al. 2007). Within the periphery and in TGF-induced 
Tregs, transcription of Foxp3 and subsequent Treg development is dependent on IL-2 signalling 
(Zheng et al. 2007a). However, mice lacking CD25 or IL-2 have detectable Tregs, although with low 
Foxp3 expression, suggesting that the role of IL-2 in Treg development may be partially redundant 
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and other mechanisms (cytokines like IL-4 and IL-7) may compensate for IL-2 signalling during 
Treg development (Yates et al. 2007).  
IL-2 signalling is critically involved in the maintenance of in vivo Treg homeostasis. Genetic defects 
in IL-2 signalling or antibody mediated neutralization of IL-2 have revealed substantial reduction 
of Tregs in the periphery, where Tregs lacking CD25 are quickly outcompeted by WT Tregs (Bayer 
et al. 2007; Fontenot et al. 2005). In humans, genetic variations in the IL-2 and CD25 genes have 
been correlated with susceptibility to autoimmune diseases such as Type 1 Diabetes, multiple 
sclerosis and celiac disease owing to the reduction in the numbers of circulating Tregs (Cavanillas 
et al. 2010; Dendrou and Wicker 2008; van Heel et al. 2007).     
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1.2.2 Mechanisms of Treg-mediated Suppression 
 
To exert their regulatory function, Tregs are known to modulate the activity of a variety of 
components of both the innate and adaptive immune system. Following their discovery, several 
studies identified a plethora of mechanisms through which Tregs suppress and ultimately regulate 
immunity against foreign pathogens and maintain tolerance to self-antigens. A series of reports 
highlighted that the type of mechanisms through which Tregs mediated suppression was largely 
dependent on the nature of the immune response, the causing agent, the immunological makeup 
of the host and the site where suppression occurs (Corthay 2009; Sakaguchi et al. 2009; Schmidt 
et al. 2012). Nonetheless, evidence is now accumulating to indicate the role of Tregs in every 
adaptive immune response, either physiological or pathological. In this section, these different 
mechanisms are briefly described.  
With the initial experiments performed in vitro, cell-cell contact between Treg and responding T 
cells was observed to be necessary. Indeed, Treg cells failed to suppress activation of effector T 
cells when separated from the Teffs by a semi-permeable membrane in vitro. Studies by (Cao et 
al. 2007; Gondek et al. 2005) described in vitro killing of responding effector CD4 and CD8 T cells 
through the release of cytolytic proteins granzyme B and Perforin by Tregs, following direct cell-
cell contact. However, imaging studies did not detect stable contact formation between Treg-
Teffs in vivo, a prerequisite for direct cell contact mediated killing.  
Another mechanism believed to play a role in Treg mediated suppression was through removal of 
the pro-survival cytokine IL-2 from the vicinity of the activated CD4 and CD8 effector cells via the 
high affinity CD25 receptor expressed abundantly on Tregs (Busse et al. 2010). However, this ‘IL-2 
sink’ theory was plagued by the fact that in vivo activation of Teffs can remain effective in the 
absence or little presence of IL-2 depending upon the type of in vivo model used. Other 
mechanisms through which Tregs modify the microenvironment of activating/activated Teffs 
include the activities of the ecto-enzymes CD39, CD73 and that of galectins expressed by Tregs 
(Deaglio et al. 2007; Garin et al. 2007; Kubach et al. 2007). CD39 and CD73 catabolise the 
production of immunosuppressive adenosine while Galectin 1 and Galectin 10 are functionally 
important for human Tregs to be effective at suppression. Additionally, the upregulation of 
intracellular cyclic AMP by Tregs was also shown to inhibit T cell proliferation and IL-2 formation 
(Bopp et al. 2007). While these mechanisms add additional suppressive power to Tregs, they 
alone are insufficient as loss or removal of any one of these mechanisms does not replicate the 
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autoimmune and lymphoproliferative phenotype occuring in the absence of Tregs. This suggests 
that the key mechanisms crucial for Treg function lie elsewhere. 
Tregs are also known to downplay immune responses by directly interfering with the ability of 
antigen presenting cells (APCs) to activate effector T cells. Tregs outcompete Teffs in forming 
aggregates around APCs, thereby physically restricting access of antigen presentation to Teffs 
(Onishi et al. 2008; Schneider 2006). 
In several in vivo models, Tregs mediate suppression though the action of secreted 
immunoregulatory cytokines. Tregs are known to produce high amounts of membrane-bound and 
soluble immunoregulatory cytokine TGF-β (Nakamura et al. 2001). TGF-β1 deficient mice develop 
T cell mediated autoimmunity shortly after birth and mice with T cell-specific TGF-β1 deficiency 
show enhanced Th1 and Th2 responses and immunopathology including colitis (Li et al. 2006; Li et 
al. 2007; van Ginkel et al. 1999). 
IL-10, another immunoregulatory cytokine secreted by Tregs, has been identified to exert 
immunosuppressive effects on several cell types (Moore et al. 2001). Interestingly, blocking IL-10 
or using Tregs deficient in IL-10 abrogates the protective effect of Tregs on T cell in transfer-
induced colitis model of inflammation (Asseman et al. 1999). Interestingly, IL-10 mediated 
immunosuppression by Tregs seems to control memory/antigen-experienced T cells during 
prevention or cure of colitis rather than the naïve cells (Asseman et al. 2003; Uhlig et al. 2006). IL-
10 or IL-10 receptor deficient mice do not develop autoimmunity, but are susceptible to colitis in 
the presence of triggering flora (Kuhn et al. 1993; Spencer et al. 1998). In one study, Tregs were 
observed to need IL-10 (and not TGF-β) to control IFN-γ production by T cells in the inflamed skin 
(Sojka and Fowell 2011). Recent studies have further confirmed that IL-10 receptor signalling is 
required in Tregs as well as in Th17 cells in order to suppress colonic Th17 responses (Chaudhry et 
al. 2011). 
The cytokine IL-35 is yet another Treg-secreted immunosuppressive cytokine that directly inhibits 
conventional T cell proliferation (Collison et al. 2007). In a model of inflammatory bowel disease, 
Tregs deficient in IL-35 show reduced suppressive ability (Collison et al. 2007). However, unlike in 
mice, human Tregs do no produce IL-35 (Bardel et al. 2008). Nonetheless, treatment of naïve T 
cells with IL-35 in humans and mice results in the generation of a so-called iTR35 regulatory 
population that mediates suppression via IL-35 without requiring IL-10, TGF-β, or Foxp3 (Collison 
et al. 2010).  
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1.2.2.1 CTLA-4 in Treg function 
 
Several mechanisms of suppression may be employed by Tregs to achieve immune regulation 
depending upon a number of factors including the location of the immune response. However, it 
has been hypothesised that one central core mechanism of suppression, under the control of 
Foxp3, must be shared by every Treg cell in any location in both human and mice (Tang and 
Bluestone 2008a). CTLA-4 dependent suppression is a likely candidate for such a core mechanism. 
Unlike conventional T cells, regulatory T cells constitutively express CTLA-4. As mentioned 
previously, CTLA-4 contributes to maintaining tolerance towards self-antigens through a variety of 
molecular mechanisms including modification of APCs and the production of IDO. Thus, Tregs are 
believed to be endowed with the ability to suppress the activity of conventional T cells using 
CTLA-4 in a similar manner to that used by other conventional T cells that express CTLA-4.  
Indeed, CTLA-4 deficient Tregs are believed to have impaired suppressive ability in vivo. In one 
study, antigen specific Tregs deficient in CTLA-4 were unable to prevent disease in a mouse model 
of autoimmune diabetes (Schmidt et al. 2009). Additionally, Treg-specific deletion of CTLA-4 in 
mice using a Foxp3-Cre system precipitated in autoimmune disease similar to that in CTLA-4 
deficient mice, although the life span of these mice was significantly extended (Chikuma and 
Bluestone 2007; Wing et al. 2008). The less severe phenotype of these mice compared to that of 
CTLA-4 deficient mice is likely due to CTLA-4 expressed by conventional T cells. As described 
before, CTLA-4 expressed by conventional T cells following activation plays a key role in 
preventing autoimmunity and maintaining immune homeostasis. In another study, CTLA-4-
deficient Tregs were unable to control the expansion of CD4 target cells within a lymphopenic 
environment and were unable to inhibit the cytokine production associated with homeostatic 
expansion (Sojka et al. 2009). 
Foxp3 together with other transcription factors are required to upregulate the expression of 
CTLA-4 by binding to the promoter region of the CTLA-4 gene, indicating that Foxp3 may sustain 
the high expression of CTLA-4 in Tregs (Marson et al. 2007; Y. Wu et al. 2006). 
Studies have also highlighted the ability of Treg-expressed CTLA-4 to modulate the activity of 
APCs. Indeed, Tregs that lack CTLA-4 were unable to inhibit DC upregulation of CD80 and CD86 as 
compared to WT Tregs (Hou et al. 2015b). Similarly, ligation of CD80 and CD86 by CTLA-4 
expressed by Tregs induced the activation of the IDO pathway (Grohmann 2002) leading to the 
production of immunosuppressive kynurenin or the activation of transcription factor foxo3, which 
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mediates inhibition of cytokine production by DCs Transcription factor foxo3 controls the 
magnitude of T cell immune responses by modulating the function of dendritic cells (Dejean et al. 
2009). 
 
1.2.2.2 CD31 and regulatory T cells 
 
So far, very few studies have addressed the role of the Ig-like CD31 molecule specifically on the 
regulatory T cell subset. Given the involvement of this molecule in T cell activation, cytokine 
production and migration, CD31 may play a crucial role in maintaining tolerance through its action 
on regulatory T cells. The recent study by (Ma et al. 2012) investigated this aspect and observed 
CD31-deficient CD4+CD25+ FOXP3+ Tregs to display defective regulatory functions in vivo. Similar 
findings were also observed in vivo by the study by (J. Haas et al. 2007), who reported reduction in 
CD31-expressing Tregs in patients with multiple sclerosis (MS). They also reported a reduction in 
this Treg pool within the peripheral blood with aging. However the molecular mechanism 
underlying this effect is at present unclear. The functional consequences of homophilic 
engagement of CD31 between T cells and Tregs has not been investigated. As CD31 can modulate 
ZAP-70 activity (Ma et al. 2010) and TCR-triggering is necessary for Treg function, one can 
speculate that the modulation of Treg-proximal TCR signaling (ZAP-70) through engagement of 
CD31 by APCs is required for their optimal suppressive activity.  This aspect of Treg cell biology 
remains to be investigated.     
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1.2.3 Tregs in Transplantation 
 
Tregs have been described to be crucially involved in the induction and maintenance of tolerance 
post-transplant, as well as the prevention of graft rejection in animal models (Reviewed inWalsh 
et al. 2004). Similarly, evidence suggests that the levels of Foxp3 and intra-graft Treg frequency 
can be correlated to the clinical graft acceptance, survival and function of the transplanted grafts 
(Chauhan et al. 2009; Zuber et al. 2013). Indeed, strategies have been devised to promote 
tolerance of transplanted graft through selective generation of Treg within grafts by 
pharmacological means. Notably, the immunosuppressive drug rapamycin (sirolimus) inhibits 
signalling by its eponymous target, the mammalian target of rapamycin (mTOR) which integrates 
cellular metabolism and proliferation pathways and has been observed to enhance generation of 
Tregs while suppressing T effector cell proliferation following transplantation (Saunders et al. 
2001).   
Adoptive transfer of Tregs has emerged as an attractive therapeutic alternative to conventional 
immunosuppressive strategies that are involved in transplantation to ensure graft survival and 
prevention of graft rejection (Nagahama et al. 2007). These strategies have an advantage in 
reducing the risks of uncontrolled infection and tumour growth associated with conventional 
immunosuppressive strategies which rely solely on pharmacological agents to prevent graft 
rejection.  
Overview of rejection and transplantation tolerance   
Once an organ/tissue is grafted onto a recipient, the T cells of the recipient respond to antigens 
that are displayed by the graft in a similar fashion as to any foreign protein. Rejection of graft 
tissue occurs as a consequence of polymorphisms in histocompatability genes, primarily those 
located within the MHC. The T cells from the recipient respond to foreign (allogeneic) MHC. As a 
result a large population of activated effector cells, primarily T cells and macrophages are 
generated which mediate graft destruction. 
There are two key pathways through which alloresponsive T cells can recognise antigens present 
in the transplanted tissue (Reviewed in Afzali et al. 2007). In the direct pathway, the responding T 
cells recognise intact MHC molecules on the surface of donor derived APCs, whereas in the 
indirect pathway, recipient APCs process donor derived allo MHC molecules into peptides which 
are then presented to T cells by self- MHC molecules. It is widely believed that direct pathway of 
recognition contributes to the immediate or acute phase of rejection mediated when graft 
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resident donor APCs migrate to the surrounding lymphoid tissue where they stimulate 
alloresponsive T cells (Benichou 1999). As the donor derived APCs are relatively short lived, the 
indirect pathway of allorecognition predominates as the alloresponse progresses and thus forms 
the chronic phase of rejection. In addition to these two pathways, a semidirect pathway of 
allorecognition has been observed in which host/recipient APCs acquire intact MHC molecules 
from donor APCs from the graft via means of cell-cell contact and are thus able to recognise self-
antigens via the direct recognition pathway (Herrera et al. 2004). Thus the semidirect pathway 
enables a single host APC to present allopeptides via self-MHC to CD4+ T helper cells as well as 
stimulate cytotoxic CD8+ T cells via a donor acquired Class I MHC molecule.    
Experimental methods of induction of transplantational tolerance can be divided into two 
categories. Central tolerance refers to the process by which bone marrow transplants are 
preceded to organ transplants in an attempt to induce generation of hematopoietic chimerism 
(Sprent and Kishimoto 2001). As such, donor reactive T cells which develop are deleted in the 
thymus during thymocyte maturation in a manner similar to self-reactive T cells. Peripheral 
tolerance strategies rely on blocking/modulating T cell activation or growth factor receptor 
pathways in mature T cells through pharmacological agents or antibodies (Mueller 2010). 
Conversely, Tregs were observed to be crucial for maintaining peripheral tolerance within 
transplanted grafts by inhibiting responses of both resident T cells as well as that of new thymic 
emigrants. 
 
1.2.3.1 Antigen specificity of Tregs in transplantation 
 
Previous studies investigating solid organ transplantation in murine models have shown antigen 
specificity of Tregs to be advantageous at preventing rejection in solid organ transplants. However 
in models of GVHD, the advantage of antigen specificity over polyclonal specificity is only 
moderate (Pidala and Anasetti 2010). Like conventional T effector cells, Tregs recognise 
alloantigens through both direct and indirect recognition pathways. Interestingly, Tregs with 
direct antigen specificity were observed to be very effective at preventing acute rejection 
following transplantation while Tregs with indirect allospecificity are crucial in preventing chronic 
rejection later after transplantation (Tsang et al. 2008). The expansion of Tregs with direct 
specificity for human transplant therapies has been easier to achieve using allogeneic monocyte-
derived dendritic cells, peripheral blood mononuclear cells (PBMCs), or allogeneic B cells as APCs 
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(W. Tu et al. 2008). These Tregs have been reported to be suppressive at very low Treg-Teff ratios 
and in human skin transplants are more potent over polyclonal Tregs at preventing rejection 
(Graca et al. 2002). Expanding Tregs with indirect allospecificity has been proven more difficult to 
achieve. The first protocols developed involved peptide-pulsing of APCs with alloantigens which is 
an inefficient process (only 1% of the available MHC molecules are occupied by the peptide) (Jiang 
et al. 2003; Tsang et al. 2006). Newer protocols using beads coated with recombinant peptide 
along with MHCII and anti CD28 mAB and tetramer based cell sorting of antigen specific Tregs 
have been used for better Treg cell-based therapies to combat chronic rejection (Masteller et al. 
2005). 
Transplantation studies have reported that the continuous presence of antigen is a requirement 
for maintenance of transplantation tolerance (Chen et al. 1996; Onodera et al. 1998). This 
observation, along with the fact that indirect allorecognition pathways proceeds once the acute 
phase of rejection has died down, suggests that the indirect pathway of allorecognition is the 
dominant pathway utilised by Tregs. Studies carried out by (Yamada et al. 2001) using mice 
lacking class II MHC (indirect recognition only) and recipients that lack MHC class II molecules in 
the periphery but possess CD4 T cells as a result of transgenic expression of class II MHC on the 
thymic epithelium (direct recognition only) indicated indirect recognition of alloantigens to be 
crucial for the ability to tolerize over direct recognition pathways. Tregs can thus achieve 
tolerance of a grafted tissue through means of recognizing a small subset of graft derived antigens 
which can then block further responses to other graft expressed antigens in a method termed 
“linked suppression”(See section 1.2.2).  
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1.3 T cell metabolism and immune regulation 
 
Although signalling through receptors such as the TCR, the co-stimulatory receptors, cytokine 
receptors and others affect the proliferation and differentiation of T cells, nutrient availability and 
environmental cues also play a key role in supporting these events. Like all other cells, T cells also 
coordinate their differentiation and proliferation with their metabolic demands and availability of 
essential nutrients. Glucose, amino acids, and lipids are the primary metabolic fuels for all 
lymphocytes. However, different T cell subsets are now being identified which exhibit unique 
metabolic patterns adapted to their function.  For example, In the study by (Peter et al. 2010), the 
authors indicated that T cells switch between highly proliferative (activated T cell and developing 
thymocyte) and quiescent (memory, naïve and anergic T cells) states characterised by distinct 
metabolic pathways in each. Furthermore, Teff cells upon activation switch from primarily 
mitochondria-dependent oxidative phosphorylation (OXPHOS) ( abundant in resting T cells) to 
aerobic glycolysis, a phenomenon termed the “Warburg effect” (Warburg 1956). This may be 
because glycolysis can fuel the demand for rapid generation of fundamental building blocks of the 
proliferating cell, such as amino acids, lipids, complex carbohydrates, and ribonucleotides that the 
relatively efficient OXPHOS cannot provide (Caro-Maldonado et al. 2012).  
 
1.3.1 T cell activation and metabolism 
 
Resting naïve or memory T cells utilise oxidation of glucose, lipids and glutamine as their primary 
source of energy. When unstimulated, resting T cells do not grow or proliferate but still require 
energy for cell survival. Thus, these cells maintain a clear demand for energy, with little need for 
biosynthesis. Consistent with these metabolic requirements, resting T cells exhibit a balanced use 
of glucose, amino acids and lipids that undergo oxidation in the mitochondria for maximal ATP 
generation (Bental and Deutsch 1993). In naïve T cells, the homeostatic survival signals from the 
TCR and cytokine interleukin-7 receptor (IL-7R) that maintain survival also maintain this basal 
metabolism (Rathmell et al. 2001). Naïve T cells that are deprived of these signals begin to 
degrade cell surface glucose transporter Glut1 and undergo cellular atrophy that leads to reduced 
rates of glucose metabolism and induction of pro-apoptotic Bcl-2 family proteins (Coloff et al. 
2011; Rathmell et al. 2000; Rathmell et al. 2001; Wofford et al. 2008). Consistent with this 
hypothesis, the study by (Jacobs et al. 2010) demonstrated that the conditional deletion of the IL-
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7 receptor in mature T cells resulted in their poor survival in vitro and in vivo which was 
associated with reduced basal rates of glycolysis and shortened lifespan.    
Upon activation through TCR and CD28 co-stimulation, T cells rapidly activate metabolic programs 
that closely resemble that of many cancer cells, with high rates of glucose uptake and aerobic 
glycolysis (Michalek and Rathmell 2010; Warburg 1956). In addition, oxidation of the amino acid 
glutamine (glutaminolysis) increases to maintain tricarboxylic acid (TCA) cycle flux and provide a 
source of ATP and biosynthetic precursors (Newsholme et al. 1985). In contrast, oxidation of lipids 
decreases while lipid synthesis increases to facilitate the building of new membranes.  
Following TCR and CD28-induced co-stimulation, the PI3K-Akt-mTOR pathway facilitates the 
trafficking of the glucose transporter Glut1 to the cell surface to enhance glucose uptake (Barthel 
et al. 1999). Furthermore, PI3K-Akt-mTOR signals induce the activity of glycolytic enzymes as well 
as the nuclear transcription factors sterol-regulatory element binding proteins (SREPBs) to 
stimulate lipid synthesis (Krycer et al. 2010). Previously, (Luu et al. 2012) have shown that Akt and 
mTOR kinases acutely upregulate SREPB-2, a nuclear transcription factor that controls cholesterol 
production also necessary for building membranes. Additionally, the nuclear hormone receptor 
estrogen related receptor-alpha (ERRα) increases following T cell activation (Michalek et al. 
2011b) and can induce the expression of TCA and electron transport genes, essential for efficient 
mitochondrial metabolism. 
While glucose and glutamine metabolism increase following T cell activation, lipid metabolism 
switches from oxidation to synthesis. This occurs mainly through signalling and substrate-
mediated inhibition mechanisms. The PI3-Akt pathway was presented by (Deberardinis et al. 
2006) to downregulate the activity of the enzyme Carnitine palmitoyltransferase Ia (CPT1a) which 
leads to inhibition of lipid oxidation. The CPT1a enzyme is responsible for the formation of acyl 
carnitines enabling the transport of long chain fatty acids into the mitochondria for oxidation thus 
controlling FAO. Furthermore, production of the lipid biosynthesis precursor malonyl-CoA from 
TCA derived citrate further inhibits CPT1a and fatty acid oxidation (McGarry et al. 1977).  
While aerobic glycolysis serves as the primary source of energy following T cell activation, 
mitochondrial OXPHOS continues and can increase (reviewed in Waickman and Powell 2012). 
However, rather than lipid oxidation, the mitochochondrial oxidation of glucose and glutamine 
serves as the primary source of oxidative energy. Previously, (O'Rourke and Rider 1989) showed 
that 10% of the glucose in activated lymphocytes  was driven to the mitochondria and entirely 
oxidized, which could support approximately 65% of the ATP generated by the cell. (Roos and 
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Loos 1973) also showed that 15% of the total ATP generation came from aerobic glycolysis, while 
the rest from OXPHOS.  
Additionally, the oxidation of glutamine also contributes as an energy source. Following entry into 
the TCA cycle as α-ketoglutarate, glutamine-derived carbons can exit the mitochondria as malate 
or citrate. These can then be used for lipid synthesis or to generate lactate and produce NADPH 
by malic enzyme and replenish cytosolic NAD+ by lactate dehydrogenase (Caro-Maldonado et al. 
2012). 
Once an immune response begins to subside, the vast majority of Teffs die off while a few 
develop into long lasting memory T cells. This transition from stimulated to long-lived quiescent T 
cells involves metabolic reprogramming, as cells no longer require biosynthesis and instead 
require efficient supply of ATP. Thus memory T cells switch from glycolysis to oxidative 
metabolism. In support of this hypothesis, inhibiting glycolysis and stimulating lipid oxidation at 
the peak of an immune response has been shown to enhance memory T cell development 
(Sukumar et al. 2013). In CD8 memory T cells, mitochondrial lipid oxidation dominates. 
Additionally, unlike in naïve T cells, CD8 memory T cells display much higher levels of lipid 
oxidation and vastly higher mitochondrial spare respiratory capacity (SRC) (van der Windt et al. 
2012). The SRC represents the extent to which cells can increase oxygen consumption beyond the 
basal rate of respiration, with adequate nutrients, when placed under stress. Thus, the SRC does 
not measure the direct rates of OXPHOS but reflects the cell’s ability to respond and rapidly 
increase respiration and, therefore, ATP production.  The SRC is mediated through increase in the 
electron transport as well as by an increase in the overall density of mitochondria per cell. More 
recently, the study by (van der Windt et al. 2012) have demonstrated that the source of the 
memory T cell oxidative metabolism and SRC is largely mediated through lipid oxidation; a process 
regulated in part through the expression of CPT1a. Indeed, their study indicated that modulation 
of CPT1a influences both SRC and memory generation.   
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Figure 4    T cell metabolic reprogramming 
In naïve and memory T cells, mitochondrial oxidation of glucose and fatty acids through the TCA 
cycle supplies the energy for basic cellular functions. After activation, β-oxidation of fatty acids 
decreases and other metabolic processes (indicated in red), including glycolysis and glutaminolysis, 
increase. The glucose catabolic pathways shifts more towards production of NADPH and 5-carbon 
ribose (via the pentose phosphate pathway, (PPP)) at glucose -6-phosphate (G-6-P) and detours 
toward lactate production (aerobic glycolysis) at pyruvate. Meanwhile, glutaminolysis provides the 
α-ketoglutarate (α-KG), which enters the mitochondrial TCA cylcle, provides energy and a carbon 
resource for lipids. This metabolic reprogramming is optimised for cell growth and proliferation by 
providing carbon and ATP. Once differentiated, long lived memory CD8 T cells rely on the β-
oxidation of fatty acids as a source of energy. F-6-P, fructose-6-phosphate; 3-P-G, glycerate-3-
phosphate; Pyr, pyruvate; Lac, lactate; FFA, free fatty acids; OAA, oxaloacetate; PEP, 
phosphoenolpyruvate; P-5-C, 1-pyrroline-5-carboxylate; Glu, glutamate; Orn, ornithine. Figure 
adapted from (Wang and green, 2012). 
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1.3.2 Metabolic Pathways in Tregs 
 
Functionally distinct T cell subsets exhibit diverse energetic and biosynthetic pathways for their 
energy requirements. Several reports have highlighted the existence of different metabolic 
‘signatures’ in Treg and Teff cells that affect their differentiation and function. These are briefly 
described below. 
1.3.2.1 Lipid oxidation  
 
One of the key metabolic features that distinguish Tregs from Teffs is their dependency on lipid 
oxidation as a primary energy source. Unlike activated Teffs, Tregs display high fatty acid 
oxidation (FAO) rates. The study by (Michalek et al. 2011c) demonstrated that the addition of the 
drug Etomoxir, known to block fatty acid oxidation, led to the reduction in the number of Tregs 
generated under Treg differentiating conditions in vitro (Michalek et al. 2011c). Etomoxir is an 
inhibitor of CPT1, a rate-limiting enzyme in FAO located on the outer surfaces of the inner and 
outer mitochondrial membranes. Thus, the authors conclude that FAO is necessary for Treg 
differentiation. 
A recent study by (H. Zeng et al. 2013c) has indicated that Tregs require lipid and cholesterol 
metabolism, with the mevalonate pathway particularly important for coordinating Treg cell 
proliferation and upregulation of the co-stimulatory receptors CTLA-4 and ICOS to establish Treg 
functional competency. In this study, Tregs treated with statins, pharmacological inhibitors of 3-
hydroxy-3-methylglutaryl-CoA reductase (HMGCR, the rate-limiting enzyme of the mevalonate 
pathway), impaired the suppressive activity of Tregs in in vitro suppression assays. This functional 
defect could be corrected upon the addition of mevalonate, the immediate downstream product 
of HMGCR. The authors conclude that upregulated lipid biosynthesis via the mevalonate pathway 
promotes the expression of effector molecules and the immunosuppressive activity of Tregs. 
Figure 5 below depicts the mevalonate pathway in T cells and statin-mediated inhibition of this 
pathway adapted from (Zeiser et al. 2009). 
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Figure 5    Statin inhibition of the mevalonate pathway in T cells 
Statins such as Simvastatin and Atorvastatin block the activity of HMG-CoA reductase, the rate 
limiting enzyme of this pathway which causes reduction in farnesylated and geranylated 
downstream proteins. In addition, downstream prenylation of GTPases such as Rho-B, Rac1 and 
Ras , necessary for binding to cell membranes is disengaged. This is thought to inhibit activation 
and regulate Th1/Th2 polarisation. Figure adapted from (Zeiser et al. 2009). 
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1.3.2.2 AMP-activated protein kinase (AMPK) pathway 
 
The AMP-activated protein kinase (AMPK) is a heterotrimeric kinase consisting of a catalytic α 
subunit, a regulatory β subunit, and an AMP-binding γ subunit. AMPK acts as an intracellular 
energy sensor and is activated in response to low energy levels indicated by fluctuations in AMP: 
ATP ratio. AMP binding to the γ subunit results in allosteric activation of this enzyme (W. H. Lee 
and Kim 2010). In addition, AMPK can also be activated in an AMP-independent manner mediated 
by phosphorylation of threonine-172 on the α subunit by upstream kinases. Following activation, 
AMPK restores ATP homeostasis through the upregulation of several genes involved in processes 
such as glucose oxidation and, more importantly, lipid oxidation. Among these is CPT-1, crucial for 
mitochondrial oxidative lipid metabolism (Kompare and Rizzo 2008). Additionally, AMPK also 
preserves CPT-1 activity by inhibiting acetyl-CoA carboxylase which is itself a suppressor of CPT-1, 
thus further promoting fatty acid oxidation (W. H. Lee and Kim 2010). 
(Michalek et al. 2011c) have demonstrated that both nTregs and iTregs display high levels of 
AMPK activity, and pharmacological activation of AMPK by metformin, a drug used to treat 
diabetes mellitus increased Treg generation in vitro. In addition, activation of AMPK via metformin 
increased the Treg population in the CD4+ T cell compartment in an in vivo murine model of 
asthma (Michalek et al. 2011a). Here, the authors described that mice sensitised by aerosol to 
ovalbumin in the presence of metformin, and challenged 21 days later exhibited an increase in 
the frequency and number of Foxp3+ Tregs in the draining lymph nodes as compared to mice 
immunized in the absence of metformin. However, no change in airway responsiveness was noted 
even though there were fewer lymphocytes recovered in the bronchial alveolar lavage in the 
metformin treated animals. 
In models of EAE, T cells from mice afflicted with EAE show reduced levels of AMPK protein and 
genetic deletion of AMPK in mice renders them more susceptible to EAE. In this study, 
AMPK−/− mice were observed to have higher clinical scores, CNS cellular infiltration, and ex 
vivo levels of IFN-γ production than their WT counterparts (Nath et al. 2009). Moreover, in the 
study by (MacIver et al. 2011), knocking out liver kinase B1 (LKB1), an upstream activator of 
AMPK resulted in similar observations such as increased IFN-γ and IL-17 pro-inflammatory 
cytokine production by the LKB1-/- T cells. Taken together, these studies suggest AMPK activity to 
be a crucial metabolic pathway of Tregs. An overview of the AMPK pathway is depicted in the 
Figure 8 of Section 1.3.3.2.  
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1.3.2.3 Glucose oxidation 
 
Recent studies have suggested that Tregs do not maintain an obligatory reliance on a particular 
fuel source such as lipids, but rather on the mitochondrial oxidative metabolism of either lipids or 
glucose. Pyurvate dehydrogenase (PDH) is an enzyme that catalyses the conversion of cytosolic 
pyruvate into mitochondrial acetyl-CoA for oxidative metabolism and thus, serves as a key 
bifurcation point between T cell glycolytic and oxidative metabolism. PDH is inhibited by the PDH 
Kinase (PDHK), which suppresses pyruvate oxidation and instead promotes its conversion into 
lactate via lactate dehydrogenase (LDH). In a study by (Ostroukhova et al. 2012), inhibition of 
PDHK1 via Dichloroacetate (DCA, inhibitor of PDHK1) led to upregulation of IL-10 production and 
induction of Foxp3. In this study, intraperitoneal DCA addition before intranasal ragweed 
exposure was shown to reduce lactate production and airway inflammation associated along with 
an increased number of Foxp3+ Treg cells in a mouse model of asthma. More recently, a study by 
(Gerriets et al. 2015) has confirmed that Tregs have reduced levels of PDHK1 activity and, 
furthermore, that inhibition or knockdown of PDHK1 increases Treg generation. Inhibition of 
PDHK1 in their study modulated immunity with decreased Th17 and increased Treg populations 
resulting in protection of animals against disease in a murine EAE model. An additional 
observation in their study was that inhibition of glycolysis via 2-DG reduced Teff proliferation 
while increasing Tregs proliferation in vitro. However, inhibition of the electron transport chain 
(thus, mitochondrial oxidation) by rotenone sharply reduced Treg proliferation. Collectively these 
reports highlight the importance of mitochondrial oxidation (of both glucose and lipids) in Treg 
development and function.  
 
1.3.2.4 Similarity to CD8 memory T cells 
 
The above studies indicate that Tregs display metabolic phenotypes that are similar to that of 
long-lived memory CD8 T cells. Like Tregs, CD8 memory T cells display higher AMPK activity and 
FAO (Araki and Ahmed 2013). In a study by (Pearce et al. 2009), treatment with metformin 
induced the generation of CD8 memory T cells in vivo upon Listeria monocytogenes infection. 
Recently, (Gerriets et al. 2015) have demonstrated that Tregs also have high SRC similar to what is 
observed in CD8 memory T cells. Therefore, it is likely that mitochondrial metabolism and 
oxidation of both glucose and lipids may serve as an efficient means to maintain long term 
survival of Tregs in a manner similar to what is observed in CD8 memory T cells.     
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1.3.3 The mTOR Pathway in T Cells 
 
The mammalian target of rapamycin (mTOR) pathway is a key nutrient sensing pathway that 
integrates fundamental cell processes such as proliferation, differentiation and cellular function to 
nutritional environmental status. mTOR is a 290kD serine/threonine protein kinase belonging to 
the PI3K-related kinase family that integrates signals from both internal and external stimuli to  
pathways that control aspects of cell growth and metabolism (Schieke et al. 2006).These include 
the response to hypoxia, and the biogenesis and oxidative capacity of mitochondria. mTOR also 
regulates critical processes such as cytoskeletal organization, transcription and protein synthesis 
(Dowling et al. 2010; Vivanco and Sawyers 2002). In addition, mTOR is also known to integrate 
signals from growth factors such as insulin and insulin like growth factors to the cellular 
metabolism (Vivanco and Sawyers 2002; Zoncu et al. 2011). 
mTOR derives its name from its naturally occurring inhibitor rapamycin, a powerful 
immunosuppressive compound referred to as Sirolimus (Douros and Suffness 1981). Rapamycin 
was first discovered in the soil bacterium Streptomyces hygroscopicus from the Easter islands.  
mTOR was the name given to the catalytic subunit formed by the two complexes mTORC1 and 
mTORC2. The two distinct complexes are known to phosphorylate different substrates and 
regulate distinct cellular functions. Rapamycin-sensitive mTORC1 forms the fundamental nutrient 
sensing complex that is activated by Akt kinase downstream of PI3K signalling (via the TCR, co-
stimulatory receptors, and cytokines) whereas the rapamycin-insensitive mTORC2 controls spatial 
aspects of cell growth through activation of cytoskeletal component (Cybulski and Hall 2009). 
mTORC1, composed of the serine/threonine kinase mTOR itself, the scaffolding protein RAPTOR, 
the positive accessory proteins FKBP12, Deptor, and mLST8, and a regulatory subunit PRAS40 is a 
target of Akt downstream of PI3K signalling (Laplante and Sabatini 2009). Rapamycin, as an 
immunosuppressive drug, binds to FKB12 and disrupts the formation and function of the TORC1 
complex (Sabatini et al. 1994). Conversely, TORC1 activation drives protein synthesis via 
phosphorylation of downstram kinase S6K1, which phosphorylates the ribosomal protein S6 and 
initiates the translation of messenger RNA. The mTORC2 complex is composed of mTOR, the 
accessory proteins mLST8, RICTOR, deptor, Protor1/2 and mSIN1 (Sarbassov et al. 2004). mTORC2 
activates the kinase Akt by phosphorylating serine at position 473 of the Akt kinase (Hresko and 
Mueckler 2005; Sarbassov et al. 2005) thereby activating the PI3K-Akt pathway. Thus, Akt lies 
both upstream and downstream of mTOR. mTORC2 is known to regulate cell polarisation and 
responses to chemotactic signals via G protein-coupled activation of RAS (Charest et al. 2010). 
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Interestingly, TORC2 is thought to be negatively regulated by TORC1 activity via SAPK interacting 
protein 1 (Sin1, regulatory component of TORC2) phosphorylation (Liu et al. 2013). Thus, 
rapamycin can indirectly activate mTORC2 in the short term, however, long term inhibition of 
mTORC1 (over days) by rapamycin may also inhibit mTORC2 activation (Sarbassov et al. 2006). 
Figure 6 below depicts an overview of mTOR signalling pathways in mammalian cells and is 
adapted from (Yang and Guan, 2007). 
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Figure 6    mTOR signalling network in mammalian cells 
mTORC1 is the rapamycin sensitive complex of mTOR formed of mTOR,Raptor,mLST8, FKBP12, and 
PRAS40. TSC1/2-Rheb is the major regulator of mTORC1. Signals via growth factors/PI3K-Akt are 
led downstream via TSC1/2-Rheb to activate mTORC1, thus, enabling phosphorylation of 
downstream S6K1 and 4EBP1.The mTORC2 complex, formed of mTOR, Rictor, Sin1, and mLST8 
phosphorylates Akt at Serine position 473. Arrows represent activation, bars represent inhibition, 
and dots represent binding. Figure adapted from (Yang and Guan 2007). 
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1.3.3.1 mTOR regulates peripheral T cell homeostasis, activation and differentiation 
 
As mentioned previously, different subsets of T cells have been shown to use distinct 
bioenergetics and metabolic pathways to meet their energy requirements. Given its central role in 
coupling upstream signals to that of metabolic inputs, mTOR activity is described in various 
studies as a regulator of T cell homeostasis, activation and differentiation. During the transition 
from naïve to activated, to memory, T cells coordinate an intricate network of epigenetic, 
transcriptional, and metabolic programs, many of which are directly influenced by mTOR 
activation (Chi 2012; Yang and Chi 2012; H. Zeng and Chi 2013).  
In naïve CD4 and CD8 T cells, which require low TCR and IL-7 receptor signalling to maintain T cell 
homeostasis (Sprent and Surh 2011), low levels of mTOR signalling appear to be required to 
maintain T cell quiescence. In support of this, T cells deficient in tuberous sclerosis complex 1 
(TSC1, an inhibitor of RHEB and thus, an inhibitor of mTORC1) display excessive mTORC1 signalling 
with aberrant cell cycling, reduced homeostatic proliferation in response to IL-7 and hyper-
responsiveness to TCR induced apoptosis (O'Brien et al. 2011; Wu et al. 2011; Zhang et al. 2012).  
Once stimulated, T cells that undergo activation require mTORC1 signalling to drive entry into the 
cell cycle from quiescence. In line with this, mTORC1, RHEB and Raptor deficient T cells display 
defects in antigen-induced proliferation (Delgoffe et al. 2009; Yang et al. 2013). Furthermore, 
rapamycin treatment or loss of raptor in naive, but not in proliferating T cells, blocks clonal 
expansion and promotes T cell anergy (Yang et al. 2013; Zheng et al. 2007b). Interestingly, raptor-
deficient T cells also display decreased glycolysis, OXPHOS, and/or lipogenesis (Wang et al. 2011; 
Yang et al. 2013). Collectively, these studies indicate that mTOR signalling is crucial for T cell 
activation and proliferation. 
Th1, Th2, and Th17 cells express high surface levels of the glucose transporter Glut1 and are 
highly glycolytic. Conversely, in the absence of mTOR, polarisation towards the CD4 T helper 
subsets Th1, Th2 and Th17 are all impaired. Thus, these T cells require the induction of mTOR 
activity for their differentiation. In Th1 T cells, mTORC1 activity is thought to be crucial for 
differentiation (Delgoffe et al. 2011; Lee et al. 2010). In Th2 cells, both mTORC1 and mTORC2 
activities are necessary for differentiation (Lee et al. 2010; Yang et al. 2013). The relevance of 
mTORC2 in Th1 cell differentiation is still controversial. In Th17 T cells, genetic deletion of Hypoxia 
inducible factor 1 alpha (HIF1α), a transcription factor functionally regulated by mTORC1, impairs 
transcriptional activation of RORγt and therefore, Th17 differentiation (Dang et al. 2011; Shi et al. 
2011). 
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Figure 7 below gives an overview of how mTOR signalling controls peripheral T cell fate decisions 
as adapted from (Chapman and Chi 2014). 
 
 
 
Figure 7    mTOR regulates peripheral T cell fate decisions 
In the peripheral tissues, low levels of mTORC1 signalling controls T cell quiescence. Following TCR 
and co-stimulatory signals, T cells undergo clonal expansion. Under the influence of different 
cytokines, T cell differentiate into different CD4+ Teffs lineages. CD8 T cells differentiate into either 
effector or memory T cells. The roles of mTORC1 and mTORC2 in various T cell states are indicated 
in the figure, with (+) signs representing positive roles and (–) signs indicating negative roles. 
Question marks (?) indicate pathways warranting further study or under investigation. Figure 
adapted from (Chapman and Chi 2014).   
 
 
In contrast, CD8 memory T cells, which have high lipid oxidation rates, mTOR inhibition was 
shown to be a crucial event for their differentiation. In a study by (Shrestha et al. 2014), TSC1-
deficient CD8 T cells display high mTORC1 activity and impaired CD8 memory differentiation 
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following IL-15 stimulation. Similar to CD8 memory T cells, Tregs also display high lipid oxidation 
rates. Furthermore, inhibition of mTORC1 activation has been shown to be required for 
differentiation of inducible Tregs (iTregs) and is described in detail in the next section. 
 
1.3.3.2 mTOR Inhibition and Treg Differentiation 
 
Tregs exhibit a very distinct metabolic signature which features low expression of the glucose 
transporter Glut1 and high lipid oxidation rates in vitro (Michalek et al. 2011c). These distinct 
metabolic characteristics can be directly linked to the varying mTOR activity in conventional and 
regulatory T cells. Conventional CD4 and CD8 T cells, upon activation, meet the enhanced energy 
requirement using the mTOR pathway to upregulte aerobic glycolysis. Selective inhibition of 
mTOR by rapamycin prevents the generation of Teff responses and promotes the generation of 
Tregs (Battaglia et al. 2005; Powell et al. 1999; Vanasek et al. 2001; Zheng et al. 2007b). Knocking 
out mTOR specifically in T cells was revealed  to lead to the impaired development of Teff 
responses while favouring Treg differentiation (Zeng et al. 2013a). CD4+ T cells lacking both 
mTORC1 and mTORC2 complexes fail to differentiate into any CD4 Teff lineage (Th1, Th2, or 
Th17), and preferentially develop a Treg cell phenotype (Delgoffe et al. 2009; Delgoffe et al. 
2011). In a study by (Shi et al. 2011), blocking glycolysis promoted iTreg cell generation through 
the inhibition of the transcription factor HIF1α. As described before, HIF1α is functionally 
regulated by mTORC1. 
In Tregs, AMP kinase activity and preferential lipid oxidation (described above) are a primary 
source of energy production. APMK activation is also known to inhibit mTORC1 activation. AMPK 
phosphorylates and activates TSC2, a GTPase-activating protein that forms a complex with TSC1 
which subsequently inactivates RHEB. This results in loss of activation of mTORC1 (Hardie et al. 
2006). Thus, AMPK activity in Tregs, which promotes mitochondrial oxidative metabolism 
indicates reduced mTORC1. In the study by (Michalek et al. 2011c) (described before) inhibition of 
mitochondrial lipid uptake and oxidation pathways by Etomoxir abrogated the generation of Treg 
without altering Teff differentiation. Furthermore, in this study, Tregs expressed lower levels of 
the glucose transporter Glut1 as compared to Teff, and transgenic CD4+ T cells overexpressing 
Glut1 develop fewer Treg. Overall, these studies indicate that inhibition of mTOR and 
subsequently glycolysis, while increasing FAO is crucial in the development and differentiation of 
iTregs. An overview of AMPK signalling in Tregs is provided in Figure 8 below adapted from 
(Fleming et al. 2011). 
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Figure 8    AMPK-mTORC1 signalling in Tregs 
AMPK undergoes activation due to increasing AMP: ATP ratios and upstream activation of LKB1. 
Once activated, APMK inhibits mTORC1 activity either directly or through activation of the TSC1/2 
complex. The TSC1/2 complex is a negative regulator of mTORC1. Additionally, AMPK blocks 
acetyl-CoA carboxylase (ACC), to inhibit suppression of CPT1 activation and thus increases fatty 
acid oxidation. Figure adapted from (Fleming et al. 2011). 
 
 
 
1.3.3.3 mTOR and Treg Function 
 
From the above mentioned discoveries, it could be reasonably assumed that inhibiting mTOR can 
increase Treg differentiation. However, recent findings by (H. Zeng et al. 2013b) indicate a crucial 
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role of the mTORC1 complex to the suppressive activity of Tregs . In this study, mTORC1 activity 
and Glut1 expression were higher in Tregs than naive T cells under steady state conditions. 
Selective genetic deletion of Raptor in the CD4+ Foxp3+ T cell subset led to the early onset of a 
fatal autoimmune disease in mice (H. Zeng et al. 2013b). Interestingly, this disease was described 
to be similar to that witnessed in Scurfy mice that bear a loss-of-function mutation in the Foxp3 
transcription factor, indicating impaired Treg function.    
Mechanistically, (Zeng et al. 2013a) established that the mTORC1 pathway in Tregs was necessary 
to initiate the upregulation of lipid metabolism so as to enable surface CTLA-4 and ICOS for Treg-
mediated suppression. In addition, mTORC1 is also known to induce mitochondrial oxidative 
metabolism (Cunningham et al. 2007). Taken together, these results indicate that mTORC1 activity 
is essential for Treg function. 
 
1.3.3.4 Oscillation of mTOR activity in Tregs. 
 
From the above mention studies it is clear that Tregs require mTORC1 for their functional fitness. 
However, inhibition of mTORC1 is also necessary for Treg differentiation and proliferation. This 
indicates the presence of a dynamic regulation of mTORC1 activity in Tregs. To explain this, the 
report by (Procaccini et al. 2010) described an ’oscillatory model’ of mTOR activation in Tregs. 
Here, mTOR activity in Tregs oscillates between low and high activation states. The intermittent 
reduction in mTOR signalling followed by its enhanced activation by means of TCR triggering and 
IL-2 stimulation was shown to be necessary for Treg proliferation. However, inhibition of mTOR 
signalling necessary for Treg division was short-lived and prolonged incubation with rapamycin 
(>1Hr) ablated Treg proliferation. This study identified the adipocyte hormone leptin as a key 
signal that regulates mTOR activity in vivo, promoting Treg proliferation. In addition, Treg-
produced leptin was identified to contribute to mTOR activation in an autocrine manner.     
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1.3.4 T cell metabolism and migration 
 
1.3.4.1 PI3K-Akt-mTOR axis and T cell migration 
 
Like in all other motile cells, the metabolic status that is maintained in T cells through both 
extracellular and intracellular stimuli, has a profound effect on their migration. One important 
and evolutionally conserved function of the PI3K-Akt-mTOR pathway in T cells is to regulate cell 
metabolism and protein synthesis (Jones and Thompson 2007). These processes are crucial to T 
cell migration and are therefore likely to be closely intertwined with molecular pathways involved 
in T cell migration. For example, regulation of T cell migration via chemokine receptors was 
previously shown to occur partly through the action of the catalytic subunit p110γ of the PI3K. As 
mentioned previously, p110γ-deficient CD4 and CD8 T cells show compromised migration to 
chemokines and fail to recruit inflammatory sites. T cell migration is a highly energy dependant 
process and it is plausible that chemokine induced signalling may affect T cell migration through 
regulation of metabolism. Some tentative evidence to suggest this hypothesis is provided by a 
study linking chemokine receptor signalling to cell growth and metabolism in transformed T cells 
and developing thymocytes (Janas et al. 2010; Lo et al. 2010). However a direct relationship 
between chemokine receptor signalling and T cell metabolism remains to be established. 
In addition to the effect on chemokine receptors, the indirect action of T cell metabolism on the 
expression of adhesion receptors may also regulate trafficking of T cells. Accordingly, PI3Kδ 
signalling through Akt and the Foxo transcription factors not only regulates the expression of 
CCR7 and S1P1, but also that of CD62L integrin. Transcriptional control of CD62L by p110δ was 
observed to be mediated by mTOR through regulation of the transcription factor Krüppel-like 
Factor 2 (KLF2) (Sinclair et al. 2008). KLF2 is a key modulator of homing receptor expression which 
binds to the promoter of CD62L and is necessary and sufficient for CD62L expression (Bai et al. 
2007; Carlson et al. 2006; Sebzda et al. 2008). In CD8 T cells, disruption of the PI3Kδ/Akt signalling 
prevents the down-regulation of CD62L, CCR7, and S1P1, and thus, these T cells retain a lymph 
node trafficking pattern rather than migrating to non-lymphoid inflammed tissues (Finlay and 
Cantrell 2010; Andrew N. Macintyre et al. 2011b). These observations are in line with those that 
show aberrant memory T cell trafficking or PI3Kδ inhibited memory T cell trafficking to peripheral 
sites (Jarmin et al. 2008). Similar results were seen with memory T cells from mice bearing a 
disruptive point mutation in the p110δ (p110δD910A) catalytic subunit of PI3K rendering it inactive 
(Jarmin et al. 2008). 
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Conversely, it is also worth noting that factors that may affect T cell homing and thus the 
peripheral tissue destination of T cells will also affect T cell metabolism, albeit indirectly, by 
determining the cytokine environment to which they are exposed to. A study of the 
differentiation of CD8 T cells through the related cytokines IL2 and IL15 illustrates the differential 
regulation of T cell metabolism by distinct cytokine environments. IL2 induced Akt-mTOR 
promotes elevated glucose metabolism and glycolysis while IL15 does not maintain this metabolic 
state and T cells responding to IL15 have reduced nutrient uptake and glycolysis (Cornish et al. 
2006; A. N. Macintyre et al. 2011a). 
In summary, while several studies have provided indirect evidence linking the PIP3 induced Akt-
mTOR activation pathways to the T cell metabolism, the energy requirement for T cell migration 
has only recently been investigated (R. Haas et al. 2015). However, the metabolic pathways 
required by Tregs have not been studied. This is particularly interesting given the different 
metabolic setup of conventional T cells and Tregs. 
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Chapter 2 Hypothesis and Aims 
 
In conventional T cells, CD28 and CTLA-4 receptors are known to engage signalling pathways 
that regulate adhesion and motility. Therefore, we hypothesised that these molecules would 
also regulate motility in the Treg subset which is known to express these co-receptors. In 
addition, both CD28 and CTLA-4 molecules are both constitutively expressed in Tregs and as 
such are likely to have a distinct impact on their migration compared to the effect exerted on 
conventional Teffs where CTLA-4 is only expressed transiently after activation.  
Furthermore, the novel T cell co-inhibitory receptor molecule CD31 is known to recruit 
phosphatases, which are capable of dephosphorylating key signalling effector proteins that 
regulate T cell migration. Thus, we predict that CD31 would regulate the migration of T cells.    
The specific aims of this study include: 
 To establish a role for TCR antigen recognition in the migration of Tregs  
 To assess the role of CD28 and CTLA-4 in Treg migration in vitro and in vivo and to 
determine if their impact on Treg migration occurs independently of TCR 
signalling. 
 To establish the effect of concomitant signalling of both CD28 and CTLA-4 signal 
on the overall T cell motility and thus Treg migration in vitro and in vivo 
 To assess  the impact of CD31 signalling on T cell migration to chemokines in vitro 
and in vivo  
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Chapter 3 Materials and Methods 
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3.1 Mice  
 
All mice used in the experiments of this study were 7-11 weeks. C57BL/6, BALB/c and CBA/Ca 
mice were purchased from Charles River (UK) and IFN-γR KO mice were purchased from The 
Jackson Laboratory (USA). The Foxp3-GFP (Foxp3-IRES-EGFP) knock in mice on the C57BL/6 
background were kindly provided by Dr B Malissen (Centre d’Immunologie de Marseille -
Luminy, Marseille, France). Marilyn female mice, bearing a transgenic TCR specific for  the 
male minor transplantation antigen HY peptide epitope NAGFNSNRANSSRSS and restricted 
by H2-Ab, have been previously described (Lantz et al. 2000). These mice were bred on a 
recombination activating gene 2 deficient (RAG2−/−) background. The CD28 Y170F transgenic 
mice on the C57BL/6 background were a kind gift provided by Dr K Okkenhaug. Excised 
secondary lymphoid organs from 4 week old CTLA-4KO mice (of H-2u haplotype) were 
provided by Prof D Wraith (Bristol). The CD31-/- mice were present in house and details 
regarding derivation are given in the study by (Gordon S. Duncan et al. 1999b) 
 
All in vivo experiments were conducted with strict adherence to the Home office guidelines 
(PPL 70/7443) following approval by the Queen Mary University of London Ethics committee.  
 
3.1.1 Mouse genotyping 
 
Mouse genotyping was performed by PCR. Briefly, genomic DNA was extracted from tail or 
ear clippings through NAOH-HCl method. 0.5cm clippings were treated first with 100µl 
alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA in H2O) at 95°C for 30 minutes followed by 
100ul of neutralization buffer (40 mM Tris.HCl in H20). PCR reactions were carried out using the 
thermal cycler (Applied Biosystems). PCR end products were analysed on a 0.8-1% agarose gel. 
 
Primers for CD28Y170F 
CD28-L150       5’- GTAGATAGCAACGAGGTCAGC-3’ 
CD28-R778       5’- CAGAGCAGTGATGATGAGCA-3’ 
Actin-F        5’- GGTGTCATGGTAGGTATGGGT-3’ 
Actin-R        5’- CGCACAATCTCACGTTCAG-3’ 
 
Primers for CD28Ex2 
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CD28-int2       5’- CCTGAGTCCTGATCTGTCAGACT-3’ 
CD28-ex2       5’- CTGCTTGTGGTAGATAGCAACGA-3’ 
CD28 HSV-TKv2       5’- ATTCGCCAATGACAAGACGCTGG-3’ 
 
Primers for P110δD910A 
 
D150:      5’- GGG GTC TGA ATA CAG AGA GAA T -3’ 
D153:     5’- CCA TTT ATG GCT ATT CTG TTC -3’ 
 
Primers for IFN-γR KO 
oIMR0587:               5’- CCC ATT TAG ATC CTA CAT ACG AAA CAT ACG G -3’      (wild type) 
oIMR0588:                 5’- TTT CTG TCA TCA TGG AAA GGA GGG ATA CAG -3’ (wild type) 
oIMR6916:                 5’- CTT GGG TGG AGA GGC TAT TC -3’                                (mutant forward) 
oIMR6917:                 5’- AGG TGA GAT GAC AGG AGA TC -3’                               (mutant reverse) 
 
3.2 Cells 
 
3.2.1 Endothelial Cells 
 
3.2.1.1 Isolation of primary microvascular endothelial cells 
 
Murine lung microvascular endothelial cells were isolated as previously described (Marelli-
Berg et al. 2000). Mouse lungs were diced into 2-3mm3 blocks, washed in phosphate 
buffered saline (PBS; Sigma-Aldrich, Cat# D8537) and digested in a solution containing 
0.5mg/ml Type IV Collagenase (Sigma, Cat# C5138) for 30 minutes in a humidified incubator 
maintained at 37°C. A 70um cell strainer (Fisher scientific, Cat# 22363548) was then used to 
remove undigested tissue while the digested tissue was collected and centrifuged at low rpm 
(<250g). The supernatant was aspirated and further digested in trypsin/ 
ethylenediaminetetraacetic acid (EDTA) (Gibco, Cat# E7889) at 37 °C for 5 minutes to create 
a uniform cell suspension. The cell suspension was then washed with PBS at a high centrifuge 
speed (>300g) and resuspended in DMEM (Gibco, Cat# 11966-025) containing 10% Foetal 
bovine serum (Seralab, Cat# A210009). The cells were then seeded in 2% gelatinated (Sigma-
Aldrich, Cat# 1393) 25 cm2 culture flasks (Helena biosciences, Cat# 90026) for 24 hours. 
After 24 hours, non-adherent cells were removed by washing with warm PBS and complete 
EC medium (mentioned below) was added to the culture. 
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3.2.1.2 Culture of ECs 
 
EC medium consisted of Dulbecco's Modified Eagle media (DMEM, Gibco, Cat# 41966-052) 
supplemented with 2 mM glutamine (Gibco, Cat# 250-30), 50 IU/mL penicillin (Gibco, Cat# 
15140-122), 50 μg/mL streptomycin (Gibco, Cat# 15140-122), 50 µM 2-Mercaptoethanol (2-
ME) (Gibco, Cat# 31350-010), 1mM sodium pyruvate (Gibco, Cat# 11360-039), 20mM N-2-
hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES) (Gibco, Cat# 15630-056), 1% non-
essential amino acids (Gibco, Cat# 11140-050), 20% FCS and 150μg/ml EC growth 
supplement (Sigma-Aldrich, Cat# E0760). Medium was replaced every 48 hours. When 
confluent, cells were detached with trypsin/EDTA (Gibco, Cat# T4049) and passaged.  
For functional assays, ECs were used between passages 2 and 8 and treated with 600 U/mL 
murine IFN-γ (PeproTech, Cat# 315-05) for 48 to 72 hours prior to use in experiments. This 
led to up-regulation of MHC class I, induction of MHC class II and several adhesion molecules 
(Class II upregulation shown in Figure 9 below) 
 
 
 
Figure 9    Class II MHC expression on endothelial cells 
This histograms in this figure display the surface expression of class II MHC molecules by murine 
microvascular endothelial cells observed by flow cytometry. Treatment with 600U/ml IFN-γ for a 
period between 48-72 hours induces class II MHC upregulation. Dark peaks indicate 
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expression via flurochrome labelled anti-Class II antibody while grey peaks are representative 
of isotype. 
 
 
3.2.2 Bone marrow-derived Dendritic Cells (bmDCs) 
 
3.2.2.1 Isolation of bone marrow-derived Dendritic Cells (bmDCs) 
 
Bone marrow-derived DCs were obtained from WT BALB/c (H2-d) mice. Femurs and tibias 
from 7–to-10-week-old female mice were removed and BM cells were flushed out with PBS 
using a 27 gauge needle (Becton Dickinson, Cat# 302200). Red blood cells were lysed from 
the cell suspension with lysis buffer (Sigma-Aldrich, Cat# R7757). BM cells (5 × 106) were 
seeded per well in a 6 well plate (Helena bioscience, Cat# 92006) in DC medium as described 
in section below. 
 
3.2.2.2 Culture of Dendritic cells 
 
Bone marrow-derived dendritic cells were cultured in RPMI 1640 medium (Gibco, Cat# 
21875-034) supplemented with 10% FCS, 2mM glutamine, 50 IU/mL penicillin, 50 μg/mL 
streptomycin, 50 µM 2-ME and 2% murine granulocyte-macrophage colony stimulating 
factor (GM-CSF) obtained from the supernatant of the GMCSF hybridoma (gift from Dr. Jian-
Guo Chai, Imperial College, London, UK). Cells were cultured at 37°C in the presence of 5% 
CO2. On days 3 and 5, fresh culture medium was added to the plates. 
For Treg-DC co-cultures, immature bmDCs were collected and used on day 6 of culture. For 
functional assays, immature DCs were matured overnight with 100ng/ml lipopolysaccharide 
(LPS) (Invivogen, Cat# tlrl-3pelps) and were used between 7-to-10 days post-isolation. 
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3.2.3 T cells 
 
3.2.3.1 Isolation of T cells 
 
Primary T cells were isolated from the lymph nodes and spleen of the mice. Mice were 
dissected and the lymph nodes and spleen removed. A uniform cell suspension was prepared 
by mashing the lymph nodes and spleens through a 70um cell strainer. Cells were then used 
directly or further subjected to immunomagnetic separation to obtain specific T cell subsets.  
 
3.2.3.2 Culture of HY-specific T cells 
 
Effector memory CD4+ and CD8+ T cells specific for the male-specific minor transplantation 
antigen HY peptide Dby epitope and restricted by H2-Ab and for the Uty epitope restricted 
by H2-Db, respectively, were obtained from WT female mice by 2 fortnightly intraperitoneal 
(i.p.) immunization of female mice with male splenocytes, and further expansion of isolated 
T lymphocytes with male splenocytes in vitro, as previously described (Jarmin et al. 2008; 
Marelli-Berg et al. 2004a). T cell populations were composed by approximately 20% CD8+ 
and 75% CD4+ T cells. The T cells were cultured at 37°C in the presence of 5% CO2 using T 
cell medium consisting of RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 
50 IU/mL penicillin, 50 μg/mL streptomycin, 10mM HEPES and 50 µM 2 -ME. Additionally, 
20U/ml of IL-2 (Roche, Cat# 10799068001) was supplemented to the medium. 
For use in functional assays, viable T cells were selected between days 6-8 by density 
gradient centrifugation with Ficoll-Paque (GE Healthcare, Cat# 17-1440-02).  
 
3.2.3.3 Culture of H2-d allospecific T effector cells 
 
T effector cells were isolated using negative immunomagnetic selection kits for CD4+CD25 - T 
cells (Invitrogen Dynal, Cat#11463D) from a mixture of lymphocytes cell suspension obtained 
from dissected lymph nodes and spleens of WT C57BL/6 (H2-b haplotype) mice. Purified 
CD4+CD25-T cells were then co-cultured with irradiated (60Gy) splenocytes (50x106 
splenocytes per 5x106 lymphocytes) from BALB/c (H2-d haplotype) to selectively expand H2-
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d alloantigen specific cross reactive T cells. T cells were cultured in complete T cell medium 
with 20U/ml of IL-2. 
 
3.2.3.4 Culture of H2-d allospecific Tregs 
 
CD4+CD25+ Treg cells were isolated from spleen and LNs using the Dynabeads® FlowComp™ 
Mouse CD4+CD25+ Treg Cells Kit (Invitrogen Dynal, Cat#11463D). To expand H2d-allospecific 
CD4+CD25+ Tregs, cells isolated from C57BL/6 (H2-b) mice were stimulated weekly with 
either irradiated or mytomycin C (Sigma-Aldrich, Cat# M4287) inactivated immature BALB/c-
derived (H2-d) DCs at a ratio of 5:1 (Treg:DC). The co-cultures were maintained in complete T 
cell medium supplemented with 10U/ml IL-2. Cells were harvested and seeded at an optimal 
density of 1.5 × 106 Treg cells per well of a 24-well tissue culture (Helena bioscience, Cat# 
92024) plate each week. The percentage of CD4+Foxp3+ cells after two weeks of culture was 
greater than 95%. For extremely high purity of Treg cells (>99%), CD4+CD25+Foxp3+ cells 
were obtained from Foxp3-GFP reporter mice through FACS.   
For use in functional assays, Tregs were removed from co-cultures between days 6-8. 
 
 
3.3 Antibody-mediated T cell activation 
 
Activated T cells were obtained by polyclonal stimulation of LN cells with plate-bound anti-
CD3 (1 µg/ml, eBiosciences, Cat# 16-0032-85) and plate-bound anti-CD28 (5 µg/ml, 
eBiosciences, Cat# 16-0281-86) in in complete T cell medium supplemented with 20 U/ml 
recombinant IL-2 (Roche, West Sussex, UK) for 7 days at 37°C. Antibody coating of tissue 
culture plates was performed by incubating antibodies in 200µl of Tris buffer (pH 8.5) at 37°C 
for a period of 1 hour.  
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3.4 Lymphocyte trans-endothelial migration assay 
 
Primary microvascular endothelial cells treated with IFN-γ for 48–72 h were seeded (3 × 104) 
and cultured on 2% gelatin-coated Transwell tissue culture well inserts (diameter, 6.5  mm) 
containing 3-μm pore size (Costar, Cat# CLS3472-48EA) polycarbonate membranes in EC 
medium for 16 h to from a monolayer. T cells (5 × 105) resuspended in migration medium 
(RPMI 1640 supplemented with 2% fetal bovine serum) were added to each insert and left to 
migrate through the monolayer; the well volume was also replaced with fresh migration 
media. The number of migrated T cells was determined by hemocytometric counting of the 
cells present in the well media at different time points over a 24-h period. Figure 10 below 
depicts a diagrammatic overview of this assay.  
 
 
Figure 10    lllustrative overview of in vitro migration assays 
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3.5 Lymphocyte chemokinesis assay 
 
Approx. 5–10 × 105 T cells were seeded onto Transwell™ tissue culture well inserts (diameter, 
6.5 mm) with 5-μm pore size (Costar, Cat# CLS3421-48EA) polycarbonate membranes and 
chemokine containing migration media was placed in the bottom of the well. The number of 
migrated cells was determined by hemocytometric counting of the cells present in the well 
media at indicated time points. Figure 1 above also depicts a diagrammatic overview of this 
assay. The table below indicates the chemokines and the concentrations that were used in 
this 
study. 
 
  
Chemokine Concentration 
used 
Supplier Catalogue 
no. 
MIP-3β  
(CCL19) 
200ng/ml Peprotech 250-27B 
Murine Exodus-2 
(CCL21) 
200ng/ml Peprotech 250-13 
Murine IP-10  
(CXCL10) 
300ng/ml Peprotech 250-16 
Murine SDF-1α 
(CXCL12) 
300ng/ml Peprotech 250-20A 
 
 
Table 4    Chemokine and chemokine concentrations in chemokinesis assays 
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3.6 Mixed lymphocyte reaction assay 
 
Treg suppressive ability was measured using mixed lymphocyte reaction (MLR) or mixed 
lymphocyte culture (MLC) assays. Responder T cells isolated from LNs/Spleen were activated  
by plate-bound anti-CD3 anti-CD28 antibody or DCs in triplicates in a 96 well plate following 
which Tregs were added to the wells at varying ratios in T cell medium. The co-culture plates 
were incubated for 48 hours at 37°C after which the cells were pulsed with 1μCi/well 3H 
thymidine and incubated overnight at 37°C in the presence of 5% CO2.  The reaction was 
halted by freezing the plates at -20°C; plates were later thawed and harvested using Tomtec 
harvester 96 (Receptor Technologies, Adderbury UK) and onto filter paper (Perkin Elmer). 
Cell proliferation was measured by radioactivity incorporation and read by using Wallac 
Microbeta counter for Windows (Perkin Elmer) 
 
3.7 Induction of CD28 and CTLA-4 signalling  
 
Induction of CD28 and CTLA-4 signalling was performed as has been described previously in 
the study by (Schneider et al. 2005) and by (Wells et al. 2001).To induce co-stimulatory 
signals via CD28 and CTLA-4 co-receptors for functional assay, cells were incubated with 
antibodies targeting the functional domains of the co-receptors. To induce CD28 signalling, T 
cells were treated with a mixture of hamster anti-mouse CD28 (5μg/5x106 cells) (clone: 
37.52, Bio-Rad, Cat# MCA1363) and goat anti-hamster immunoglobulin (Ig) (2.5μg/5x106 
cells) (Bio-Rad, Cat# STAR104) in migration medium for 45 minutes at 37°C in the presence of 
5% CO2. Similarly, CTLA-4 signalling was achieved by incubating T cells with a mixture of 
hamster anti-mouse CTLA-4 (5μg/5x106 cells) (clone: UC10-4F10-11, Becton Dickinson, Cat# 
553718), and goat anti-hamster immunoglobulin (Ig) (2.5μg/5x106 cells) (Bio-Rad, Cat# 
STAR104). A hamster IgG isotype control was used to observe any non-specific effects of the 
antibody stimulation (Bio-Rad, Cat# MCA2356). T cells were washed in PBS prior to use in the 
experiments. 
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3.8 Fluorescent labelling of viable T cells 
 
For labelling T cells with fluorescent probes, T cells were washed with PBS, counted and 
resuspended in PBS at a final concentration of 107/ml. If necessary, dead cells were removed 
using density gradient centrifugation with Ficoll-Paque prior to re-suspension. Labelling of T 
cells with PKH26 (Sigma-Aldrich, Cat# PKH26GL-1KT), a cell linker dye for cell membranes 
was performed using manufacture instructions. PKH26 labelling added at a final 
concentration of 5μΜ, and the cells were incubated at room temperature for 5 minutes. The 
reaction was inactivated by adding an equal volume of FBS to the cell suspension and the 
cells were washed in PBS containing 10% FBS for 10 minutes. Labell ing of T cells with 
succinimidyl ester dyes CFSE (Invitrogen, Cat# C1157) or DDAO-SE (Invitrogen, Cat# C34553) 
was performed by incubating the T cells in PBS containing final concentration of 3.3μm CFSE 
or 1.3μm DDAO-SE for 10-15 minutes at room temperature. The reaction was terminated by 
adding equal volume FBS and the cells were then washed with PBS containing 10% FBS for 10 
minutes. 
 
3.9 Peritoneal model of T cell recruitment 
 
To observe in vivo recruitment of T cells we used the previously described model of T cell 
recruitment (Mirenda et al. 2007).Either PKH26 or CFSE or DDAO-SE labelled T cells (107) 
were injected intra-venously (i.v.) into mice that have previously received IFN-γ (600U; 
administered intra-peritoneal injection (i.p.)  48 to 72 hours before. This IFN-γ treatment 
induces local upregulation of MHC molecules by the endothelium enabling T cell 
recruitment. Labelled T cells recovered via peritoneal lavage were analysed 16 hours later 
using flow cytometric analysis. In addition, the draining mesenteric lymph node and other 
secondary lymphoid tissue such as the spleen were analysed using flow cytometry to observe 
recruitment to those tissues. 
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3.10 Imaging and microscopy 
 
3.10.1 Time lapse microscopy 
 
Primary ECs were seeded onto wells of a 24-well tissue culture plate for 24hours to obtain 
confluent monolayers. A total of 5 × 105 T cells were seeded onto confluent endothelial 
monolayers and their migration was recorded using an optimized Nikon Eclipse TE2000 
microscope, equipped with a × 20 objective and Metamorph software (Molecular Devices 
LLC). Images were taken every minute over a 60-min period and the migration speed 
(μm min−1) of the cells was determined using ImageJ analysis software (National Institute of 
Health). About 30–40 cells were tracked in every experimental condition. 
 
3.10.2 Widefield deconvolution fluorescence microscopy 
 
Tissues samples were excised, embedded in Optimal Cutting Temperature compound (OCT; 
Thermo Fisher Scientific, Cat# 12678646), snap-frozen and stored until analysis. Frozen 
tissue sections were laid onto Polysine coated microscope slides (VWR International, Cat# 
47100), air dried and then fixed with ice cold acetone (Sigma, Cat# 534064) for 10 min. 
Tissue sections were washed in PBS, blocked with serum for 3 hours and stained using 
mentioned primary antibodies at 4  °C for 24 h. Excess antibody was washed away with PBS 
and tissues were stained with indicated secondary antibodies along with DAPI (4',6-
diamidino-2-phenylindole) (Invitrogen/LifeTechnologies, Cat# D1306) for 30  min at room 
temperature. Slides were washed, mounted in ProLong Gold Antifade Reagent 
(Invitrogen/Life Technologies, Cat# P36930) and visualized using a Zeiss Z1 fluo rescence 
microscope (Carl Zeiss, UK) equipped with an AxioCam MRm Cooled monochrome digital 
camera and an Apotome 2 Imaging unit. Images were acquired using a Plan Apochromat 
20x/0.8 NA objective and Axiovision software version 4.8 (Carl Zeiss, UK).  
 
 
 
 
    Materials and Methods 
111 
 
3.10.3 Confocal microscopy 
 
Cells were allowed to adhere onto poly-l-lysine coated coverslips and fixed in 4% 
paraformaldehyde (Thermo Fisher Scientific, Cat# 28906) for 5-10 minutes at room 
temperature. Where mentioned, permeabilization was carried out using 0.2% Triton X-100 
(Sigma-Aldrich, Cat# X100-500ML) in PBS for 5 minutes. Cells were then washed in PBS, 
blocked in blocking buffer (PBS containing 0.1% Fish skin gelatin (Sigma-Aldrich, Cat# G7765) 
and 1% serum of the species giving rise to secondary antibodies) for 3-6 hours and then 
stained with appropriate primary antibodies at 4°C for 16 hours in the dark. Following 
staining, cells were washed again and stained with corresponding secondary antibodies and 
DAPI for 30 minutes at room temperature. After multiple PBS washes coverslips were 
mounted onto slides using ProLong Gold antifade and then examined using a Leica SP5 
confocal microscope equipped with a 63×1.4 NA objective. Confocal images and z -stacks 
were acquired and analysed by Leica LAS software. Repositioning of scale bars and image 
layouts were prepared using Adobe Photoshop (Adobe Systems). All images in a group were 
treated equally. 
 
3.10.4 Intravital microscopy 
 
T cell–EC interactions were visualized by intravital microscopy of the cremasteric muscle 
vasculature of male mice pre-treated with intrascrotal injection of 1,200  U IFN-γ for 72 h. 
Mice were then anesthetized by i,p. administration of ketamine (150  mg kg−1) (Ketalar; 
Parke-Davis, Cambridge, UK) and 7.5 mg kg−1 xylazine (Rompun; Bayer, Newbury, UK)  and 
placed on a custom-built, heated (37 °C) microscope stage. The jugular vein was cannulated 
and the cremaster muscle was exteriorized through an incision in the scrotum. One testis 
was gently drawn out to allow the cremaster muscle to be opened and pinned outflat over 
the optical window within the microscope stage. The tissue was kept warm and moist 
throughout each experiment by superfusion with 37  °C bicarbonate buffered saline. A total 
of 2.5 × 107 CFSE (20 μm) labelled T cells were infused into the cannulated jugular vein and 
the cremaster muscle post capillary venules were imaged 1  h later using an Olympus 
BX61W1 microscope with an Olympus UMPlanFL × 20/0.50 W water immersion objective 
(Carl Zeiss). The set-up was connected to an Olympus BXUCB lamp, Uniblitz VCMD1 shutter 
driver and DG4-700 shutter instrument. The set-up used a Hamamatsu C9300 digital camera 
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with a Videoscope VS4-1845 image intensifier attached. All videos were captured and 
analysis carried out using Slidebook 5.0 software (Intelligent Imaging TTL). 
 
Rolling cells were defined as fluorescent T cells moving slower than the flowing erythrocytes, 
and rolling flux was quantified as the number of rolling cells moving past a fixed point on the 
venular wall per 5 min. Firmly adherent leukocytes were defined as fluorescent T cells that 
remained stationary for at least 30  s within a 450 um vessel segment. Transmigrated cells 
were defined as those cells in the extravascular tissue of the 340–450 μm field of view, 
either side of the vessel segments quantified at least two sections of 2–5 vessels were 
studied in each animal. 
 
3.11 Assays of T cell metabolism 
 
3.11.1 In vitro 6NBDG uptake assay 
 
Freshly isolated T cells or cultured T cells were washed in PBS and resuspended in gluc ose 
free T cell medium (Gibco, Cat# 11879-020) containing various mentioned signalling 
antibodies and incubated for 45 minutes at 37°C with 5% CO2. A final concentration of 
400µM 6-NBDG (Life Technologies, Cat# N23106) in glucose free T cell medium was then 
added to the cells and the cells were further incubated for an additional 10-15 minutes. 
Finally, the cells were washed twice with warm PBS and resuspended in flow cytometry 
buffer and placed on ice. Immediate analysis was performed using flow cytometry to observe 
fluorescence uptake by the T cells. 
 
 
3.11.2 In vivo 6NBDG uptake assay 
 
To measure glucose uptake activity of T cells in vivo, PKH26 labelled T cells (3x106) were 
injected intra-peritoneally (I.P) into mice. A second I.P injection of 6NBDG (400µM in Sterile 
water) was given to the mice immediately afterwards. After a 1 hour period, the mice were 
sacrificed and the mesenteric (draining) lymph nodes and spleen collected for analysis by 
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flow cytometry. Widefield microscopy of the peritoneal membranes was performed to 
observe influx of labelled T cells into the peritoneal membrane. PKH26+ T cells infiltrating 
the membranes were further analysed for 6NBDG uptake (green fluorescence) using image 
analysis software ImageJ. A cell count of labelled cells in 10 (10x) field views images was 
performed manually to determine differences in T cell infiltration.     
 
 
3.11.3 Measurement of ECAR and OCR 
 
Real time bioenergetics analysis of extracellular acidification rates (ECAR) and oxygen 
consumption rates (OCR) of T cells subjected to antibody stimulation was performed using 
the XF analyser (Seahorse biosciences). T cells were cultured in serum free, unbuffered XF 
assay medium (Seahorse biosciences, Cat# 102365-100) for 1 hour following which they were 
seeded (6X105/well) into the seahorse XF24 cell plates for analysis.  Perturbation profiling of 
the use of metabolic pathways by T cells was achieved by the addition of oligomycin (1 μM), 
Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 1μM), Antimycin A (1μM), 
rotenone (1 μM), D-glucose (10mM), 2-Deoxy-D-glucose (2DG, 50mM; all from Sigma-
Aldrich). Experiments with the Seahorse system were done with the following assay 
conditions: 2 min mixture; 2 minutes wait; and 4–5 min measurement. Metabolic parameters 
were then calculated. 
 
3.12 Flow Cytometry 
 
3.12.1 Cytometer and analysis software 
 
Flow cytometric analysis of T cells was performed using either a 3 laser equipped 
FACSCalibur (Becton Dickinson, Oxford, UK) connected to a Mac computer (OS 9) with 
Cellquest as the acquisition software or on a 4 laser equipped LSR II Fortessa machine 
(Becton Dickinson) using FACSDiva as acquisition software. 
Acquired samples were analysed using Flowjo (Treestar, USA) by gating on live cells on the 
forward and side scatter plot.  
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3.12.2 Surface staining 
 
For surface staining, cells were resuspended (107/ml) and stained with flurochrome 
conjugated antibodies in 100µl of Flow cytometry buffer made of PBS containing 0.1% 
sodium azide (Sigma-Aldrich, Cat# S2002-25G) and 1% FBS at 4°C for 30 minutes. CCR7 
antibody (4B12) staining was performed at 37°C for 30 mins. Optimal antibody 
concentrations for staining were calculated based on manufacturer instructions. Following 
staining, cells were washed and resuspended with flow cytometry buffer and analysed 
immediately. Alternatively, for delayed analysis, cells were fixed in fixation buffer (flow 
cytometry buffer containing 1% Formaldehyde (Sigma-Aldrich, Cat# 15,812-7)) for 30 
minutes at 4°C , washed and stored in flow cytometry buffer at 4°C. The table below 
indicates the fluorescent antibodies that were used in this study 
 
 
Antibody  Clone Conjugate  Isotype Supplier Catalogue 
no. 
Anti-CD3 
 
17A2 PE/Cy7 Rat IgG2b, κ Biolegend 100220 
Anti-CD4 GK1.5, 
RM4-5 
PE, APC, 
efluor450 
Rat IgG2a, κ eBioscience 12-0042-82 
Anti-CD8 53-6.7 PE, APC, 
FITC 
Rat IgG2a, κ eBioscience 11-0081-82 
Anti-CD11a  
(LFA-1) 
M17/4 PE Rat IgG2a, κ eBioscience 11-0111-81 
Anti-CD11c  N418 Alexa 
Fluor® 647 
Armenian 
Hamster IgG 
Biolegend 117312 
Anti-CD14 Sa2-8 PE Rat IgG2a, κ eBioscience 12-0141-82 
Anti-CD25  
(IL-2 receptor) 
PC61.5 PE, PE/Cy7 Rat IgG1, λ eBioscience 12-0251-81 
Anti-CD28 37.51 PE Syrian 
Hamster IgG 
eBioscience 12-0281-82 
Anti-CD29 
 (VLA-4) 
HMβ1-1 APC/Cy7 Armenian 
Hamster IgG 
Biolegend 102226 
Anti-CD31 
(PECAM-1) 
390, MEC 
13.3 
PE Rat IgG2a, κ eBioscience 12-0311-81 
Anti-CD40 
 
3/23 PE Rat IgG2a, κ Biolegend 124607 
Anti-CD44 
 
IM7 PE Rat IgG2a, κ eBioscience 12-0441-81 
Anti-CD49d 
(Integrin alpha 4) 
9C10 
(MFR4.B) 
PE Rat IgG2a, κ Biolegend 103705 
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Anti-CD54  
(ICAM-1) 
YN1/1.7.4 PE Rat IgG2b, κ Biolegend 116105 
Anti-CD62L 
 (L-Selectin) 
MEL-14 PE, PE/Cy7 Rat IgG2a, κ eBioscience 12-0621-81 
Anti-CD69 H1.2F3 PE, PE/Cy7 Armenian 
Hamster IgG 
eBioscience 12-0691-81 
Anti-CD80  
(B7-1) 
3H5 PE Mouse 
(BALB/c) 
IgG1, κ 
Becton 
Dickinson 
555014 
Anti-CD86  
(B7-2) 
GL1 PE Rat IgG2a, κ eBioscience 12-0862-81 
Anti-CD102 
(ICAM-2) 
3C4(mIC2/4
) 
FITC Rat IgG2a, κ Becton 
Dickinson 
553326 
Anti-CD103 
(Integrin alpha E) 
2E7 PE  Armenian 
Hamster IgG 
eBioscience 14-1031-81 
Anti-CD106 
(VCAM-1) 
429 FITC Rat IgG2a, κ eBioscience 11-1061-81 
Anti-CD119 
(IFNγ 
Receptor1)  
2E2 PE Armenian 
Hamster IgG 
eBioscience 12-1191-82 
Anti-CD152 
(CTLA-4) 
UC10-4B9 PE, PE-Cy7, 
APC 
Armenian 
Hamster IgG 
Biolegend 106306 
Anti-Mouse 
CD183 (CXCR3)  
CXCR3-173 PE Armenian 
Hamster IgG 
eBioscience 12-1831-82 
Anti CD184 
(CXCR4) 
2B11 PE Rat IgG2b, κ eBioscience 12-9991-81 
Anti CD194 
(CCR4)  
2G12 PE Armenian 
Hamster IgG 
Biolegend 131203 
Anti CD195 
(CCR5)  
HM-CCR5 
(7A4) 
PE Armenian 
Hamster IgG 
eBioscience 12-1951-81 
Anti CD197 
(CCR7)  
4B12 PE, PE-Cy7, 
APC 
Rat IgG2a, κ eBioscience 12-1971-82 
Anti I-A/I-E  
(Class II MHC) 
M5/114.15.
2 
PE Rat IgG2b, κ Biolegend 107602 
Anti-Foxp3 FJK-16s Alexa 
Fluor® 647, 
Alexa 
Fluor® 488, 
APC 
Rat IgG2a, κ eBioscience 53-5773-82 
Anti-phospho-
Akt (Ser473) 
- Purified Rabbit IgG Cell Signalling 9271 
Anti-PCNA  PC10 PE Mouse 
IgG2a, κ 
Biolegend 307908 
Anti-Vβ6  
 
RR4-7 PE Rat IgG2b, κ eBioscience 17-5795-82 
 
Table 5    Fluorescent conjugated antibodies used for flow cytometry 
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3.12.3 Intracellular staining 
 
For intracellular Foxp3 staining, eBioscience Anti-Mouse/Rat Foxp3 Staining Set APC (clone 
FJK-16S) kit was used. Cells were resuspended (107/ml) and stained with surface antigens as 
mentioned above and then fixed/permeabilized  for 30 minutes at 4°C using 
Fixation/Permeabilization working solution made from mixing 1 part of the 
fixation/permebilization concentrate (eBioscience, Cat# 00-5123) to 3 parts of the 
fixation/permebilization diluent (eBioscience, Cat#  00-5223 ). The cells were then washed 
twice in 1X permeabilization buffer (eBioscience, Cat# 00-8333) and stained with 
fluorochrome conjugated-Foxp3 antibody in 1X permeabilization buffer for 30 minutes at 
4°C. A final wash with 1X permeabilization buffer was performed and the cells were then 
centrifuged and resuspended in 200ul of flow cytometry buffer.  
 
For intracellular staining of phosphorylated antigens such as Akt, after surface staining, cells 
were fixed in ice cold 90% methanol (VWR International, Cat# 20847.307) for 10 minutes at –
20°C. Cells were then washed twice in PBS. Intracellular staining was carried out after 
initially blocking permeabilized cells in buffer (0.5% BSA/PBS + Na3VO4) at room 
temperature for 30 min and incubation with a dilution of 1:100 of Phospho-Akt (Ser473 
rabbit anti-mouse antibody )(Cell Signalling Technology, Cat#  9271) for 30 min at room 
temperature. Cells were then washed and stained with secondary APC-F(ab)2 fragment 
donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch, Cat# 711-116-152) at 1:100 for 30 
min at room temperature. After a final wash, cells were resuspended and then analyzed 
using flow cytometry. 
 
3.13 Western Blotting 
 
Total cell lysates were obtained in 3M NaCl, 1M TRIS-base (pH 7.5), 1.0% Triton X-100, 
phosphatase inhibitor cocktail 2 (Sigma-Aldrich, Cat# P5726) and protease inhibitor (Sigma-
Aldrich, Cat# P8340). 20 mg of cell lysate was subjected to SDS-PAGE, under reducing conditions. 
We used NuPAGE® 4-12% Bis-Tris Gel (LifeTechnologies, Cat# WG1401BOX) with the 
XCellSureLock™ Mini-Cell (Life Technologies, Cat# EI0001), that require 800 ml of NuPAGE® MES 
SDS Running Buffer (20X) (LifeTechnologies, Cat# NP0002). After electrophoresis, proteins were 
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transferred into a nitrocellulose filter membrane (Protan; Schleicher & Schuell BioScience) using a 
XCell II™ Blot Module (LifeTechnologies, Cat# EI0002) in, NuPAGE® transfer buffer (20X) 
(LifeTechnologies, Cat# NP0006), with NuPAGE® Antioxidant (LifeTechnologies , Cat# NP0005) and 
10% methanol. Membranes were placed in 5% nonfat milk in PBS plus 0.05% Tween 20 (PBST) 
(Cell signalling Technology, Cat# 9809) at 25°C for 1 hours to block the nonspecific binding sites. 
Filters were incubated overnight with specific antibodies, before being washed three times in 
PBST and then incubated with a peroxidase-conjugated secondary antibody (GE Healthcare). After 
washing with PBST, peroxidase activity was detected with the Lumi-light western blotting 
substrate (Roche, Cat#12015200001) or with the Supersignal West Femto (Thermo Scientific, 
Cat#34095). All antibodies were used at 1:1000 in PBST 5% BSA. The filters were also probed with 
an Actin and ERK 1/2 antibody (Santa Cruz Biotechnology Inc.), 1:1000 in PBST 5% non-fat milk, to 
normalize the amount of loaded protein. All filters were quantified by densitometric analysis of 
the bands, using the program ImageJ software. 
3.14 Statistical Analyses 
 
An unpaired student’s t-Test test was used do assess significance of all experiments 
presented. All reported P values are 2-sided. P values of less than 0.05 were considered 
significant. 
 Experimental data sets from the seahorse analyser were analysed using a one-way 
ANOVA using Bonferroni correction or Kruskal-Wallis with Dunn’s post-test to take into 
account of multiple comparisons. Results with p < 0.05 were considered statistically 
significant. Where indicated ‘n’ represent the number of replicates in in vitro experiments or 
number of animals in in vivo experiments. N signifies the number of experiments. 
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Chapter 4 Results 
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4.1 Part 1: Self-recognition of endothelium enables Treg 
trafficking  
 
 
4.1.1 Introduction 
 
CD4+ CD25+ Foxp3+ Tregs constitute a small fraction of the total T cell repertoire. Despite this 
numerical disadvantage, these Tregs form a crucial component of the immune system that 
maintains tolerance within the peripheral tissues. Tregs can exert their immunomodulatory roles 
in both lymphoid and non-lymphoid tissues. During the initial stages of an immune response, 
effective migration and localisation of Tregs within the lymph nodes is vital for the regulation of T 
cell clonal expansion and differentiation (Ding et al. 2012). However, once an effector immune 
response becomes established, regulation of local inflammation in the peripheral target tissues 
becomes crucial (Nguyen et al. 2007; Rudensky and Campbell 2006). 
The importance of Treg co-localisation with Teffs to the periphery has been highlighted in several 
studies of autoimmunity. For example, in Foxp3 deficient scurfy mice, widespread autoimmunity 
can be circumvented by the adoptive transfer of Foxp3+ Tregs. Interestingly, restoration of Treg 
compartment with a-1, 3-fucosyltransferase VII-deficient Tregs that are incapable of migrating to 
skin results in the prevention of autoimmune disease in all tissues but the skin (Dudda et al. 
2008). Similarly, loss of CCR4 expression in Tregs disables their recruitment to the skin and lung 
resulting in skin and lung inflammatory diseases (Sather et al. 2007).  
During an effector immune response in the periphery, the establishment of an optimal Treg:Teff 
ratio is essential for immune regulation (Tang et al. 2012). Thus rapid recruitment of Tregs relative 
to Teffs is required to control tissue damage emphasizing the need for efficient recruitment (Fan 
et al. 2010). Given that Tregs exhibit reduced proliferative potential (comparatively to Tnaive and 
Tcm) and have extremely low proportions in the peripheral blood, this suggests the existence of 
mechanisms that favour their convergence and localisation to the inflammatory sites. 
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Similar to Teffs, following activation, Tregs also acquire distinct chemokine receptors and 
adhesion molecules enabling their recruitment and retention to sites where regulation is required 
(Bach 2003; Luster 2002; Wood and Sakaguchi 2003). For example, activated Tregs express αE 
(CD103) β7, the ligand for E cadherin, which enables their efficient localisation into inflamed tissue 
to suppress the effector phase of the immune response (Huehn et al. 2004; Lehmann et al. 2002). 
There is evidence that suggest the existence of Treg subsets which preferentially localise to 
distinct inflammatory environments.  For instance, CXCR3 expressing Tregs are capable of 
migrating and regulating Th1 cell induced inflammatory responses within the liver, and CNS in EAE 
(Muller et al. 2007). CCR6+ Tregs accumulate in Th17 cell induced inflammatory sites that also 
include the CNS in EAE models (Yamazaki et al. 2008).  However, the redundancy in the molecular 
interactions mediating Treg recruitment to several distinct tissue sites suggest that further 
mechanisms must be in place which enhance Treg recirculation during inflammation.  
Furthermore, it is unclear how Tregs are able to effectively and rapidly access, as well as 
accumulate to, non-lymphoid tissue relative to Teffs. Given that Treg mediated suppression needs 
to be coordinated with a sufficient delay to allow the effector response to ensue, but prior to the 
occurrence of tissue damage, mechanisms must exist to ensure these timely events. 
As we have previously mentioned, the endothelial cells lining microvascular vessels are capable of 
capturing, processing and displaying antigens on MHC molecules in response to inflammatory 
stimuli (Marelli-Berg and Jarmin 2004b). This allows T cells bearing specific TCRs for those 
antigens to be recruited, enabling antigen-specific T cell recruitment into tissues. There is 
evidence that Tregs also traffic in response to antigen recognition. Recently, a study has reported 
that Tregs recruit and compartmentalize in a site-specific manner in the lymph nodes over time, 
an effect that may be regulated by antigen recognition as indicated by the enrichment of recently 
activated CD69-expressing Tregs in the lymph nodes after adoptive transfer (Lieberman et al. 
2012). In addition, mice expressing an OX40-cre allele that is prominently expressed within Tregs 
cells, and a conditional null allele for the gene encoding p56Lck (thus, impaired TCR signalling) 
exhibit preferential redistribution of Tregs to lymph nodes rather than to non-lymphoid tissue 
associated with abnormal Treg cell homeostasis (Kim et al. 2009). 
Assuming the widely accepted theory suggesting that Tregs recognize self-derived peptides, it is 
possible that self-peptide presentation by the endothelium may drive the rapid and efficient 
recruitment of Tregs to inflamed tissue thus reaching the functional numbers necessary for 
regulation. Furthermore, the exact mechanism through which an optimal Treg:Teff ratio becomes  
established thus preventing tissue destruction remains to be identified. 
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4.1.2 Aims 
 
Given that Tregs express TCRs with affinities for self-derived antigens and that TCR-driven antigen 
recognition is crucial for recruitment of antigen specific T cells to the periphery, we hypothesize 
that recognition of self-derived peptides displayed by the endothelium may be an essential 
component for the efficient recruitment of Tregs towards non-lymphoid inflammatory tissue. 
Furthermore, Class II MHC upregulation and peptide display by the endothelium in response to 
localised inflammatory stimuli, such as IFN- γ, could serve as a strategic element for Treg 
recruitment. To test this hypothesis we designed the following experimental strategies. 
 
1. Adopt and optimise existing methods for in vitro expansion of Tregs of known antigen 
specificity in numbers sufficient for in vivo trafficking studies.  
2. Assess the role of cognate recognition of self-derived peptides displayed by the 
endothelium in Treg recruitment. 
3. Assess the role of IFN- γ -induced Class II MHC upregulation in Treg recruitment. 
4. Elucidate the mechanism through which optimal Treg:Teff ratios necessary for regulation 
are established in peripheral immune responses. 
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4.1.3 Results 
 
4.1.3.1 Expansion of Foxp3 expressing regulatory T cells. 
 
Tregs constitute a minute fraction of the total T cell repertoire. In normal wild type mice 
approximately 4-12% of their CD4+ T cell compartment constitutes Foxp3+ cells (L. Zhao et al. 
2007), while in humans this ranges from 4-9% (Baecher-Allan et al. 2001).  Although this highlights 
the remarkable efficiency with which the Tregs regulate the immune responses, it poses 
challenges for the study of the migratory and homing characteristics of these cells in vivo. 
Therefore, we optimized an existing Treg culture protocol that enabled us to expand allospecific 
Treg populations in vitro.  
Briefly, purified regulatory T cells were first isolated from the lymph nodes and spleens of 
C57BL/6 mice using commercially available magnetic cell sorting kits. These kits utilize negative 
selection of CD4+ cells followed by positive selection of CD25+ cells. CD25 a receptor for IL-2, a 
pro survival and proliferation cytokine, is expressed constitutively on regulatory T cells in mice. 
However, conventional naÏve T cells are also known to upregulate the CD25 receptor following 
activation. Therefore in order to obtain pure regulatory T cell populations we utilised the Foxp3-
GFP reporter mice (C57BL/6 background).  Foxp3 is a nuclear transcription factor crucial for Treg 
function and serves as a key marker for Treg identification in mice. From these mice we were able 
to sort GFP positive Foxp3 expressing CD4 T cells using flow cytometry. Once isolated, the 
CD4+CD25+ Foxp3+ Treg populations were stimulated with immature bone marrow derived 
dendritic cells in the presence of IL-2. While splenic antigen presenting cells have been shown to 
induce low Treg proliferation, immature bone marrow derived dendritic cells are excellent 
promoters of Treg proliferation (Marguti et al. 2009; Zhou et al. 2013). Using a ratio of 1:5 
(DC:Treg), the Tregs from a H2-B (C57BL/6) background were re-stimulated every 7 days using 
bone marrow derived dendritic cells (bmDCs) from H2-D (BALB/) mice. The proliferation observed 
was comparable to that of Teff populations during the first 3 days of co-culture. In this manner, 
only those Tregs which recognised allo-antigens receive proliferative signals thus skewing the TCR 
reactivity of this polyclonal population towards allo-antigens overtime. These expanded Tregs 
were seen to inhibit the proliferation of allogeneic responder T cells in an in vitro mixed 
lymphocytic reaction (Figure 11). 
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Figure 11    Allospecific Tregs (H2-B) expanded by in vitro culture with BALB/c-derived, 
(H2-D) immature DCs and IL-2 can suppress allogeneic T cell proliferation. 
This panel shows increasing numbers of allospecific Tregs added to co-cultures of C57BL/6 
conventional naïve T cells (105) stimulated with H2-D (BALB/c) -derived DCs (103, black bars), or 
CD3/CD28 activating antibodies (red bars). T-cell proliferation was measured as 3HTdR 
incorporation in triplicate cultures (N=5). Error bars represent standard deviations. Statistical 
significance was calculated with unpaired Student’s t-test. *P<0.05, **P<0.01. 
 
Flow cytometric analysis showed that the Tregs upregulated expression of surface markers 
indicative of memory, such as chemokine receptor CCR4 and alpha E integrin chain (CD103) 
(Figure 12). The loss of L-Selectin (CD62L) over extended periods of in vitro culture was also 
observed, consistent with observations from other groups.  
Using this technique, we were successful in the generation of allospecific Treg and Teff 
populations from wild type and Foxp3-GFP reporter mice. 
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Figure 12    Allospecific Tregs (H2-D) expanded by in vitro culture with BALB/c-derived, 
(H2-D) immature DCs and IL-2 express surface markers indicative of memory 
Panel a. indicates surface staining of chemokine receptor and adhesion molecules on the in vitro 
expanded allospecific Tregs as analysed through flow cytometry. The histograms are 
representative of 3 experiments (N=3). The dotted lines in the histograms represent staining using 
antibody isotype controls.  
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4.1.3.2 Self-Recognition is required for Treg Trafficking 
 
It has been well established that T cells selectively recruit to inflamed non-lymphoid tissue 
through recognition of specific antigens that are displayed by the endothelial cells lining the 
nearby vessels (Marelli-Berg et al. 1999b) (Marelli-Berg et al. 2004b). Local inflammatory stimuli 
induce these endothelial cells to capture process and display antigens on MHC molecules. Given 
that regulatory T cells have antigen specificity towards self-derived peptides, we hypothesised 
that Tregs would respond to self-antigen presentation by the endothelium, which would lead to 
efficient Tregs migration in vivo. In order to assess Tregs recruitment in vivo, we utilized an 
established murine model of Treg recruitment to antigen-enriched peritoneum. In this model, a 
low dose of IFN- γ given via the intra-peritoneal (i.p.) route induces local upregulation of MHC 
molecules. We first compared the recruitment of Tregs from the circulation into the peritoneum 
of syngeneic (C57BL/6, H2-B) and irrelevant (CBA/Ca, H2-K) mice. CD4+ T cells isolated from 
Foxp3-GFP reporter mice (107/mouse) were pooled (to ensure equal numbers of Treg populations 
in the cell preparation) and injected intravenously (i.v.) in IFN-γ-treated or untreated recipients. 
Significantly larger number of Tregs (GFP+) migrated to the peritoneal cavity of syngeneic 
recipients previously exposed to IFN-γ, compared with those detected in the lavage of IFN-γ-
treated irrelevant (CBA/Ca, H2-K) mice and non-treated syngeneic recipients after 16 hours 
(Figure 13).  
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Figure 13    Antigen recognition facilitates Treg trafficking. 
Total CD4+ T cells from Foxp3-GFP reporter mice (107/mouse) were injected intravenously into 
syngeneic H2-B (C57BL/6) or irrelevant H2-K (CBA/Ca) mice that had received an intraperitoneal 
injection of 600 U IFN-γ 72 h earlier. Some C57BL/6 recipient received saline solution alone. The 
presence of GFP+ Tregs in the peritoneal lavage, dLN and spleen was analysed by flow cytometry 
16 h later. Tregs were identified by gating on the CD4+GFP+ population. Representative dot plots 
are shown in panel a. The mean number of Treg cells (in the total CD4+ population) of Treg cells 
detected in the peritoneal cavity and lymphoid organs are shown in panel b. Error bars represent 
standard deviations. Statistical significance was calculated with unpaired Student’s t-test. (n=3, 
N=4) **P<0.01. (c) GFP+ Tregs retrieved in the same sites from IFN-γ-treated syngeneic C57BL/6 
recipients were stained with anti-CD69-PE/Cy7 (clone H1.2F3). CD69 expression was analysed by 
flow cytometry, shown in panel c. The dotted line shows non-specific staining with an Isotype-
matched control antibody. The histograms are representative of three cell preparations. 
 
Interestingly, 50% of Tregs recruited to the peritoneal cavity and draining lymph nodes exhibited 
high expression of CD69 indicative of recent T cell receptor engagement in this population. In 
addition, Tregs were preferentially recruited to the draining lymph nodes (dLNs, mesenteric) of 
IFN-γ-treated syngeneic, but not irrelevant mice, suggesting that antigen presentation also affects 
their localization to secondary lymphoid tissue. 
To further confirm that antigen recognition drives Treg recruitment we tested the possibility that, 
within a polyclonal Treg population, Tregs are selectively recruited based on their TCR specificity. 
To this aim, we enriched GFP-tagged Tregs cross-reactive for H2-D alloantigens by in vitro 
expansion using immature BALB/c derived bone marrow derived dendritic cells and IL-2 as 
described earlier. Next, we carried out in vitro based lymphocyte migration assays to observe 
transendothelial migration of these in vitro expanded Tregs through IFN- γ treated endothelial cell 
monolayers of allogeneic (BALB/c, H2-D), syngeneic (C57BL/6, H2-B) and irrelevant (CBA/Ca, H2-K) 
origin.  Interestingly, migration of H2-D allospecific Tregs through allogeneic endothelium was 
greater than through endothelium of syngeneic and irrelevant origin (Figure 14).  
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Figure 14    Allospecific Tregs migrate more efficiently through allogeneic endothelium 
in vitro. 
H2-D-allospecific Tregs expanded via in vitro culture were then placed over 48hr IFN-γ-treated 
syngeneic H2-B (C57BL/6), allogeneic H2-D (BALB/c) or irrelevant H2-K (CBA/Ca) endothelial cell 
monolayers in a trans-endothelial transwell migration assay. Following 24Hr, the number of 
migrated cells in the bottom of the transwell was evaluated by hemocytometric counting. Results 
were expressed as average percentage of migrated cells Error bars represent standard deviations. 
Statistical significance was calculated with unpaired Student’s t-test. (n=3, N=4) *P<0.05 
 
Following these in vitro experiments, we observed trafficking of these expanded cross-reactive 
Tregs into the peritoneum of allogeneic (BALB/c, H2-D), syngeneic (C57BL/6, H2-B) and irrelevant 
(CBA/Ca, H2-K) recipient mice using the peritoneal model of T cell recruitment described above. 
Similar to the in vitro experiments, the migration of these Tregs was significantly higher to the 
peritoneal cavity and draining mesenteric lymph nodes in IFN- γ treated alloantigen-expressing 
(BALB/c, H2-K) recipients (Figure 15). 
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Figure 15    Allospecific Tregs migrate more efficiently to the peritoneal cavity of 
allogeneic mice. 
CFSE-labelled H2-D-allospecific Treg cells were injected intravenously (107/mouse) into allogeneic 
H2-D (BALB/c), syngeneic H2-B (C57BL/6) or irrelevant H2-K (CBA/Ca) mice that had received an 
intraperitoneal injection of 600 U IFN-γ 72 h earlier. The presence of GFP+ Tregs in lavage, 
mesenteric dLNs, non-dLNs and spleen was analysed by flow cytometry 16 h later. Representative 
dot plots are shown in panel a. The mean number of Treg cells (in the total CD4+ population) 
detected in the peritoneal cavity and lymphoid organs is shown in panel b. Error bars represent 
standard deviations. Statistical significance was calculated with unpaired Student’s t-test. (n=3, 
N=4) *P<0.05, **P<0.01. 
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Having established that antigen recognition plays a role in Treg migration to inflamed non-
lymphoid tissue, we investigated whether recognition of endogenous peptides (putative ‘self-
antigens’) in the context of self-MHC Class II molecules is instrumental in efficient Treg localisation 
to target tissue. To address this, the GFP –Foxp3 reporter mice were crossed with a TCR-
transgenic mouse strain bearing TCR specificity for the HY-derived peptide in the context of H2-Ab 
(Marilyn mice). The male minor histocompatibility antigen HY encoded by the Y chromosome, is 
expressed by all male cells. Subsequently, HY-specific T cells are removed in the thymus by 
negative selection in males but are present in females. In the F1 Marilyn GFP-Foxp3 mice, the 
mean percentage of CD4+ Vβ6+ Marilyn T cells as a proportion of total lymphocytes was 12.2% 
(±2.5%). In the same mice, the mean percentage of naturally occurring Tregs (GFP+) as a 
proportion of Marilyn T cells was 3.5% (±1.4%). CD4+ T cells purified from the female F1 Marilyn 
GFP-Foxp3 mice were purified and pooled and injected into IFN- γ treated male or female 
syngeneic (C57BL/6) recipients. These recipient mice were genetically identical to the donor mice 
with the exception of the HY antigen, which is only expressed in male animals. Foxp3+ Vβ6+ T 
cells were seen to be higher in the peritoneal cavity and dLNs of IFN-γ treated male mice than in 
that of female mice treated with IFN-γ (Figure 16). These data suggest that recognition of self-
peptides in the context of self-MHC Class II molecules can drive the recruitment of Tregs to non-
lymphoid tissue.  
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Figure 16    Self-recognition drives Treg recruitment 
Total CD4+ T cells from GFP-Foxp3 Marilyn F1 mice (107/mouse) were injected intravenously into 
syngeneic male or female C57BL/6 mice that had received an intraperitoneal injection of 600 U 
IFN-γ 72 h earlier. An anti-Vβ6 antibody was used to identify Marilyn T cells. The presence of GFP+ 
Vβ6+ Tregs in lavage, dLN and spleen was analysed by flow cytometry 16 h later. Tregs were 
identified by gating on the CD4+ T-cell population. Representative dot plots are shown in panel a. 
The mean number of Treg cells (in the total CD4+ population) of Treg cells detected in the 
peritoneal cavity and lymphoid organs is shown in panel b. Error bars represent standard 
deviations. Statistical significance was calculated with unpaired Student’s t-test. (n=3, N=2) 
*P<0.05.  
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4.1.3.3 IFN-γ induction of MHC Class II expression by the endothelium is required for 
Treg recruitment. 
 
For T cells to efficiently localise to antigen specific sites within the non-lymphoid tissue, 
endothelial cells lining the microvasculature react to inflammatory stimuli by presenting 
processed antigens bound to Class II MHC molecules that are displayed for specific T cell 
recruitment (Marelli-Berg and Jarmin 2004b). To further evaluate the requirement for MHC Class 
II expression by the endothelium in the recruitment of Tregs, we performed in vitro trans-
endothelial migration assays to observe the migration of Tregs from Foxp3-GFP reporter through 
IFN-γ pre-treated endothelium, where Class II MHC was blocked using an antibody. Treg migration 
through activated endothelium treated with the Class II MHC blocking antibody prior to the 
migration assay was diminished compared to the activated endothelium treated with an isotype 
control antibody (Figure 17).  
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Figure 17    Antibody mediated blockade of class II MHC inhibits Treg trans-endothelial 
migration in vitro. 
H2-D-allospecific Tregs expanded via in vitro culture were placed over 48hr IFN-γ -treated 
syngeneic H2-B (C57BL/6) endothelial cell monolayers in a trans-endothelial transwell-based 
migration assay. In parallel, H2-D-allospecific Tregs migrated through syngeneic H2-B (C57BL/6) 
endothelial cell monolayers previously treated with 500 μg anti-MHC class II antibody (clone 
M5/114, BioXCell). Following 24Hr, the number of migrated cells in the bottom of the transwell 
was evaluated by hemocytometric counting. Results were expressed as average percentage of 
migrated cells. Error bars represent standard deviations. Statistical significance was calculated 
with unpaired Student’s t-test. (n=3, N=4) *P<0.05, **P<0.01. 
 
Similarly, to observe this effect in vivo, we carried out experiments where freshly isolated Tregs 
from Foxp3-GFP reporter mice were injected into IFN-γ pre-treated (i.p.) mice that had either 
been given an intra-peritoneal injection of a Class II blocking antibody or its corresponding isotype 
control. As expected, the recruitment of GFP+ Tregs into the peritoneum and draining lymph 
nodes of mice that had received the Class II blocking antibody was significantly reduced as 
compared to those that had received the isotype control (Figure 18).  
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Figure 18    Treg recruitment requires MHC class II molecule expression by target tissue 
Total CD4+ T cells isolated from Foxp3-GFP reporter mice were injected intravenously into 
syngeneic C57BL/6 mice (107/mouse) that had received an intraperitoneal injection of 600 U IFN-γ 
72 h earlier. Prior to Treg adoptive transfer, recipient mice received either 500 μg anti-MHC class II 
antibody (clone M5/114, BioXCell) or isotype control antibody. The presence of GFP+ Tregs in the 
peritoneal lavage, dLN, ndLN and spleen was analysed by flow cytometry 16 h later. Tregs were 
identified by gating on the CD4+GFP+ population. Representative dot plots are shown in panel a. 
The mean number of Treg cells (in the total CD4+ population) detected in the peritoneal cavity and 
lymphoid organs is shown in panel b. Error bars represent standard deviations. Statistical 
significance was calculated with unpaired Student’s t-test. (n=3, N=3) *P<0.05. 
 In addition to inducing MHC Class II molecule expression by the endothelial cells, IFN-γ can also 
induce upregulation of adhesion markers such as VCAM-1 and ICAM-1 which can also affect the 
recruitment of T cells (Figure 19)(Paleolog et al. 1992). 
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Figure 19    Expression of adhesion and co-stimulatory molecules by the endothelium. 
Murine primary microvascular endothelial cells (ECs) were stimulated with either IFN-γ (600U/ml 
for 48 hours) or TNF (10ng/ml for 48 hours) or cultured in medium alone. In panel a. histograms 
indicate the expression of VCAM-1, ICAM-1 and MHC class II molecules by endothelial cells 
measured by flow cytometry. Dotted lines indicate untreated ECs whereas dashed lines indicate 
isotype antibody controls. Solid line histograms indicate cytokine-treated ECs. Panel c shows the 
expression of the co-stimulatory molecules CD80 (B7-1) and CD86.In panel b and d, the average 
delta mean fluorescence intensity (ΔMFI = MFI of stimulated ECs – MFI of unstimulated ECs) 
measured in triplicate samples from 2 experiments of identical design is shown.  
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To address the contribution of these molecules in the recruitment of Tregs in our model we 
repeated the above experiments using TNF- α treatment of ECs instead of IFN-γ.  Previously, it has 
been shown that TNF-α treatment is unable to activate the promoter of CIITA that is necessary for 
IFN-γ induced MHC upregulation (Nikcevich et al. 1999). Furthermore, TNF-α treatment of 
endothelial cells showed marked upregulation of adhesion molecules such as VCAM-1 and ICAM-1 
with no induction of Class II MHC on the murine ECs (Figure 19). Thus, to address the contribution 
of these molecules in the recruitment of Tregs in our model, experiments were carried out where 
recruitment of GFP tagged Tregs in the peritoneum of syngeneic mice pre-treated with 20ng TNF-
α were analysed. As shown in Figure 20, pre-treatment of mice with TNF-α did not increase 
migration of Tregs, while the recruitment of endogenous monocytes was increased in the 
peritoneum and draining lymph node. These data further support the non-redundant role of IFN-γ 
in sustaining Treg trafficking to inflammatory sites. 
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Figure 20    TNF  does not enhance Treg recruitment to target tissue. 
Total CD4+ T cells from Foxp3-GFP reporter mice (107/mouse) were injected intravenously into 
syngeneic C57BL/6 or irrelevant CBA/Ca mice that had received an intraperitoneal injection of 
20 ng TNF-α(Peprotech) or control saline 48 h earlier. The presence of GFP+ Tregs in lavage, dLN, 
ndLN and spleen was analysed by flow cytometry. Representative dot plots are shown in panel a. 
The mean number of Treg cells (in the total CD4+ population) present in the peritoneal lavage and 
lymphoid organs is shown in panel b. The recruitment of endogenous monocytes in lavage, dLN, 
ndLN and spleen was analysed by CD68 staining. The mean number of monocytes detected in the 
peritoneal cavity and lymphoid organs of at least three recipients is shown in panel c. Error bars 
represent standard deviations. Statistical significance was calculated with unpaired Student’s t-
test. (n=3, N=4) *P<0.05. 
 
Treg function has been shown to be dependent on IFN-γ signalling. Furthermore, Tregs 
themselves are also known to produce low levels of IFN-γ (Koch et al. 2009). Therefore, we sought 
to investigate whether the requirement for IFN-γ is in part due to its ability to facilitate Treg 
localisation to target tissue by enhancing antigen presentation. To distinguish between the 
contribution of IFN-γ by either target tissue or Treg cells, we injected purified CD4+ T cells from 
either Interferon gamma receptor knockout (IFN-γRKO, labelled with PKH26) into syngeneic wild 
type mice or purified CD4+ T cells from Foxp3-GFP reporter mice into IFN-γRKO syngeneic 
recipients, in both cases following IP treatment with IFN-γ.(Figure 21) Recruitment of Tregs from 
IFN-γRKO mice to the peritoneum and draining lymph nodes was similar to that of Tregs from WT 
mice. In contrast, recruitment of WT Tregs into the peritoneum and dLN of IFN-γRKO mice was 
significantly reduced suggesting that IFN-γ acts through the endothelium via MHC Class II 
upregulation and self-antigen presentation in sustaining efficient recruitment of Tregs.   
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Figure 21    Treg accumulation requires target tissue responsiveness to IFN-γ stimulation 
(a,b) Total CD4+ T cells from IFN-γ receptor KO mice (107/mouse) were labelled with 2 μM PKH26 
and injected intravenously into syngeneic WT H2-B (C57BL/6) or irrelevant H2-K (CBA/Ca) mice 
that had received an intraperitoneal injection of 600 U IFN-γ 72 h earlier. The presence of 
PKH26+, CD4+CD25+ Tregs in the peritoneal lavage and dLN was analysed by flow cytometer 16 h 
later. In panel a, representative dot plots of IFN-γR KO Treg cells detected in the peritoneal lavage 
and dLN are shown. The mean number of Treg cells (in the total CD4+ population) present in the 
peritoneal cavity and dLN is shown in panel b. (n=3, N=4) *P<0.05. Total CD4 T cells from Foxp3-
GFP reporter mice (107/mouse) were injected intravenously into WT C57BL/6 or IFN-γ receptor KO 
mice that had received an intraperitoneal injection of 600 U IFN-γ72 h earlier. The presence of 
PKH26+, CD4+CD25+ Tregs in the peritoneal lavage and dLN was analysed by flow cytometry 16 h 
later. Tregs were gated on CD4+GFP+ population. Representative dot plots are shown in panel c. 
The mean number of Treg cells (in the total CD4+ population) present in the peritoneal cavity and 
dLN is shown in panel d. Error bars represent standard deviations. Statistical significance was 
calculated with unpaired Student’s t-test. (n=3, N=2) *P<0.05.  
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Previous studies have shown that CXCR3 is required for efficient Treg recruitment to some 
inflammatory sites (Muller et al. 2007; Santodomingo-Garzon et al. 2009). In addition, IFN-γ is 
known to induce CXCR3 ligands such as CXCL10 (A D Luster and Ravetch 1987a). Therefore we 
analysed CXCR3 expression on Tregs and their migration to CXCL10 in vitro. A relatively small 
fraction of Tregs expressed CXCR3,  and did not migrate efficiently in response to CXCL10 as 
compared with the CCR7 ligands CCL19 and CCL21 (Figure 22). These data highlight that the 
diminished production of CXCL10 by IFN-γRKO recipients is unlikely to significantly impact the 
recruitment of Tregs to target tissue. 
 
Figure 22    In-vitro expanded H2-D-allospecific Tregs express low CXCR3 and reduced 
migration to CXCL10 in vitro. 
The expression of CXCR3 and CCR7 by GFP+ Treg cells was analysed by flow cytometry (a) and their 
migration in response to their respective ligands CXCL10(300 ng ml−1) and CCL19/21 (200 ng ml−1) 
was assessed by a 6hr in vitro chemokinesis transwell assay (106/well) (b). The number of migrated 
cells in the bottom of the transwell was evaluated by hemocytometric counting from 3 replicate 
wells (n=3). Results were expressed as average percentage of migrated cells. Data are 
representative of three independent experiments of identical design (N=3). Error bars represent 
standard deviations. Statistical significance was calculated with unpaired Student’s t-test. 
*P<0.05, ***P<0.001 
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4.1.3.4 Cognate recognition of alloantigen presented by the endothelium induces Treg 
recruitment. 
 
Previously, cognate recognition of antigen displayed by the endothelium has been shown to play a 
crucial role in the recruitment of Teffs into non-lymphoid tissue both in vitro (Greening et al. 
2003; Marelli-Berg et al. 1999b) and in vivo (Marelli-Berg et al. 2004b; Savinov et al. 2001; Savinov 
et al. 2003). Recent studies have shown that recruitment of Teffs is facilitated by both 
perivascular DCs and endothelial cells (Calderon et al. 2011; Walch et al. 2013). Administration of 
IFN-γ (72 hours prior) via the intraperitoneal route was shown to induce Class II MHC expression 
in the vascular endothelium of the peritoneal membrane and in the dLN (Figure 23), and was 
mainly upregulated by CD11c+ cells in the dLN. However, CD11c+ cells were not detected in the 
peritoneal membranes. Thus, it is likely that the endothelium plays a key role in recruitment of 
Tregs in this model.  
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Figure 23    IFN-γ treatment induces MHC class II expression in the peritoneum and 
Draining lymph nodes. 
The peritoneal membrane, dLN and ndLNs from C57BL/6 mice that had received 600 U IFN-γ or 
control saline i.p. 72 h earlier were stained with anti-CD31 (green fluorescence) and anti-MHC II 
mAbs (red fluorescence) and analysed by wide-field fluorescence microscopy). Nuclei are 
highlighted by DAPI (blue). Representative pictures taken by wide field fluorescence microscopy 
are shown. Scale bar: 10 µM 
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To directly visualise this phenomenon in vivo, intra vital microscopy experiments were carried out 
in which H2-D allospecific Tregs selected by in vitro culture were injected intravenously into 
allogeneic (BALB/c) or irrelevant (CBA/Ca) recipients that received intra-scrotal injections of IFN-γ 
72 hours earlier. The labelled Tregs were observed within the microvascular bed of the cremaster 
muscle for up to 40 minutes. While no differences in rolling flux were observed in the groups, 
Tregs were seen to have higher T cell adhesion and transendothelial migration in the BALB/c 
blood vessels as compared to the CBA/Ca blood vessels (Figure 24).  
 
Figure 24    Treg recruitment to non-lymphoid tissue is induced by cognate recognition 
of the endothelium in vivo 
Allogeneic male H2-D (BALB/C) and H2-K (CBA/Ca) mice were treated with intrascrotal 
administration of IFN-γ (1,200 U in 400 μl saline). After 72 h, fluorescently labelled (CFSE) Treg cells 
were injected intravenously after surgical exteriorization of the cremaster muscle and T-cell 
interactions with venular walls were visualized and quantified by intravital microscopy for up to 
40 min. (a) rolling; (b) velocity; (c) firm adhesion; (d) extravasation. Results are from six mice per 
group, and significant differences between the H2-D in comparison with the H2-K strains of mice 
are shown by asterisk. Error bars represent standard deviations. Statistical significance was 
calculated using unpaired Student’s t-test.*P<0.05 (N=2) 
 
No CD11c+ DCs were observed in the cremaster muscle through fluorescence microscopy. In 
addition, dissected and sectioned cremaster muscles visualized by fluorescence microscopy 
showed increased Treg influx in BALB/c cremaster muscles as compared to CBA/Ca controls 
(Figure 25). 
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Figure 25    H2-D-allospecific Tregs are recruited to IFN-γ treated allogeneic H2-D 
(Balb/c) cremaster muscle and not to H2-K (CBA/Ca) treated IFN-γ cremaster muscles. 
Cremaster muscle sections from the previous experiment were fixed in 4% PFA and visualized by 
fluorescent microscopy indicating a large tissue influx of T cells in cremaster tissues from BALB/c 
but not control CBA/Ca mice. Nuclei are stained by DAPI (blue). Scale bar, 10 μM.  
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4.1.3.5 Antigen specific Treg recruitment requires PI3K P110δ activity 
 
 The results above indicated that TCR defined antigen specificity; via cognate antigen recognition 
displayed by endothelium facilitates recruitment of Tregs to sites of inflammation. To investigate 
the molecular mechanism underlying the antigen driven Treg trafficking, we sought to further 
characterise the molecular mechanism involved downstream of the TCR. The class I 
phosphoinositide 3-kinases (PI3K) have been described to have important functions in immune 
cells. In particular, the class I PI3K isoform p110δ is expressed at high levels in leukocytes and is a 
major isoform controlling a number of antigen-evoked immune responses. Loss of PI3K p110δ 
signalling has previously shown to result in diminished primary and secondary T cell responses. 
Genetic inactivation of PI3K p110δ in naïve T cells has been shown to result in their failure to 
differentiate into Th1 and Th2 subsets.  
Additionally, in mice, loss of PI3K p110δ has been implicated in reduced Treg numbers and 
function. Although Treg cells deficient in p110δ have been shown to be responsive to IL-2 and 
only partially lose their suppressive ability in vitro, they are unable to maintain their suppressive 
potential in vivo (Patton et al. 2006). Previous studies have shown that Teffs bearing a functionally 
inactive variant of the P110δ subunit lost TCR-induced migration and failed to localise to antigenic 
tissue efficiently (Jarmin et al. 2008). Thus, we sought to investigate whether the loss of 
suppressive function in p110δ deficient Tegs observed in vivo could be explained partly through 
aberrant trafficking and localisation of the p110δ deficient Tregs to antigenic sites.  
To investigate this hypothesis, we performed in vitro trans-endothelial migration experiments of 
Tregs with direct anti-H2-D (BALB/c) allospecificity through both H2-D (BALB/c, allospecific)- and 
H2-K (CBA/Ca, irrelevant)-expressing endothelial cell monolayers following pharmacological 
inhibition of p110δ activity. Tregs with direct H2-D (BALB/c) allospecificity were treated with 
either PI3K p110δ selective inhibitor IC87114 or PBS containing vehicle (1% dimethylsulphoxide) 
at 37oC for 1 hour. Post treatment, the migration of both sets of Tregs was observed through IFN-
γ pre-treated endothelial monolayers of H2-D (BALB/c) and H2-K (CBA/Ca) origin. The migration of 
Tregs through H2-D (BALB/c) endothelium was significantly impaired upon PI3K p110δ inhibition 
as compared to the vehicle controls, while the modest migration observed through irrelevant H2-
K (CBA/Ca)-derived ECs remained unaffected by the p110δ inhibition (Figure 26).   
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Figure 26    PI3K p110δ activity is required for antigen-driven Treg TEM in vitro. 
H2-D-allospecific Tregs were treated with 5 μM IC87114 or with vehicle control for 30 min at room 
temperature and subsequently washed before use. Vehicle control-treated (filled symbols) and 
inhibitor-treated (open symbols) T cells (5 × 105/well) were seeded onto allogeneic H2-D (BALB/c) 
and irrelevant H2-K CBA/Ca mice-derived IFN-γ-treated EC monolayers. T-cell migration measured 
at 6 h is shown. Data are representative of at least three independent experiments of identical 
design. Error bars represent standard deviations. Statistical significance was calculated using an 
unpaired Student’s t-test.*P<0.05. 
  
To evaluate the role of p110δ in Treg migration in vivo, we compared the recruitment of IC87114- 
and vehicle-treated Tregs with direct H2-D (BALB/c) allospecificity from circulation into the 
peritoneum of IFN-γ treated allogeneic H2-D (BALB/c) and irrelevant H2-K (CBA/Ca) mice. Equal 
numbers of IC87114-treated Tregs labelled with DDAO-SE and vehicle-treated Tregs labelled with 
CFSE were co-injected i.v into H2-D (BALB/c) and H2-K (CBA/Ca) recipients that had received an i.p 
injection of IFN-γ 48 hours earlier. Upon p110δ inhibition, Treg migration was unaffected in the 
CBA/Ca recipients while p110δ inhibition significantly reduced recruitment of inhibitor-treated 
Tregs in the peritoneal cavity and the draining lymph nodes of the H2-D (BALB/c) recipients 
(Figure 27). These results indicate that PI3k p110δ activation by the TCR contributes to the 
recruitment of Tregs by cognate endothelium in a manner similar to that operating in Teff 
migration. 
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Figure 27    PI3K p110δ activity is required for antigen-driven Treg recruitment in vivo 
H2-D-allospecific Tregs were treated with 5 μM IC87114 or with vehicle control for 30 min at room 
temperature and subsequently washed before use. CFSE-labelled vehicle-treated Tregs and DDAO 
SE-labelled IC87114 Tregs were co-injected (107/mouse) intravenously into H2-D (BALB/c) and H2-
K (CBA/Ca) mice that had received intraperitoneal injections with 600 U IFN-γ 72Hr earlier. The 
presence of labelled T cells in the peritoneal cavity and dLNs was analysed after 24 h through flow 
cytometry. Representative dot plots from 3 experiments are shown in panel a. The mean number 
of Treg cells (in the total CD4+ population) detected in the peritoneal cavity and dLNs is shown in 
panel b. Error bars represent standard deviations. Statistical significance was calculated using an 
unpaired Student’s t-test. (n=3, N=3) *P<0.05. 
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4.1.3.6 Tregs can inhibit recruitment of Teffs into antigen rich target tissue 
 
It is thought that similar to Teffs , naturally occurring Tregs require initial activation within the 
draining lymph nodes to enable them to migrate into sites of antigen rich tissue, and also utilise 
similar molecular mediators (PI3K P110δ) that direct their recruitment to antigen presenting 
endothelium (Jarmin et al. 2008; Q. Tang and Bluestone 2006). Thus, other mechanisms must 
exist to sustain Treg migration and maintain their preferential accumulation into target tissue 
allowing the establishment of optimal Treg:Teff ratios for termination of the T effector responses 
during the late stages of the immune response.  
To address this issue we investigated whether Tregs infiltrating into target antigen-rich tissue 
were capable of affecting the recruitment of Teff cells. Teffs with the same allospecificity as the 
Tregs cells were generated by i.p injection of BALB/C splenocytes into C57BL/6 recipients for a 
period of 7 -10 days. The total lymphocytes of the recipients were then removed and purified for 
their CD4+ population. These were further expanded with inactivated BALB/c splenocytes for 7 
days to generate an allospecific CD4 T cell population composed of a mixture of effector memory 
and central memory subsets (Figure 28).  
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Figure 28    Phenotype of allospecific conventional memory T cells. 
H2-D -allospecific memory/effector T cells were generated by in vitro stimulation of naïve 
CD4+CD25- T cells from H2-B (C57BL/6) mice with H2-D (BALB/c)-derived) splenocytes. Expression 
of the surface molecules indicated above each histogram was analysed by flow cytometry. The 
dotted lines represent antibody isotype control staining. 
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Time lapse imaging of both allospecific Tregs and Teff/cm, populations over CBA/Ca endothelial 
monolayers revealed no differences of intrinsic mobility between the two T cell groups (Figure 
29).  
 
 
Figure 29    Timelapse microscopy reveals no intrinsic differences between motitlity of 
Treg and Teff/cm cells. 
H2-D-allospecific Treg or H2-D -allospecific conventional T cells were seeded onto confluent H2-K 
(CBA/Ca)-derived EC monolayers pre-treated with IFN-γ (300 U ml−1) for 72 h. T-cell migration was 
monitored by timelapse microscopy. The crawling speed (μm min−1) of T cells was measured using 
ImageJ analysis software. About 30–40 cells were tracked in each experimental condition. Error 
bars represent standard deviations. Statistical significance was calculated using an unpaired 
Student’s t-test. N=2. 
 
Adoptively transferred H2-D allospecific T cells preferentially accumulated within the peritoneal 
cavity of the IFN-γ treated H2-D (BALB/c) recipients. (Figure 30) However, upon co-injection with 
equal number of H-2D specific Tregs, their localisation to the peritoneal cavity and draining lymph 
nodes was inhibited. Teff/cm populations were present within the non-draining lymph nodes and 
spleen of the co injected mice ruling out that Tregs induced apoptosis of the Teff/cm population. 
These results suggest that Tregs recruited into antigenic tissue can inhibit the further influx of 
antigen specific T effector cells. 
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Figure 30    Treg cells inhibit the recruitment of primed conventional T cell into target 
tissue. 
H2-D-allospecific conventional T cells (107/mouse) were labelled with 1 μM DDAO SE and co-
injected intravenously with CFSE-labelled H2-D-allospecific Tregs (107/mouse) into H2-D (BALB/C) 
mice that had received an intraperitoneal injection of 600 U IFN-γ 72 h earlier. The presence of 
DDAO SE+ Teff/cm and CFSE+ Tregs in the peritoneal cavity, dLN, ndLN and spleen was analysed 
16 h later by flow cytometry. Representative dot plots and the mean number of labelled cells 
present in the peritoneal lavage are shown in panels a and b, respectively. Error bars represent 
standard deviations. Statistical significance was calculated using an unpaired Student’s t-test. 
*P<0.05 (n=3, N=2). 
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4.1.4 Discussion 
 
Previous studies from our group have demonstrated that display of antigen by the endothelium in 
response to inflammatory stimuli such as IFN-γ enables the recruitment of T cells that express 
specific TCRs capable of recognizing those antigens (Marelli-Berg et al. 2004a). Antigen-driven T 
cell recruitment adds an additional level of specificity to selective migration to non-lymphoid 
inflammatory antigenic tissue. In this study, we have extended this function of the endothelium to 
the recruitment of Tregs. Furthermore, we showed that Treg trafficking to non-lymphoid 
inflammatory tissue is directed through the display of self-antigens. We also show that Tregs 
inhibit further recruitment of Teffs to the same site, thus favouring the establishment of the 
optimal Treg:Teff ratios necessary for regulation. 
As we have mentioned previously, Tregs like Teffs constitute a heterogeneous pool that express 
homing and chemokine receptors depending on their target tissue and the type of inflammatory 
response (Gratz and Campbell 2014). However, Tregs have been shown to use combinations of 
homing molecules that can redundantly function to control their migration (Campbell and Koch 
2011). Thus, we hypothesised the existence of additional mechanisms that would allow for the 
efficient recruitment of Tregs towards antigen bearing target tissue sites. 
Our results here indicate a property of the target tissue site, namely the endothelium lining the 
microvascular vessels, which enables the efficient recruitment of Tregs. This concept can be 
illustrated in the studies observing Treg migration in allotransplantation. Despite the presence of 
alloreactive Treg in high frequency (>10%) (Lin et al. 2008), MHC mismatched vascularized tissue 
grafts are rejected acutely via direct allorecognition (Issa et al. 2013). The explanation that 
allospecific Tregs are not in sufficient numbers relative to the responding allospecific conventional 
T cells does not fully explain the lack of regulation of the alloresponses compared to the efficient 
control of autoimmunity. In addition, adoptive transfer of a large number of polyclonal Tregs is 
relatively inefficient as compared to Tregs with selected specificity for the alloantigen (Issa et al. 
2013; Tang et al. 2012). These observations can be explained by the absence of cognate 
endothelium within the graft sites thereby causing inefficient Treg recruitment and regulation of 
alloresponses. Assuming that Tregs would promptly recognize self –MHC peptide complexes on 
autologous endothelium, they would be able to rapidly migrate into target tissue to suppress, for 
instance, autoimmune responses. In transplantation, only a fraction of Tregs would cross-react to 
allogeneic endothelium and gain access to the allograft sites in sufficient numbers to regulate 
alloresponses. Moreover, unlike conventional T cell activation, which is restricted topographically 
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to the lymph nodes, Tregs activation can occur in non-lymphoid target tissue and subsequently 
induce migration towards draining lymph nodes (N. Zhang et al. 2009). Thus the absence of 
cognate endothelium in allografts might result in delayed and inefficient recruitment and 
subsequent activation. In line with this, the recent study by (Fan et al. 2010) analysing the 
dynamics of alloresponses in vivo demonstrated that rapid invasion of effector T cells followed by 
delayed arrival of Tregs were ineffective in controlling tissue damage. Similarly, in therapeutic 
settings, autologous Tregs are not as efficient as allospecific Treg in preventing graft rejection 
(Issa et al. 2013; Tang et al. 2012). 
Naturally occurring Tregs produce little or no IFN-γ on their own following activation (Koch et al. 
2009). However our results show that Treg recruitment is kick-started and strictly dependent on 
IFN-γ mediated MHC Class II molecule expression on the endothelium. Thus, it is likely that IFN-γ 
produced by other sources such as activated T cells would initiate their recruitment. This 
highlights the sequential coordination of migratory events by Teffs and Tregs during a physiologic 
immune response which orchestrates the synchronised development of effector and regulatory 
elements. In the first steps, IFN-γ produced through activation or recruitment of conventional T 
cells would subsequently induce endothelial display of MHC Class II thereby allowing the entry of 
Tregs. Treg recruitment would then dampen the T cell mediated inflammation and likely prevent 
further Teff recruitment and activation thus resolving the inflammation. 
This scenario is indirectly supported by the observations here, which show abrogation of Teff 
recruitment when both Tregs and Teff are simultaneously recruited to the target tissue. In 
contrast, both populations arrived and co-localised in the spleen and draining lymph nodes of IFN-
γ treated recipients suggesting that Tregs must be activated as a consequence of local production 
of IFN-γ( by conventional cells) for this effect to occur. 
It is unclear how Tregs prevent further recruitment of conventional Teffs. Given that migrating 
Tregs are first engaged by cognate endothelium in our model, it is possible that they can 
modulate the extravasation cascade. Previously, the report by (James et al. 2003) has shown that 
anergic T cells can inhibit recruitment of other T cells to target tissue in vivo by inhibiting 
chemokines via the activity of dipeptidyl peptidase (CD26) (James et al. 2003). This mechanism 
might also be functional in Tregs. Tregs have also been shown to prevent stable conjugate 
formation between APCs and Teff cells in the LN in vivo (C. E. Tadokoro et al. 2006). To date, no 
reports have highlighted Treg mediated inhibition of Teff recruitment via a direct action of the 
Tregs on the endothelium. However, it is likely that Tregs may indirectly reduce endothelial 
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recruitment of Teffs by inhibiting the cytokine production of Teffs or through production of 
immunoregulatory cytokines such as TGFβ and IL-10 (N. Zhang et al. 2009).      
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4.2 Part 2: CD28 and CTLA-4 regulate Treg migration  
 
4.2.1 Introduction 
 
While TCR-induced signalling is instrumental for regulating migration of T cells during immunity, 
signals provided by co-stimulatory receptors also impact migration. Two of the best characterised 
co-stimulatory receptors are CD28 and CTLA-4, which bind to the B7 family co-stimulatory 
molecules CD80 (B7.1) and CD86 (B7.2). Historically, studies have implicated their role in several 
aspects of T cell biology ranging from T cell development in the thymus to T cell activation, 
proliferation, and cytokine secretion. Although both receptors share considerable homology and 
similar ligand specificity, their impact on T cell functions are known to be quite distinct from each 
other (reviewed in M.-L. Alegre et al. 2001b; Sansom 2000). A simplistic overview of the body of 
studies up to date indicates that CD28 acts as a positive regulator and CTLA-4 as an opposing 
inhibitory regulator of T cell functions. The interplay between positive and inhibitory co-
stimulation involves a complex network of signalling pathways, the integration of which greatly 
impacts the outcome of the ensuing immune response.  
Both CD28 and CTLA-4 receptors are known to engage pathways that regulate adhesion and 
cytoskeletal rearrangements and were therefore predicted to have a role in regulating T cell 
migration. In a study by (Mirenda et al. 2007), antibody-mediated CD28 stimulation induced 
adoptively transferred memory CD8+ T cells to migrate to extra-lymphoid tissue, with enhanced 
infiltration into kidney, liver, spleen, gut and heart independently of TCR-derived signals and 
homing receptor expression. Interestingly, they also observed that CTLA-4 mediated signals 
induced an opposite effect by preventing T cell migration. CD28 and CTLA-4 were therefore 
proposed to positively and negatively control the entry of primed T cells into non lymphoid tissue, 
respectively by regulating T cell motility. Since conventional T cells transiently express CTLA-4 only 
after activation/priming (Freeman et al. 1992), the functional role of CTLA-4 on the migration of in 
this T cell population is limited to the timeframe of CTLA -4 expression.  
Tregs play a vital role in maintaining immune homeostasis. An imbalance in their number or 
function is thought to contribute to a variety of inflammatory and autoimmune conditions (Dejaco 
et al. 2006). Crucial to their function, is their ability to effectively localise into the target tissue 
where suppression and tolerance are to be achieved (Burrell et al. 2012).  
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Unlike conventional T cells, Tregs express both CD28 and CTLA-4 receptors constitutively. A recent 
study observing the spatiotemporal expression of CTLA-4 at the Treg-APC immunological synapse 
(IS) has shown a very different regulation of the effect of CTLA-4 signals than those observed in 
Teffs (Yokosuka 2010). While CTLA-4 in Teffs prevents CD28 mediated recruitment of PKC-θ and 
CARMA1 scaffolding protein inhibiting activation and proliferation, PKC-θ recruitment to the IS is 
largely absent in Tregs. Instead, CTLA-4 recruits protein kinase C-η (PKC-η) member of the protein 
kinase family which positively regulates Treg function (Kong et al. 2014). Likewise, while CTLA-4 
mediated recruitment of phosphatases such as SHP-1, SHP-2 and PP2A in Teffs (Chuang et al. 
2000; Marengere et al. 1996) have been shown to be crucial for its inhibitory function, these are 
rarely recruited along with CTLA-4 to the Treg IS (Yokosuka 2010). Thus, differential integration of 
these and other signalling pathways in Tregs could favour migration distinctive from that seen in 
Teffs.  
Little is known about the interplay of CD28 and CTLA-4 signals and the effect of concomitant 
delivery engagement of both receptors in the regulation of Treg migration. In a recent report from 
(Lu et al. 2012), Tregs were shown to differ from conventional T cells in resisting CTLA-4-mediated 
reversal of TCR stop-signal. In their study, CTLA-4 signalling reduced the contact times of DO11.10 
x CD4+CD25− Tconvs, but not DO11.10 x CD4+CD25+ Tregs, with OVA peptide presenting DCs in 
lymph nodes. Additionally, they observed that concentrations of anti-CTLA-4 that showed reversal 
of anti-CD3 stop-signal on Foxp3-negative cells had no effect on Foxp3-positive cells. 
Tregs and Teffs also display distinct metabolic programmes to support their survival and 
differentiation (Michalek et al. 2011c). While Teffs are highly glycolytic, Tregs rely more on 
oxidative phosphorylation of fatty acids as their main source of energy.  
A key metabolism regulating kinase; the mammalian target of rapamycin (mTOR) and AMP-
activated protein kinase (AMPK) pathways are generally thought to play important and opposing 
roles in cell fate decision by regulating T cell metabolic responses in both Teffs and Tregs 
(Michalek et al. 2011c). In Teffs, T cell activation stimulates the mammalian target of rapamycin 
complex (mTOR) to upregulate glycolysis and diminishes lipid oxidation (Michalek and Rathmell 
2010). In addition, selective signalling from the two different components of mTOR-mTORC1 and 
mTORC2 can direct T cell differentiation in different ways (Delgoffe et al. 2011). This study 
demonstrated that differentiation into the Th1 and Th17 subsets of helper T cells was selectively 
regulated by signalling from mTOR complex 1 (mTORC1), while differentiation into the Th2 subset 
was regulated by signalling from mTOR complex 2 (mTORC2). In contrast, inhibition of mTOR has 
been shown to favour the development of iTregs. For example, in the study by (Esposito et al. 
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2010), rapamycin-mediated inhibiton of EAE was associated with the disappearance of 
CD4(+)CD45RB(high) effector T (T(eff)) cells and selective expansion of T(reg) cells bearing the 
CD4(+)CD45RB(low)FoxP3(+)CD25(+)CD103(+). In addition, the study by (Battaglia et al. 2005) 
demonstrated that inhibiting mTOR by rapamycin treatment selectively expanded the naturally 
occurring CD4+CD25+FoxP3+ Treg cells in vitro. 
However, Tregs also display a requirement for signalling through the mTOR catalytic subunit 
mTORC1 for engaging lipid oxidation and also for their functional fitness. In the recent study (H. 
Zeng et al. 2013c), disruption of mTORC1 through Treg-specific deletion of the essential mTORC1 
component raptor led to a profound loss of Treg-cell suppressive activity in vivo. They concluded 
that mTORC1 signalling maintains Treg suppressive activity by inducing cholesterol and lipid 
metabolism and by upregulating the Treg receptors CTLA-4 and ICOS. In addition, they also 
demonstrated that mTORC1 maintains Treg function partly through inhibition of mTORC2.   
   Most of these and other studies of the metabolic properties of Teff and Treg have focused on 
how they impact function and differentiation. Recently, a study from our group (R. Haas et al. 
2015) has demonstrated that the glycolytic pathway is engaged during Teff cell migration. In their 
study, inhibiting Teffs basal or chemokine induced aerobic glycolysis through the glycolysis 
inhibitor 2-deoxyglucose (2-DG) or via rapamycin-mediated inhibition of mTOR resulted in 
decreased chemotaxis in vitro and in vivo. Yet, little is known about which pathways are essential 
for Treg motility and migration.  
Emerging evidence from recent discoveries suggest that energy metabolism can also indirectly 
affect T cell homing pathways by regulating differential expression of adhesion and chemokine 
receptors. In the recent report by (Sinclair et al. 2008), loss of CD62L and CCR7 associated with 
activation of naïve T cells was shown to be regulated by mTOR signalling and upstream PI3k 
p110δ signalling. This CD62L and CCR7 loss prevents effector T cells re-entering secondary 
lymphoid organs and facilitates their redirection to peripheral tissues. This paper also highlighted 
that the pathways that regulate T cell metabolic switches are also closely integrated with those 
that are known to affect T cell migration. One example is the PI3K-Akt-mTOR pathway. CD28 
recruitment of PI3K and subsequently downstream Akt activation has been shown to be crucial 
for recruitment of primed Teffs to antigenic tissue (Mirenda et al. 2007); in addition PI3K-Akt 
activation is also required for CD28-induced glucose transporter GLUT1 expression, and glycolysis 
upregulation (Jacobs et al. 2008).  We hypothesized that CTLA-4 signals, by blocking CD28-induced 
Akt activation, might also prevent the increase in glucose utilization. This could potentially imply a 
role for CTLA-4 in regulating energy metabolism and migration. Should this be the case, 
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differential expression and activation of downstream pathways by CTLA-4 on Tregs might 
underlay their unique metabolic phenotype or differential use of metabolic pathways.  
4.2.2 Aims  
 
The study by (Mirenda et al. 2007) has implicated both CD28 and CTLA-4 co-receptors in 
regulating migration of primed T cells to antigenic sites. In addition, their study highlighted that 
this regulation was independent of TCR-derived signals and homing receptor expression. Given 
the ample evidence to suggest that Tregs  and Tconv display differences in their co-receptor 
expression, downstream signalling and metabolic pathways, we hypothesized that differential 
expression of these receptors by Tregs may underlay differences in the trafficking patterns of Teff 
and Treg cells.  
In this part of the study, the overall aim was to investigate the effect of CD28- and CTLA-4-induced 
signals, delivered either separately or in conjunction, on Treg migration and to establish if their 
affects, if any, were TCR- and/or homing receptor- dependent. Secondly, we sought to identify the 
metabolic pathways that are engaged during Treg motility and migration and assess whether 
CD28 and CTLA-4 signals impacted Treg migration by altering such metabolic pathways. To 
address these issues we conducted the following experiments: 
1. Assessment of in vitro and in vivo Treg migration in response to antibody mediated 
triggering of CD28, CTLA-4 and both co-receptors. 
2. Characterisation of CD28 and CTLA-4 signalling to investigate dependency on TCR 
signalling and to identify any differences brought about in the expression of receptors 
that are known to modulate motility (i.e chemokine receptors, adhesion molecules). 
3. Analysis of Treg motility following selective inhibition of metabolic pathways using 
predefined metabolic inhibitors, so as to identify those that are essential for motility. 
4. Analysis of the effect of CD28 and CTLA-4 signalling on metabolic pathways essential for 
Treg migration.  
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4.2.3 Results 
 
4.2.3.1 The anti CD28 (clone 37.51/37.52) and anti CTLA-4 (clone UC10-4F10-11 ) 
antibodies bind specifically to the extracellular domains of CD28 and CTLA-4. 
 
Both CD28 and CTLA-4 co-stimulatory receptors share considerable homology and bind to the 
same ligands on APCs. The stimulating anti- mouse CD28 (clone 37.51/37.52) is a well-established 
antibody which induces CD28 signals.   
In the study by Schneider et al 2006, an anti-CTLA-4 antibody (clone UC10-4F10-11) was used to 
induce signalling in T cells that could reverse the TCR induced stop-signal. In another study, Olsson 
et al reported that ligation of CTLA-4 using this same antibody suppressed CD28-mediated 
activation of transcription factors NF-κB and AP-1 in T cell blasts.  Thus we selected this antibody 
to induce signalling via the CTLA-4 receptor.  Additionally, we tested the reactivity of this antibody 
towards the CD28 co-receptor. To achieve this, we performed a flow cytometry based iso-control. 
Here we co-stained T cells with increasing concentrations of unlabelled anti-CTLA-4 antibody with 
a fixed concentration of PE conjugated anti-CD28 antibody. As a control, we co-stained cells with 
increasing concentrations of unlabelled anti-CD28 antibody with a fixed concentration of PE 
conjugated anti-CD28 antibody. As shown in Figure 31, increasing concentration of unlabelled 
anti-CTLA-4 antibody had no effect on the anti-CD28 PE staining of the T cells. In the case of the 
control, increasing unlabelled anti-CD28 antibody concentrations diminished anti-CD28 PE 
staining indicating competition between the two antibodies for the same binding sites. 
 Together with above mentioned reports indicating the anti-CTLA-4 (UC10-4F10-11) antibody acts 
as a signal inducing antibody, these results suggest that this murine anti-CTLA4 antibody is 
capable of selectively inducing signalling via the CTLA-4 receptor and does not bear any cross 
reactivity with the epitope of the murine anti-CD28 antibody. 
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Figure 31    Anti CTLA-4 antibody (clone UC10-4F10-11) is does not bear cross reactivity 
to CD28 
An iso-control experiment was performed to test cross reactivity of the anti CTLA-4 antibody to 
CD28. Foxp3+ Tregs isolated from Foxp3-GFP C57BL6 mice were stained with a fixed concentration 
(1ug) of PE conjugated anti CD28 and increasing concentrations of either unlabelled anti CTLA-4 
or, as a control, unlabelled anti CD28 antibody. The data plots indicate mean fluorescent intensity 
of the PE Anti-CD28 staining of Foxp3+ Tregs on the Y axis and increasing concentration of 
unlabelled antibody on the X axis. N=1.  
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4.2.3.2 CD28 and CTLA-4 co-receptors regulate migration of Tregs differentially. 
 
In conventional T cells, both CD28 and CTLA-4 co-receptors have been shown to regulate T cell 
migration and motility. Within the lymph nodes, CD28 activation promoted egression and 
migration of memory T cells towards the non-lymphoid tissue bearing the specific antigen. 
Furthermore CTLA-4 signalling antagonized the pro-migratory effect of CD28 and prevents Teff 
localisation to antigen-rich tissue. CTLA-4 engagement by APCs during T cell-APC interaction was 
also shown to reverse the TCR induced stop signal, thereby promoting detachment from the APC. 
Although both co-receptors share the same ligand specificity, CTLA-4 binds to its receptors with 
much higher affinity and competes with CD28 for ligands. Thus, through reversal of the TCR 
induced stop signal, CTLA-4 can outcompete and inhibit CD28 pro-migratory signalling by 
facilitating disengagement. However less is known regarding the role of the CD28 and CTLA-4 
signalling on the migration of Tregs, which express both CD28 and CTLA-4 co-receptors 
constitutively (Figure 32).  
 
Figure 32    CD4+Foxp3+ Tregs expressed CTLA-4 constitutively while CD4+ Foxp3- Teffs 
express CTLA-4 only after activation. 
CD4+CD25-FOXP3- T cells and CD4+CD25+FOXP3+ Tregs were isolated from C57BL6 mice spleens 
and lymph nodes and purified through cell sorting. The T cells were then subjected to activation 
using plate bound anti-CD3 (1ug/ml) and anti CD28 (5ug/ml) for a period of 4 days at 37°C with 
5% CO2. T cell populations were sampled at indicated time points and stained for both Foxp3 and 
CTLA-4 expression using the method described earlier. Dot plots indicate CD4+ T cells gated on 
either Foxp3+ or Foxp3- T cell populations as analyzed by flow cytometry. n=3, N=3  
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Tregs might display a migratory pattern different to Teffs as a result of the concomitant signalling 
of both receptors. To address this hypothesis, we observed the trans-endothelial migration of in 
vitro expanded Tregs following antibody-mediated stimulation of CD28 and CTLA-4 receptors. 
CD4+Foxp3+ Tregs isolated via flow activated cell sorting from Foxp3-eGFP reporter mice were 
expanded ex vivo through co-culture with sub-lethally irradiated immature bone marrow dendritic 
cells and IL-2. On day 7 of co-culture, Tregs were removed from culture, subjected to antibody-
mediated CD28 and/or CTLA-4 ligation and seeded onto IFN-γ activated endothelial cell 
monolayers in a transwell assay to observe trans-endothelial migration. Our results indicated that, 
while CTLA-4 stimulation did not inhibit Treg migration per se, CTLA-4-induced inhibitory signalling 
prevented CD28-induced enhancement of migration through the endothelium. These results 
suggest that CTLA-4 acts by inhibiting CD28-induced migration in Tregs (Figure 33). 
 
Figure 33    CTLA-4 activation abolishes the pro-migratory activity induced in Treg cells 
by CD28. 
CD4+CD25+Foxp3+ Tregs were isolated from Foxp3-GFP C57BL6 mice and expanded through co-
culture with sub-lethally irradiated immature bone marrow-derived allogeneic (H2-D) dendritic 
cells. Following 7 days of co-culture, expanded allospecific Tregs were treated with CD28 and/or 
CTLA-4 antibody-mediated ligation. As a control, Tregs were treated with an isotype-matched 
control antibody and secondary antibodies. Tregs were then placed over IFN-γ-treated (a) 
syngeneic, (b) allogeneic or (c) irrelevant endothelial cell monolayers grown on a 3-µm pore 
polycarbonate transwell and incubated for 24 hours at 37°C with 5% CO2. The number of migrated 
cells was evaluated by hemocytometric counting. Results are expressed as a percentage of 
migrated cells after 24 hours. Error bars represent standard deviations. Statistical significance was 
calculated with unpaired Student’s t-test. (n=3, N=4) *P<0.05.  
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4.2.3.3 CD28- and CTLA-4-mediated regulation of Treg migration occurs independently 
of the TCR   
 
While CD28 signals have been shown to augment the TCR signalling pathway, there is 
considerable evidence to suggest that CD28 signals can affect pathways independent of the TCR. 
In one study, CD28 ligation by recombinant B7 molecules on primary human CD4+ T cells without 
any TCR stimulus were shown to upregulate the survival factor Bcl-xl and the inflammatory IL-8 
and BAFF genes, in a NF-κB-dependent manner (Marinari et al. 2004). In terms of T cell 
cytoskeletal rearrangements, CD28 induction of F actin reorganisation by the Ras homologue 
Cdc42 occurs independently of ZAP-70 [z-chain (TCR)-associated protein kinase of 70 kDa] 
activation (Salazar-Fontana et al. 2003). Additionally, TCR independent signalling by CD28 also 
activates the Rho GTPases Vav1 (Michel et al. 2000).   
In order to address whether CD28/CTLA-4 regulation of Treg motility can occur independently of 
TCR triggering, we performed in vitro trans-endothelial migrations assays to observe the 
migration of Tregs in contexts where co-stimulatory signals would be delivered with/without TCR 
engagement. Tregs isolated from H2-B (C57BL/6) mice were expanded in vitro against H2-D 
alloantigens (BALB/c) to generate Tregs selected for their specificity for H2-D alloantigens, as 
described in Materials and Methods. Following antibody-mediated CD28 and/or CTLA-4 
crosslinking, Treg migration through endothelial monolayers formed from IFN-γ activated 
endothelial cells isolated from allogeneic H2-D, (BALB/c), syngeneic H2-B (C57BL/6) and irrelevant 
H2-K (CBA/Ca) backgrounds was monitored. Due to their weak affinity towards self-antigens, 
these Tregs are likely to have low affinity reactions with the self-antigen displayed by the 
syngeneic (H2-B) endothelium in addition to the strong allo-antigens reactivity against the 
allogeneic (H2-D) endothelium, while no TCR engagement would occur against antigens displayed 
by the endothelium of irrelevant origin. Thus, each endothelial variant represents a different level 
of TCR engagement. CD28 induced pro-migratory signals leading to enhanced transendothelial 
migration irrespective of the endothelial origin, which were abrogated by CTLA-4 stimulation. This 
suggests that CD28 induced migration and CTLA-4 induced inhibition of this event can occur in the 
absence of signals provided by the TCR [Figure 33 (b-c)].  
In addition to these experiments, we observed the effects of CD28 and CTLA-4 stimulation on F- 
actin reorganisation in Tregs using confocal microscopy. Tregs were plated onto anti-CD28 and/or 
anti-CTLA-4 antibody-coated tissue culture plates and images were taken by confocal laser 
scanning microscopy following 5-10 minutes of incubation (Figure 34). Rapid aggregation of F-
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actin towards the polarised edges can be visualised in the case of CD28 triggering. Although CTLA-
4 triggering had little effect on its own, it inhibited CD28-induced actin rearrangement and 
polarisation. Phorbol myristate acetate (PMA) treatment served as a positive control showing F-
actin upregulation with little directionality and polarisation. These experiments provide further 
evidence to suggest that TCR-independent signalling by CD28/CTLA-4 regulates Treg migration, as 
no TCR/CD3 stimulation was present. 
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Figure 34    CTLA-4 inhibits CD28 induced actin reorganisation and polarisation. 
 
CD4+CD25+Foxp3+ Tregs were isolated from Foxp3-GFP C57BL6 mice and expanded through co-
culture with sub-lethally irradiated immature bone marrow-derived allogeneic (H2-D) dendritic 
cells. Tregs were harvested after seven days and added to wells of a tissue culture plate containing 
glass coverslips coated with anti CD28 and/or anti CTLA-4 antibodies. As controls, an isotype-
matched control antibody was used for coating and PMA was added in the medium of some wells 
as a positive control for F actin up regulation. Cells were quickly spun down at low speeds to 
facilitate attachment, and subsequently fixed, pemeabilised and stained for F actin (Red) and DNA 
(Blue). The coverslips were mounted and imaged using a confocal microscope. (a)Images represent 
maximum projections of a Z scan of ten 1um slices. CD28 stimulation increased F actin and 
polarisation of F actin (arrows), while CTLA-4 did not. CTLA-4 triggering together with CD28 
prevented F actin upregulation and polarisation. (b) Bar graph represents the mean of the 
corrected total cell fluorescence of F actin from 15-20 individually observed cells using Image J. 
Error bars represent standard deviations. Statistical significance was calculated with unpaired 
Student’s t-test. (n=3, N=4) *** p<0.005       
 
Following in vitro trans-endothelial migration assays, we carried out similar experiments in vivo 
using the intra-peritoneal model of T lymphocyte recruitment. CD4+CD25 Tregs isolated through 
immunomagnetic selection from H2-B background mice were co-cultured with sub lethally 
irradiated allogeneic (H2-D) bmDCs and IL-2 to selectively expand Tregs crossreactive to H2-D 
alloantigens. 
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To establish whether CD28 and CTLA-4 co-stimulation can regulate Treg migration into non-
lymphoid tissue in vivo, prior to adoptive transfer, allospecific (H2-D) Tregs were treated with 
CD28, CTLA-4 or both crosslinking antibodies and their migration into the peritoneal cavity of 
either allogeneic H2-D (BALB/c) or irrelevant H2-K (CBA/Ca) donor mice given IFN-γ i.p. injection 
48 hours earlier was observed 24 hours later. Thus antigen presentation and TCR engagement 
would only occur in H2-D background recipients.  
These in vivo experiments recapitulated the in vitro findings in that greater number of Tregs 
accumulated in the peritoneal cavity of mice when the Tregs were pre-treated with CD28 
stimulation (Figure 35). Fewer Tregs were recovered from the peritoneal lavage when CTLA-4 
stimulation was given together with CD28 stimulus while CTLA-4 triggering on its own did not 
have a significant effect. Interestingly, similar results were also obtained when using H2-K, CBA/Ca 
irrelevant) as recipient mice (Figure 36). This experiment further suggested that CD28 and CTLA-4 
regulate trafficking of Tregs into target non lymphoid tissue independently of the TCR signal.  
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Figure 35    CTLA-4 prevents CD28-induced Treg migration in vivo. 
In vitro expanded allospecific Tregs were treated with CD28 and/or CTLA-4 antibody-mediated 
ligation. Tregs were then labelled with PKH26 and injected intravenously into BALB/c (allogeneic) 
mice that were given intra-peritoneal injections of IFN-γ 48 hours earlier. Equal number of Tregs 
treated with corresponding isotype control and secondary antibodies were labelled with CFSE and 
co-injected. 24 hours later, cells were recovered from the indicated tissues and analysed using flow 
cytometry. (a)Dot plots shown represents percentage of Treg cells in the recovered CD4+ donor 
population. (b) Bar graphs indicate absolute number of labelled cells recovered. Error bars 
represent standard deviations. Statistical significance was calculated with unpaired Student’s t-
test. (n=4, N=3)  * p<0.05  
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Figure 36    CD28 and CTLA-4 regulate Treg migration independently of the TCR signals 
induced by antigen recognition in vivo. 
Tregs isolated from H2-B (C57BL/6) mice and expanded by in vitro co-culture with immature H2-D 
(BALB/c) derived bmDCs to generate H2-D allospecific Tregs. These allospecific Tregs were then 
treated with CD28 and/or CTLA-4 antibody-mediated ligation, labelled with PKH26 and injected 
intravenously into H2-K (CBA/Ca, irrelevant) mice that were given intra-peritoneal injections of 
IFN-γ 48 hours earlier. As before, equal number of Tregs treated with an isotype control and 
secondary antibodies were labelled with CFSE and co-injected. Cells were then recovered from 
indicated tissues 24 hours later and analysed using flow cytometry.(a)Dot plots shown represents 
percentage of Treg cells in the recovered CD4+ donor populations.(b) Bar graphs indicate absolute 
number of labelled cells recovered . Error bars represent standard deviations. Statistical 
significance was calculated with unpaired Student’s t-test. (n=4, N=3)  * p<0.05 
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4.2.3.4 Glycolytic pathways are essential for Treg migration 
 
In view of the above findings we sought to investigate other signalling pathways and mechanisms 
through which CD28 and CTLA-4 co-receptors might be able to exert their effects on Treg 
migration. Previously, CD28-mediated induction of PI3K signalling was shown to be necessary for 
effective localisation to antigenic sites following antigen rechallenge (Mirenda et al. 2007). In 
conventional T cells, both CD28 and CTLA-4 have been shown to activate the PI3K-Akt pathway 
(Helga Schneider et al. 2008). As mentioned earlier in Section 1.3.4.1, the PI3k-Akt and 
subsequent downstream mTOR pathways initiated by CD28 are known to upregulate glucose 
metabolism. With this in mind and our own recent evidence suggesting that aerobic glycolysis is 
necessary for T cell migration (R. Haas et al. 2015); we set out to investigate whether metabolic 
changes induced by CD28/CTLA-4 could be responsible for the regulation of Treg migration by 
these receptors.  
First we sought to identify the metabolic pathways utilized by Tregs cells for migration. Unlike 
conventional and effector T cells, Tregs are known to utilize AMP kinase activity and preferentially 
use lipid oxidation for their energy requirements (Michalek et al. 2011c) during differentiation and 
development. Thus, we first tested the hypothesis that Tregs may use lipid oxidation as a means 
to provide energy for migration. H2-D allospecific Tregs were assessed for their migration through 
H2-B (syngeneic) endothelial monolayers in an in vitro trans-migration assays where the Tregs 
were pre-treated with Etomoxir, an inhibitor of fatty acid oxidation. Etomoxir blocks the activity 
of the enzyme carnitine palmitoyltransferase 1A (CPT1-A) which shuttles fatty acids into the inner 
membrane of the mitochondria for oxidation.  No differences in Treg migration following 
treatment with Etomoxir were observed (Figure 37). Similarly, following treatment with Etomoxir, 
H2-D allospecific Tregs that were injected in vivo into  IFN-γ i.p injected H2-B recipient mice did 
not reveal any differences in migration to the peritoneal cavity as compared to untreated Tregs 
(Figure 38).  
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Figure 37    Blockade of Fatty acid oxidation does not inhibit Treg migration in vitro. 
In vitro expanded Tregs, removed after 7 days of co-culture were treated with the CPT-A inhibitor 
etomoxir for 4 hours before being placed over IFN-γ-treated syngeneic endothelial cell monolayers 
grown on a 3-µm pore polycarbonate transwell and incubated for 24 hours at 37°C with 5% CO2 . 
Tregs treated with the vehicle only were used as a control. The migrating cells at the bottom were 
determined through hemocytrometric counting. Results are expressed as a percentage of 
migrating cells after 24 hours. Error bars represent standard deviation. Statistical significance was 
calculated with unpaired Student’s t-test. (n=4, N=3)   
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Figure 38    Blockade of Fatty acid oxidation does not inhibit Treg migration in vivo. 
In vitro expanded Tregs, removed after 7 days of co-culture were treated with the CPT1-A inhibitor 
Etomoxir for 4 hours before being labelled with PKH26 and intravenously injected into C57BL/6 
(syngeneic) mice that had received an intraperitoneal injection of IFN-γ 48-72 hours earlier. Equal 
number of vehicle treated, CFSE labelled Tregs were co-injected as a control. Cells were recovered 
from tissues indicated after 24 hours and analysed using flow cytometry.(a)Dot plots show 
percentage of Treg cells in the recovered in CD4+ donor populations from one representative(n=4). 
(b) Bar graphs indicate average of absolute number of labelled cells recovered .Error bars 
represent standard deviation (n=4)   
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While oxidation of fatty acids has been shown to be the dominant metabolic pathway utilised by 
Tregs under steady state, it is possible that glucose metabolism in Tregs is retained for other 
highly energy-dependent processes such as migration. We therefore tested the possibility that, 
like conventional T cells, Tregs utilise glycolysis for migration by inhibiting glycolysis using the 
glucose analogue 2-deoxyglucose (2-DG). Migration of Tregs was inhibited by the glycolysis 
inhibitor 2-DG both in vitro (Figure 39) and in vivo (Figure 40). 
 
 
Figure 39    Blocking Glycolysis abrogates Treg migration in vitro. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with the glycolysis 
inhibitor 2-DG for 4 hours before being placed over IFN-γ-treated syngeneic endothelial cell 
monolayers grown on a 3-µm pore polycarbonate transwell and incubated for 24 hours at 37°C 
with 5% CO2 . Tregs treated with a vehicle only were used as a control. The migrating cells at the 
bottom were determined through hemocytrometric counting. Results are expressed as a 
percentage of migrated cells after 24 hours. Error bars represent standard deviation. Statistical 
significance was calculated with unpaired Student’s t-test. (n=4, N=3) * P>0.05 
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Figure 40    Blocking Glycolysis abrogates Treg migration in vivo. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with the glycolysis 
inhibitor 2-DG for 4 hours before being labelled with PKH26 and intravenously injected into 
C57BL/6 (syngeneic) mice that had received an intraperitoneal injection of IFN-γ 48-72 hours 
earlier. Equal numbers of vehicle-treated, CFSE-labelled Tregs were co-injected as a control. Cells 
were recovered from tissues indicated after 24 hours and analysed using flow cytometry. (a)Dot 
plots shows percentage of Treg cells in the recovered in CD4+ donor populations from one 
representative. (b) Bar graphs indicate average of absolute number of labelled cells recovered. 
Error bars represent standard deviation. Statistical significance was calculated with unpaired 
Student’s t-test. (n=4, N=3) * p<0.05 
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In line with these experiments, activation of glycolysis using the electron transfer chain Complex I 
inhibitor, metformin, which stimulates glycolysis via AMPK, increased Treg migration in vitro 
(Figure 41) and in vivo (Figure 42).  
 
 
Figure 41    The anti-diabetic drug metformin increases Treg migration in vitro. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with metformin for 4 
hours before being placed over IFN-γ-treated syngeneic endothelial cell monolayers grown on a 3-
µm pore polycarbonate transwell and incubated for 24 hours at 37°C with 5% CO2. Tregs treated 
with a vehicle only were used as a control. The migrating cells at the bottom were determined 
through hemocytrometric counting. Results are expressed as a percentage of migrated cells after 
24 hours. Error bars represent standard deviation. Statistical significance was calculated with 
unpaired Student’s t-test. (n=4, N=3) * P>0.05 
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Figure 42    The anti-diabetic drug metformin increases Treg migration in vivo. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with metformin for 4 
hours before being labelled with PKH26 and intravenously injected into C57BL/6 (syngeneic) mice 
that had received an intraperitoneal injection of IFN-γ 48-72 hours earlier. Equal number of vehicle 
treated, CFSE labelled Tregs were co-injected as a control. Cells were recovered from tissues 
indicated after 24 hours and analysed using flow cytometry. (a)Dot plots shows percentage of Treg 
cells in the recovered in CD4+ donor populations from one representative. (b) Bar graphs indicate 
average of absolute number of labelled cells recovered. Error bars represent standard deviation. 
Statistical significance was calculated with unpaired Student’s t-test. (n=4, N=3) * p<0.05 
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Prolonged use of metabolic inhibitors can significantly impact cell survival and can thus influence 
migration studies.  Therefore, we measured cell apoptosis after treatment with the metabolic 
inhibitors using an annexin V/propium iodide staining assay. Exposure to the various metabolic 
inhibitors, at the concentrations and durations used, did not affect the surface molecule 
phenotype (Figure 43), or survival of the Treg population (Figure 44).  
Collectively, these results suggest that Tregs utilise glycolysis as a means of energy production for 
migration rather than the dominant fatty acid oxidation pathway used for energy during a resting 
state.   
 
 
Figure 43    Flow cytometric characterisation of Tregs treated with various metabolic 
inhibitors. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with the indicated 
metabolic inhibitors for a period of 4-6 hours before being analyzed using flow cytometry. 
Histograms represent staining while the adjacent numerical values represent the mean 
fluorescence intensity of staining. Isotype–matched control for the antibodies used is denoted in 
the bottom of each plot (pink histograms). n=3, N=2 
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Figure 44    Metabolic inhibitors did not induce apoptosis in Tregs 
Apoptosis of Tregs treated with the various metabolic inhibitors/drugs indicated was measured 
using an annexin V/propium iodide live/dead cell distinguishing assay. Following treatment with 
the metabolic inhibitors, Tregs were analysed using flow cytometry and divided into live (Annexin 
V -ve, PI -ve), necrotic (Annexin V -ve, PI +ve), early apoptotic (Annexin +ve, PI -ve) and apoptotic 
(Annexin +ve, PI +ve) cell populations. Untreated Tregs and Tregs subjected to heat induced 
apoptosis were used as negative and positive controls respectively. (a)The quadrant dot plots are 
representative of one data set. (b) The bar graphs represent cumulative data showing the means 
of the percentages of apoptotic and early apoptotic Treg cells. (n=4, N=3).Error bars are indicative 
of standard deviations.   
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4.2.3.5 CD28/CTLA4 regulate glycolysis in Tregs 
 
The central hypothesis of this study is that CD28 and CTLA-4 may regulate Treg migration via 
signaling pathways that affect Treg metabolism.  Therefore, we first investigated the effects of 
CD28 and CTLA-4 signals on the extracellular acidification rate (ECAR), which quantifies proton 
production as a proxy for lactate production, and thus reflects overall glycolytic flux; and the 
oxygen consumption rate (OCR), a measure of mitochondrial respiration, in real time via the use 
of the Seahorse analyzer. CD4+Foxp3+ CD25+ Tregs isolated from the spleen and lymph nodes of 
Foxp3-GFP reporter mice mouse, through flow activated cell sorting (FACS), were co-cultured with 
sub-lethally irradiated immature bmDCs and IL-2 for 7 days. Following incubation, expanded Treg 
populations were plated into the XF analyser for real-time analysis of ECAR and OCR in response 
to CD28 and or CTLA-4 ligation. Antibody mediated triggering of the CD28 receptor on Tregs 
doubled the ECAR upon glucose addition compared to the cells treated with an isotype control 
highlighting an increase in the overall ECAR following CD28 stimulation (Figure 45). Interestingly, 
triggering the CTLA-4 receptor did not have an effect on the ECAR on its own but when activated 
during CD28 triggering CTLA-4 signals prevented CD28-induced ECAR upregulation. The OCR did 
not seem to differ in any of the conditions tested (Figure 46). 
    Results 
182 
 
 
Figure 45    CTLA-4 inhibited CD28 induced upregulation of ECAR in Foxp3+ve Tregs 
In vitro expanded Tregs, harvested after 7 days were first rested in serum free, unbuffered XF 
assay medium (Seahorse biosciences) for 1 hour. Cells were subsequently seeded (6X105/well) into 
the seahorse XF24 cell plates for analysis. Real time analysis of ECAR was performed using the XF 
analyser. Wells were injected first with anti CD28 and/or anti CTLA-4 antibodies along with an 
appropriate secondary antibody for crosslinking. Isotype-matched and secondary antibodies were 
used as controls. A second injection followed at the time point indicated (dashed line) introducing 
D-glucose into the wells. (a) The line data plot shows real time analysis of ECAR. (b) Cumulative 
data here indicates the mean from three experiments (n=5, N=3) at (i) baseline and (ii) after 
addition of glucose. Statistical test involved using a one way ANOVA with Bonferroni correction 
*p>0.05, **p>0.005, ***p>0.0005       
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Figure 46    The OCR of Foxp3 +ve Tregs does not change in response to CD28/CTLA-4 
stimulation 
In vitro expanded Tregs, harvested after 7 days were first rested in serum free, unbuffered XF 
assay medium (Seahorse biosciences) for 1 hour following which they were seeded (6X105/well) 
into the seahorse XF24 cell plates for analysis. Real time analysis of OCR was performed using the 
XF analyser. Wells were injected first with anti CD28 and/or anti CTLA-4 antibodies along with an 
appropriate secondary antibody for crosslinking. Isotype-matched and secondary antibodies were 
used as controls. A second injection followed at the time point indicated (dashed line) introducing 
D-glucose into the wells.  Statistical test involved using a one-way ANOVA with Bonferroni 
correction.  
 
CD28 signaling in conventional T cells was previously shown to increase the expression of surface 
glucose transporter Glut1 (Jacobs et al. 2008). We therefore measured glucose uptake by Tregs in 
response to CD28 and/or CTLA-4 signaling by using the glucose uptake reporter 6NBDG. 6NBDG 
does not undergo phosphorylation by the hexokinases and thus accumulates within the cells in its 
fluorescent form. CD4+ CD25+ Tregs isolated from the spleen and lymph nodes of C57BL/6 mice, 
through flow activated cell sorting (FACS), were co-cultured with sub lethally irradiated immature 
bmDCs and IL-2 for 7 days. Following incubations, expanded Tregs were removed from culture 
and subjected to glucose starvation for 1 hour. Tregs were then cultured in 6NBDG-containing, 
glucose-free, serum-free medium following antibody-mediated CD28 and/or CTLA-4 crosslinking. 
6NBDG uptake was enhanced in response to CD28 stimulation (Figure 47). As expected, CTLA-4 
stimulation on its own did not affect 6NBDG uptake, but when present along with CD28 
stimulation it inhibited the CD28-induced enhancement of 6NBDG uptake. These results suggest 
that CD28 signaling increases glycolysis, while CTLA-4 can prevent CD28-induced increase of 
glycolysis. 
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Figure 47    CTLA-4 inhibits CD28-induced glucose uptake in Tregs 
In vitro expanded Tregs, harvested after 7 days were first rested in glucose free and serum free, T 
cell medium for 1 hour. T cells underwent antibody stimulation of CD28 and/or CTLA-4 as 
previously described. Tregs were then re-suspended in medium containing the glucose uptake 
indicator 6-NBDG for 10 minutes after which they were placed on ice and analyzed immediately by 
flow cytometry. Non-fluorescent glucose analog 2-DG was used as a negative control for staining. 
(a) The histograms are representative of all conditions in one representative experiment. (b) The 
bar graph represents the average MFI from 3 different experiments. (n=3, N=3). Error bars 
represent standard deviation. Statistical significance was calculated with unpaired Student’s t-test. 
***P>0.005 
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CD28/CTLA-4 regulates Treg migration through modulation of glucose metabolism 
To test whether CD28/CTLA-4-induced changes to Treg glycolysis affected their migration, we 
compared Treg migration in the presence or absence of glucose in the surrounding medium 
following activation of CD28, CLTA-4 or both receptors in trans-endothelial migration assays.  As 
expected, CD28 stimulation induced an increase in migration of Tregs in glucose-sufficient 
medium. In contrast, Treg migration was not modified by CD28 stimulation in the absence of 
glucose (Figure 48), suggesting that glucose uptake is necessary for the effects of CD28 signals on 
Treg motility. The results were not influenced by any cell death associated with glucose 
deprivation as baseline levels of migration remained similar in both glucose sufficient and 
deficient medium (Figure 48) and as shown by trypan blue mediated live/dead cell staining 
performed at the end of the assay (Figure 49).   
 
Figure 48    Extracellular Glucose is essential for CD28- induced Treg migration in vitro. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with CD28 and/or CTLA-
4 stimulation before being placed over IFN-γ-treated syngeneic endothelial cell monolayers grown 
on a 3-µm pore polycarbonate transwell and incubated for 24 hours at 37°C with 5% CO2. Tregs 
treated with the isotype-matched and secondary antibodies were used as a control. In these 
assays, Tregs were re-suspended in either serum-free or serum-free & glucose-free medium. 
Migrated cells in the bottom chamber were enumerated by hemocytometric counting. Results are 
expressed as a percentage of migrated cells after 24 hours. Error bars represent standard error of 
means. Statistical significance was calculated with unpaired Student’s t-test. * P>0.05, (n=3, N=4) 
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Figure 49    Tregs display similar survival in glucose free medium 
In vitro expanded Tregs, harvested after 7 days of co-culture with immature bmDCs were 
incubated for 24 hours at 37°C with 5% CO2 in either serum-free or serum-free, glucose-free 
medium. Live/dead cell discrimination of Tregs from both media was then assessed through trypan 
blue staining and hemocytometric counting. Error bars represent standard deviations. Statistical 
significance was calculated with unpaired Student’s t-test. (n=3, N=3) 
 
Next, we sought to investigate whether this effect could be observed in a physiological 
environment in vivo, using a previously described tissue infiltration model measuring infiltration 
of i.p. injected T cells into the peritoneal membrane (Mirenda et al. 2007). Tregs were first 
subjected to antibody-mediated CD28 and CTLA-4 stimulation following which they were labeled 
with the in vivo tracking dye PKH26. Cells were then injected i.p. into recipient mice that were 
also given an i.p injection of 6NBDG simultaneously to visualize Treg glucose uptake in parallel 
with Treg migration. This approach overcomes the barrier posed by the rapid loss of fluorescence 
associated with 6NBDG injected via other routes that would otherwise make it impossible to track 
T cells and their glucose uptake when injected by a different route. CD28 stimulation led to an 
increased number of Tregs infiltrating the peritoneal membrane, which was accompanied by 
enhanced 6NBDG uptake by the infiltrating Treg cells. Both of these effects were prevented by 
CTLA-4 co-ligation (Figure 50). These results suggest that Treg cells, which acquire enhanced 
motility in vivo following CD28 stimulation, are also likely to enhance glucose consumption in vivo.  
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Figure 50    CTLA-4 inhibition of CD28-induced glucose uptake prevents Treg migration in 
vivo 
In vitro expanded Tregs were treated with CD28 and/or CTLA-4 antibody-mediated ligation. Tregs 
were then labelled with PKH26 and injected via the intra-peritoneal route into C57BL/6 mice that 
were given intra-peritoneal injections of IFN-γ 48 hours earlier. A co-injection of 6NBDG was given 
immediately afterwards and the mice were sacrificed within 1 hour. The peritoneal membranes 
were removed and imaged using a fluorescence microscope to determine the number of 
infiltrating cells (b) and (c) 6NBDG (green) uptake by the infiltrating cells. DAPI was used as a 
nuclear stain. The images (a) are representative of the each condition where green and red can be 
seen together in tandem (yellow). (b) Bar graphs represent cumulative data indicating number of 
cells counted manually in 10 10x fields of view. (c) Bar graphs represent cumulative data showing 
the mean CTFC of 6NBDG from 10-12 cells from one 10x field of view. Error bars represent 
standard deviations. Statistical significance was calculated with unpaired Student’s t-test. *** 
p<0.0005 (n=4, N=2) 
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We further explored the link between co-stimulation, migration and metabolic regulation by 
assessing the metabolic activity and migration of CTLA-4 KO Tregs. Mice deficient in CTLA-4 
display uncontrolled T cell proliferation similar to lymphoproliferative disorder. Tregs were 
isolated from 4 week-old CTLA-4 KO (H2-B background) mice and expanded in vitro by co-culture 
with immature bmDCs from BALB/c (H2-D) mice to selectively expand H2-D allospecific CTLA-4 KO 
Tregs. H2-D allospecific Tregs from age-matched WT mice were used for comparison.  A 
comparative analysis of ECAR between the WT and CTLA-4 KO Tregs, determined via the seahorse 
analyser, revealed that the glycolytic activity of CTLA-4-deficient cells was constitutively higher 
compared to that of their WT counterpart (Figure 51). Surprisingly, mitochondrial respiration was 
also significantly more elevated in CTLA-4 KO Tregs. These results suggest a hyper-metabolic 
signature displayed by CTLA-4 KO Tregs that is associated with their proliferation. Addition of a 
recombinant B7-1 (CD80) molecule in the Seahorse increased the glycolytic response of CTLA-4 
Tregs, presumably due to dominant CD28 signalling, while their OCR remained unchanged. In 
contrast, the ECAR of CTLA-4-competent Treg cells remained unchanged, likely due to 
simultaneous activation of CD28 and CTLA-4 signalling by the B7-1 molecules. 
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Figure 51    CTLA-4KO Tregs display inherently higher ECAR compared to WT Tregs 
CTLA-4 KO Tregs and WT Tregs isolated from lymph nodes and spleens of age matched CTLA-4KO 
or WT mice by immunomagnetic seperation were co-cultured with immature bmDCS and IL-2 to 
facilitate in vitro expansion. Expanded Tregs from both CTLA-4KO and WT mice were then 
analysed for their metabolic profiles using the Seahorse XF analyser.  The plot depicts real time 
analysis of ECAR observed in CTLA-4KO Tregs using the XF analyser. Cumulative data here 
indicates the mean from three experiments at (b) baseline and (c) after addition of glucose. 
Statistical test involved using a one way ANOVA with Bonferroni correction *P>0.05  n=3, N=4 
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In parallel, we tested H2-D allospecific CTLA-4 KO Treg migration through IFN-γ-activated 
syngeneic (H2-B) endothelium in an in vitro trans-endothelial migration assay following 
stimulation with B7-1 recombinant protein. Here, CTLA-4 KO Tregs displayed enhanced migration 
through the endothelium when subjected with B7-1 stimulation while CTLA-4-competent H2-D 
allospecific WT Tregs did not respond to any such stimulation (Figure 52). These results further 
suggest that CTLA-4 signals inhibit CD28 induced pro-migratory signals and associated glycolysis. 
 
 
Figure 52    CTLA-4KO Tregs increase migration in response to B7-1 stimulation. 
CTLA-4 KO Tregs were isolated and expanded as described in the legend to Figure 44. Tregs were 
then placed over IFN-γ-treated allogeneic endothelial cell monolayers grown on a 3-µm pore 
polycarbonate transwell and incubated for 24 hours at 37°C with 5% CO2. The number of migrated 
cells was evaluated by hemocytometric counting. Results were expressed as average percentage 
of migrated cells at 24 hours after migration. Error bars represent standard deviations. Statistical 
significance was calculated with unpaired Student’s t-test * p< 0.05; ** p< 0.01 , n=3,N=4 
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CD28/CTLA-4 regulation of Treg migration is dependent on PI3K-Akt but independent of 
mTORC1  
In most T lymphocytes, the mTORC1 complex of the mTOR kinase couples upstream PI3K/Akt 
signalling with the control of glucose uptake and glycolysis (Chi 2012; Powell and Delgoffe 2010; 
Rao et al. 2010). Conversely, Tregs exhibit metabolic characteristics that are more akin to that of 
long lived CD8 memory T cells. CD8 memory T cells have higher mitochondrial mass than CD8 
effectors and they use primarily fatty acid oxidation to meet their energy demands. Indeed CD4 
Tregs also have a higher mitochondrial mass than that of CD4 effectors (Figure 53) suggesting an 
increased mitochondrial oxidative capacity. 
 
Figure 53    CD4+CD25+ Tregs display higher mitochondrial mass than CD4+CD25- Teffs 
Purified CD4+CD25+ Treg  and CD4+CD25- Teff cells populations, isolated from lymph nodes of 
C57BL/6 mice by immunomagnetic separation were stained with mitotracker green dye and 
analysed using flow cytometry to indicate the total mitochondrial mass within the cells. These 
CD4+CD25+ Treg populations displayed high levels of Foxp3 expression (<95%). The histogram 
represents mitochondrial uptake of the mitotracker green dye in the Treg cells from 3 experiments. 
(n=3, N=3) 
 
Inhibiting mTORC1 with rapamycin favours the development of both CD8 memory T cells and CD4 
Tregs after infection. However, Tregs still maintain mTORC1 activity for non-proliferative 
functions such as their ability to supress the activation of T cells (H. Zeng et al. 2013c). In (Mirenda 
et al. 2007) study, PI3K activation via CD28 was shown to be necessary for enhancement of 
memory CD8 T cell migration in vivo. In their study, abrogation of CD28 recruitment of PI3K 
through a point mutation in the cytoplasmic domain (CD28Y170F) resulted in the loss of CD28-
induced memory T cell migration.  We therefore sought to investigate which components of this 
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PI3K-Akt-mTOR axis are essential for co-stimulation regulated Treg metabolism and subsequently 
migration. 
We started by investigating the role of CD28-induction of the PI3K pathway on the metabolism 
and migration of Tregs isolated from CD28Y170F transgenic mice. The CD28 Y170F transgenic mice 
carry a point mutation in the cytoplasmic tail of CD28, which prevents recruitment and 
subsequent activation of PI3K in all T cells (Okkenhaug et al. 2001). These mice have normal Treg 
thymic output. However, they display fewer Tregs in the periphery and secondary lymphoid tissue 
(Figure 54). 
 
 
Figure 54    CD28Y170F mice display lower numbers of Tregs in the periphery than WT 
mice 
Tregs from the indicated tissues from CD28Y170F and corresponding age matched WT mice were 
identified by CD4+Foxp3+ staining and flow cytometry. The dot plots are representative from 3 
individual mice. 
 
This may be a consequence of poor induction of the survival factor BCL-xl resulting from the point 
mutation in the cytoplasmic tail of CD28. In the next set of experiments we investigated migratory 
and metabolic features of CD28Y170F Tregs. First, we compared migration of Tregs isolated and 
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expanded from both WT and CD28 Y170F mice using in vitro trans-endothelial migration assay. 
Similarly to what was reported for CD28Y170F Teff, Tregs from CD28 Y170F mice failed to display the 
enhancement in extravasation through endothelial monolayers when subjected to CD28 
stimulation observed in the WT Tregs (Figure 55). 
 
 
Figure 55    CD28 stimulation fails to enhance trans-endothelial migration of CD28Y170F 
Tregs in vitro. 
CD4+CD25+ Tregs isolated from CD28Y170F or WT mice by immunomagnetic selection were 
expanded in vitro through co-culture as described in Figure legend 44. These Tregs were 
stimulated with CD28 and/or CTLA-4 antibody-mediated ligation. As a control, Tregs were treated 
with an isotype-matched control and secondary antibodies. Trans-endothelial migration of these 
Tregs was then assessed through IFN-γ-treated endothelial cell monolayers in a transwell assay. 
The number of migrated cells was evaluated by hemocytometric counting. Results were expressed 
as average percentage of migrated cells after 24 hours. Error bars represent standard 
deviation.Statistical significance was calculated with unpaired Student’s t-test; *** p< 0.005 n=4, 
N=2  
 
Second, we compared CD28 Y170F Treg migration with that of WT Tregs in vivo using the intra-
peritoneal recruitment model. Due to the fewer numbers of CD28 Y170F Tregs, we modified our in 
vitro Treg expansion protocol by co-culturing purified CD4 T cells from CD28 Y170F with immature 
allogeneic dendritic cells for a period of 2 weeks to selectively induce proliferation amongst the 
Treg populations. We then observed their migration in vivo by identifying recovered cells in the 
peritoneal lavage that were both labelled (i.e adoptively transferred) and stained positively for 
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the Treg nuclear transcription factor Foxp3. For adequate comparison, WT Tregs were also 
generated in a similar fashion from age-matched controls. Similar to the results obtained in vitro, 
Tregs from CD28 Y170F mice failed to upregulate their migratory activity upon CD28 stimulation 
when compared to WT Tregs in vivo (Figure 56). These results confirm the pivotal role of PI3K-
mediated signals in CD28 induced Treg migration. 
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Figure 56    CD28 stimulation fails to enhance migration of CD28Y170F Tregs in vivo. 
Enriched CD4+CD25+ Tregs from CD28Y170F mice were expanded through co-culture with sub-
lethally irradiated immature bmDCS and IL-2. T cells were then labelled with PKH26 and injected 
intravenously into mice that were given intra-peritoneal injections of IFN-γ 48 hours earlier. Equal 
number of T cells treated with corresponding isotype-matched control and secondary antibodies 
were labelled with CFSE and co-injected. 24 hours later, cells were recovered from the indicated 
tissues, stained for Foxp3 and analysed using flow cytometry. In a parallel experiment, CD4+ 
CD25+ Tregs from WT mice were used to observe CD28 induced migration as a control. (a)Dot 
plots shown represents percentage of Treg cells in the recovered CD4+ donor (PKH26 labelled) 
population. (b) Bar graphs indicate absolute number of labelled cells recovered in 4 mice (n=4). 
Error bars represent standard deviations.  * p<0.05 
 
Further, since CD28 co-stimulation induces glucose uptake and glycolysis via the PI3K-Akt 
signalling pathway, we predicted that CD28 Y170F Tregs would be less efficient at inducing glycolysis 
upon CD28 triggering. To test this hypothesis, we analysed the ECAR/OCR rates of the CD28 Y170F 
Tregs and WT Tregs before and after CD28 stimulation. Remarkably, the baseline ECAR of the 
CD28 Y170F Tregs was significantly lower to that of WT Tregs (Figure 57). Perhaps this occurred due 
to inefficient CD28 signalling in their development and proliferation during the in vitro expansion. 
In addition unlike WT Tregs, CD28 Y170F Tregs were unable to upregulate the ECAR following CD28 
stimulation. 
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Figure 57    CD28Y170F Tregs display inherently lower ECAR compared to WT Tregs 
CD28Y170F Tregs and WT Tregs isolated from lymph nodes and spleens of age matched CD28Y170F or 
WT mice by immunomagnetic separation were co-cultured with immature bmDCS and IL-2 to 
facilitate in vitro expansion. Expanded Tregs from both CD28Y170F and WT mice were then analysed 
for their metabolic profiles using the Seahorse XF analyser.  The plot depicts real time analysis of 
(a) ECAR and (b) OCR observed in CD28Y170F Tregs using the XF analyser. Cumulative data here 
indicates the mean ECAR from three experiments at (c) baseline and (d) after addition of glucose. 
Statistical test involved using a one way ANOVA with Bonferroni correction ***P>0.005  n=3, N=4 
 
 Lastly, we tested the contribution of mTORC1 in CD28-induced Treg migration. To this 
aim, we monitored migration of Tregs following a short treatment with the mTORC1 inhibitor 
rapamycin. In vitro trans-endothelial migration assays of Tregs treated with rapamycin did not 
reveal any differences compared to the untreated Tregs in their migration (Figure 58). 
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Figure 58    In vitro migration of Tregs is supported by an mTORC1 independent 
mechanism. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with the mTORC1 
inhibitor rapamycin (dose) for 4 hours before being placed over IFN-γ-treated syngeneic 
endothelial cell monolayers grown on a 3-µm pore polycarbonate transwell and incubated for 24 
hours at 37°C with 5% CO2 . Tregs treated with a vehicle only were used as a control. Migrated 
cells in the bottom chamber were quantified by hemocytrometric counting. Results are expressed 
as a percentage of migrated cells after 24 hours. Error bars represent standard error of means.* 
P>0.05 
 
These results are contrary to what has been observed in CD4 effector cells as seen by (R. Haas et 
al. 2015) study which showed that rapamycin mediated glycolysis inhibition in Teffs reduces their 
migration . While this dose did not affect the migration of Tregs it did impact proliferation as was 
seen by staining for the proliferating nuclear cell antigen (PCNA) (Figure 59).  
 
 
 
 
    Results 
198 
 
 
Figure 59    Inhibition of mTORC1 in Tregs with rapamycin can disrupt their proliferation 
in vitro. 
In vitro expanded Tregs were treated with rapamycin for 4-6 hours following which they were 
stained for the proliferating cell nuclear antigen (PCNA).The histograms represent PCNA staining 
of the Treg cells by Flow cytometry. (n=3, N=3) 
 
In vivo Tregs treated with rapamycin did not exhibit any differences in migration in the peritoneal 
model of recruitment when compared to untreated Tregs (Figure 60). Additionally, CD28-induced 
migration of Tregs that was observed earlier remained similar when Tregs were pre-treated with 
rapamycin before adoptive transfer (Figure 60). Collectively these results imply that mTORC1 
activity is dispensable in Treg migration. Furthermore, these results suggest that CD28/CTLA-4 
regulation of Treg metabolism and migration occur via signalling molecules other than mTORC1. 
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Figure 60    CD28 induced in vivo migration of Tregs can occur independently of mTORC1 
activity. 
In vitro expanded Tregs, harvested after 7 days of co-culture were treated with CD28 antibody-
mediated ligation along with the mTORC1 inhibitor rapamycin for 4 hours before being labelled 
with PKH26 and intravenously injected into C57BL/6 (syngeneic) mice that had received an 
intraperitoneal injection of IFN-γ 48-72 hours earlier. As a control, Tregs were treated with an 
isotype-matched control antibody and secondary antibodies were labelled with CFSE and co-
injected.  Cells were then recovered from tissues indicated after 24 hours and analysed using flow 
cytometry. (a)Dot plots shows percentage of Treg cells in the recovered in CD4+ donor populations 
from one representative. (b) Bar graphs indicate average of absolute number of labelled cells 
recovered (n=4). Error bars represent standard deviation. Statistical significance was calculated 
with unpaired Student’s t-test. * p<0.05γ 
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CTLA-4 inhibits glycolysis induced by CD28, disrupting its ability to induce migration. 
We next interrogated the molecular mechanisms by which CTLA-4 disrupts CD28-induced 
upregulation of glycolysis and migration. To this aim, we performed western blots to observe 
changes in expression of key enzymes along the glycolytic and lipid oxidation pathways following 
CD28 and/or CTLA-4 stimulation in Tregs. We analysed the expression of key glycolytic enzymes 
such as the rate-limiting enzymes Hexokinase and its isoenzyme Glucokinase, Aldolase, Enolase-1, 
as well as an enzyme required for fatty acid oxidation carnitine palmitoyltransferase 1A (CPT1-A) 
(Figure 61). Stimulation of Tregs with CD28 stimulation resulted in upregulation of enzymes 
involved in glycolysis. Specifically, CD28 stimulation greatly increased expression of the 
hexokinases, Hexokinase I and Glucokinase (Hexokinase IV or GCK).  
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Figure 61    CTLA-4 inhibits CD28 induced glycolysis and engages FAO in Tregs. 
In vitro expanded Tregs harvested after 5 days of co-culture with immature bmDCs were treated 
with CD28 and/or CTLA-4 antibody-mediated ligation. As a control, Tregs were treated with an 
isotype-matched control antibody and secondary antibodies. (a) Cells were then recovered and 
analysed using western blotting as shown in the figure. (b) Bar graphs represent cumulative data 
from the three sets of blotting gels (n=4, N=3). Error bars represent standard deviation. Statistical 
significance was calculated with unpaired Student’s t-test. n=3, N=3, ***p<0.0005. 
    Results 
202 
 
Hexokinases phosphorylate glucose to glucose-6 phosphate, an enzymatic reaction relevant to all 
pathways of glucose utilization, including glycolysis and the pentose phosphate pathway. 
Interestingly, the hexokinase isoenzyme GCK was not known to be expressed by Tregs.   
Concomitant triggering of CTLA-4 reduced CD28-induced Hexokinase I and GCK expression. 
Strikingly, while not affecting the expression of glycolytic enzymes, CTLA-4 signalling greatly 
induced expression of CPT1-A, the rate-limiting enzyme for fatty acid oxidation. These results 
suggest a novel role of CTLA-4 inhibition of CD28 signalling. Collectively, the results imply that 
CTLA-4 signalling not only inhibits the glycolytic pathways that fuel CD28 induced Treg migration, 
but also reverts the Tregs back towards fatty acid oxidation, the predominant metabolic pathway 
of Tregs observed under steady state conditions.      
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4.2.4 Discussion 
 
In this part of the study, we have investigated the effect of CD28 and CTLA-4 stimulation on the 
migration of Tregs. We show that glycolysis is an essential process for Treg migration in vivo and 
in vitro and CD28-mediated signalling induces glucose uptake and glycolysis in Tregs, thus 
enhancing Treg migration. Furthermore, our results demonstrate that CTLA-4 signalling in Tregs 
counteracts CD28 induced glycolysis thereby inhibiting Treg migration.   
Our results revealed differences to those studies examining conventional T cells alone. In 
(Mirenda et al. 2007) study, CTLA-4 signals to T6 cell clones, that display constitutive expression of 
weakly expressed CTLA-4, were shown to inhibit migration. Here, we show that although Tregs do 
indeed express CTLA-4 constitutively, CTLA-4 on its own does not affect Treg migration. Instead 
we observed a more dynamic role for CTLA-4 acting through disruption of the pro-migratory 
signals brought through CD28 signalling. 
Importantly, our studies reveal a direct, active role of CTLA-4 in the regulation of Treg metabolism 
and migration. As we have previously mentioned CTLA-4 can act through several different 
mechanisms to elicit its inhibitory role. For example, CTLA-4 can out compete CD28 for ligands 
and physically displace ligands off the APC surfaces (Hou et al. 2015a; Soskic et al. 2014). Although 
it is possible that this mechanism might contribute to the inhibitory effect on CD28 induced 
enhancement of Treg migration and metabolism, in our studies, which have been conducted by 
triggering CD28 and CTLA-4 signals by antibody ligation, CTLA-4 signals directly inhibit CD28-
induced events, including cytoskeletal rearrangements and glycolysis.Furthermore, our results 
indicate that CTLA-4 not only passively prevent CD28 effects,which would be compatible with a 
competition mechanism, but also upregulates CPT1a on its own. This suggests that CTLA-4 
signalling activity on Tregs affects transcriptional and/or post-transcriptional events.  
In the previous chapter, we showed that cognate recognition of antigen-presenting endothelium 
by the Treg TCRs facilitated their extravasation and recruitment to antigen-rich tissue. The 
present study suggests that CD28 can act independently of the TCR. Although debated 
extensively, there is evidence from independent studies to suggest that TCR-independent 
signalling by the co-stimulatory receptor CD28 exists. In one study, F actin based cytoskeletal 
rearrangement via CD28 stimulation occurs independently of the TCR signals. In this context, it is 
important here to note that these results apply to CD28 and CTLA-4 regulation of migration in an 
in vitro activated cohort of Tregs, conventional naïve T cells did not seem to respond well to CD28 
stimulation alone (FMB, unpublished observations). Moreover, there is no evidence suggesting 
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accumulation of naïve T cells in the lymphoid tissue of CD28KO, B7-1/2KO and CD28Y170F mice. As 
the majority of freshly isolated naïve Tregs are not truly naïve (due to their self-reactivity) it will 
be important to investigate whether freshly isolated Tregs are susceptible to CD28/CTLA-4-
regulation of migration.  
In a physiological context, these results imply that APCs such as DCs would be able to modulate 
Treg motility to tissues independently of antigen presentation. Such interactions may occur when 
co-stimulation is provided without TCR triggering at the end of an immune response or during 
resting immune state where all antigen has been removed. This would effectively enable Treg 
recruitment to antigenic sites even at the very late stages of the immune response thus, 
mediating tolerance in a timely manner.     
We subsequently concentrated on the metabolic regulation of migration of Tregs via co-
stimulatory CD28 and CTLA-4 receptors. Fatty acid oxidation and the AMPK pathways are believed 
to be the dominant energy production pathways during development and differentiation of Tregs 
(Michalek et al. 2011c). In addition, our observations pinpoint glycolysis and not fatty acid 
oxidation to sustain migration in Tregs.  
In addition to this novel finding, we show that the anti-diabetic drug metformin can also increase 
Treg migration. Although the exact mechanism of action of metformin is unclear, there is 
evidence that metformin can activate the AMPK pathways which can induce both FAO and 
glycolysis. Given that the inhibitor of FAO did not reveal any differences in the migration of Tregs, 
we concluded that glycolysis played a key role in Treg migration.   
Based on these observations, we tested the possibility that CD28/CTLA-4-mediated regulation of 
Tregs could occur via modulation of the glycolytic pathway. Given that both co-receptors are 
known to be associated with the PI3K-Akt pathway, which can regulate both metabolism and 
migration, we focused our investigation on the role of PI3K in these events. Crucially, we 
hypothesized that CD28 mediated induction of both glycolysis and migration would effectively 
require the action of the PI3K-Akt signalling pathway. Evidence suggesting this was first provided 
by the study by (Frauwirth et al. 2002), which implicated PI3K in CD28-mediated control of 
glucose metabolism. To test this hypothesis we have utilized Tregs from the CD28Y170F mice and 
shown that these Tregs are unable to display CD28 enhancement of migration both in vitro and in 
vivo. Furthermore these Tregs displayed poor upregulation of glycolysis in response to CD28 
signals as compared to WT tregs. Collectively these results imply that CD28 stimulation of Tregs 
induces both glycolysis and motility, a feature that is dependent on the PI3K pathway. 
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Interestingly our results also indicate that the activation of downstream mTORC1 was dispensable 
for migration.  This implies that the downstream target of CD28 induced PI3K-Akt pathway may 
differ to those that are linked to metabolic control and subsequently migration.  
Our study also shows that CTLA-4 inhibits the CD28-mediated effects on Treg migration by 
abrogating the signals that couple glycolysis to migration. 
In addition, a broad analysis of enzymatic control of key metabolic pathways also revealed that 
CTLA-4 may act not only as a counterbalance to CD28 signalling, but also may be required to 
restore the dominant FAO essential for other processes such as survival and proliferation. CPT1 A 
is a key enzyme involved in FAO. We have shown that CTLA-4 signalling induced upregulation of 
CPT1A in Tregs. Additionally CTLA-4 signalling disrupted CD28 mediated upregulation of glycolytic 
enzymes, particularly the hexokinases, Hexokinase I and GCK. Thus, these results imply that the 
constitutively expressed CTLA-4 on Tregs acts by facilitating a shift from glycolysis towards FAO 
thereby restricting motility and migration induced by the CD28 co-stimulatory receptor.      
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4.3 Part 3: The inhibitory co-receptor CD31 regulates T cell 
migration 
 
 
4.3.1 Introduction 
 
CD31 is an immunoglobulin-like receptor expressed by platelets, endothelial cells and on all 
hematopoietic cells including T and B lymphocytes. Homophilic interactions of CD31 expressed at 
high density at the lateral borders of endothelial cells with CD31 expressed on leukocytes have 
been shown to facilitate TEM in vitro and in vivo (reviewed in Marelli-Berg et al. 2013).  
Historically, CD31 was regarded as a marker of endothelial cell lineage and its functional role in 
adaptive immunity has not been given much insight (Marelli-Berg et al. 2013). Recent studies 
have established the involvement of CD31 in the regulation of T cell homeostasis, effector 
function and trafficking. One of the reasons why CD31 was not studied in the context of regulating 
T cell migration was the observations that CD31-deficient mice display a very mild phenotype 
under steady state conditions with a normal number of T cells (Gordon S. Duncan et al. 1999b), 
and that T cells which undergo differentiation and acquire a memory phenotype were believed to 
not display CD31 (Demeure et al. 1996).  However, under situations of immunological stress CD31 
defciency has been reported to have very different results.  For example, in models of EAE and 
CIA, CD31 deficiency has shown to enhance disease (Graesser et al. 2002; Tada et al. 2003; Wong 
et al. 2005). Several other observations of models of disease where CD31 deficient mice have 
much severe disease outcome are given in the Table 3. Secondly, CD31 loss on memory T cells has 
been reported to be a consequence of enzymatic shedding rather than transcriptional 
downregulation. In one study, CD31 activity after shedding could be restored using a peptide 
containing the CD31 amino acid residues 551-574 (Fornasa et al. 2010). Furthermore, human 
memory T cells have also been shown to acquire CD31 expression after TEM as a result of 
membrane transfer from ECs in vitro (Brezinschek et al. 1999). 
Given that CD31 is expressed by both T cells and DCs and can engage in homophilic interactions, it 
is likely that CD31 signalling between APCs and T cells plays a role in conventional antigen 
presentation and T cell priming. The recent study by (Ma et al. 2012) has analysed this role of 
CD31 mediated interaction in T cell activation where CD31 deficient mice were shown to display a 
trend towards accelerated and pronounced allograft rejection. Their results were attributed to 
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enhanced proliferation of CD31-deficient T cells following immunization with diminished Treg 
suppression. Interestingly, their experiments also revealed enhanced activation induced cell death 
(AICD) in the CD31-deficient T cells. Here, the CD31 signals were shown to induce the activity of 
extracellular –signal –regulated kinase (Erk) activity, which is associated with pro- survival 
pathways, independently of the TCR signals. Thus, while CD31 signals regulate T cell activation, 
they also play a role in promoting T cell survival after activation. Therefore, the severe 
exacerbation observed in the models of autoimmunity, tumour and transplant rejection in CD31-
deficient mice cannot be fully explained by CD31 mediated effects on T cell activation alone. 
In addition to its engagement during interactions with antigen presenting DCs, CD31 triggering on 
T cells can also occur following interaction with other CD31-expressing cells. Among those that 
express CD31 abundantly are platelets and ECs. Platelets are known for their regulatory role in 
both non-specific inflammatory responses as well as in T cell-dependent adaptive immune 
responses (Semple et al. 2011).  
Most importantly, frequent CD31 interactions between ECs and T cells are bound to occur during 
lymphocyte recirculation and have only recently been thoroughly investigated.  Given that T cell 
interactions with antigen presenting endothelium are crucial for T cell recruitment and 
subsequent activation in antigen rich tissue and that CD31 engagement modulates the efficiency 
of TCR signals (Ma et al. 2012), recent studies have tried to elucidate the role of CD31 in antigen-
dependent T cell recruitment. 
A recent study by (Manes and Pober 2011) indicates that blockade of CD31 prevents migration of 
human effector memory T cells induced by antigen presenting ECs. Furthermore, the study by (Ma 
et al. 2012) further expanded upon the relative contribution of CD31 mediated interactions in the 
regulation of T cell trafficking by separately assessing the effect of CD31 deficiency in the T cells 
and endothelium. Here, CD31 interactions between T cell and endothelium were shown to 
facilitate the recirculation of memory T cells and their inflammation induced extravasation to 
antigen rich sites confirming the previous study by (Manes and Pober 2011). Loss of CD31 on T 
cells exclusively displayed inhibition of antigen specific recruitment to antigenic sites. In addition, 
the authors also indicate that selective loss of CD31 from the endothelium inhibits the 
recruitment of both antigen specific memory T cells during inflammatory conditions as well as 
naïve T cell recruitment to secondary lymphoid tissue during rest. While the latter observation 
may not be visible in the CD31 deficient mice displaying normal colonisation of lymphoid tissues 
due to compensatory mechanisms in TEM, such as CD99, JAMs and ICAMs interactions, the 
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former could account for the observations of exasperated disease severity in the various disease 
models in CD31 deficient mice described before. 
Thus, one possible explanation for endothelial CD31s role in regulating memory T cell recruitment 
could be on account of compromised endothelial permeability (reviewed in Marelli-Berg et al. 
2013). Indeed, TCR interaction with antigen loaded MHC by the ECs is known to transiently 
increase permeability through reorganisation of the endothelial cytoskeleton via means of rapid 
RhoA activation (Boulday et al. 2004). This transient effect could enable the migration of antigen 
specific T cells through vascular endothelium. Additionally, CD31 may stabilize the adherens 
junctions through its previously described dephosphorylation of β-catenin and enhancing 
anchorage of the vascular endothelial (VE)-cadherin complex thus behaving as a molecular 
‘gatekeeper’ (Biswas et al. 2006). However, the overall explanation here suffers from a crucial 
drawback i.e. the observation that CD31 deficiency is not associated with any other cardinal signs 
of vascular leakage in CD31 deficient mice. Thus, while loss of CD31 from the endothelial junctions 
may partially account for enhanced memory T cell extravasation, other mechanisms may exist 
through which CD31 regulates effector and memory T cell extravasation into the antigen rich non-
lymphoid tissue.  
Within T cells, the Ig like CD31 receptor bears a distinctive feature in its cytoplasmic domain 
highlighting its role as a negative co-inhibitory receptor. Two immunoreceptor tyrosine inhibitory 
motif (ITIM) domains in its cytoplasmic domain are phosphorylated following TCR stimulation, and 
these have been shown to recruit protein-tyrosine phosphatases (PTPs), such as the Src homology 
2 (SH2)-domain-containing protein SHP-2 as wells as SHP-1 leading to inhibition of TCR signalling 
(P. J. Newman 1999; D. K. Newman et al. 2001). However, the effect of recruitment of 
phosphatases on other signalling processes, particularly those that are crucial for T cell 
recruitment, such as chemokinesis have not been previously investigated. 
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4.3.2 Aims 
 
Given that inhibition of TCR signalling by CD31 and vascular leakiness in the CD31 deficient 
endothelium cannot entirely account for the enhanced disease severity reported in various 
models of disease in the CD31 deficient mice, we predict the existence of another mechanism for 
this co-inhibitory receptor in regulating T cell recruitment. As mentioned before, CD31 homophilic 
interactions between T cells and ECs are crucial for recruitment of antigen specific T cells to 
antigen rich tissue. Loss of CD31 from either ECs or T cells has been shown to inhibit antigen 
specific recruitment. In this part, we further investigate the role of CD31 on T cells in influencing 
their migration. Here we hypothesise that the recruitment of phosphatases via the cytoplasmic 
ITIM upon phosphorylation may affect processes such as chemokine-dependent recruitment of T 
cells into tissues. Furthermore, given that CD31 deficient mice display no obvious phenotype 
during resting immune conditions we predict a differential role for this molecule in activated and 
naïve T cells. To test these hypotheses we carried out the following experiments. 
1. Analysis of in vitro and in vivo chemokinesis of T cells from CD31-deficient mice compared 
to those obtained from WT mice. 
2. Assessment of the impact of CD31-mediated regulation of T cell migration on both naïve 
and activated (primed) T cells. 
3. Identification of signalling pathways that may be differentially regulated by CD31 in both 
cell types that could account for the phenotypes observed in CD31-deficient mice under 
resting and inflammatory states.   
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4.3.3 Results 
 
4.3.3.1 CD31 regulates Chemokine –Induced T cell Migration in vitro  
 
While CD31-deficient mice exhibit enhanced disease severity in models of T cell mediated 
inflammation such as autoimmune encephalomyelitis and collagen induced arthritis, these mice 
retain healthy secondary lymphoid architecture through their lifespan. In addition, WT and CD31 
deficient naïve T cells adoptively transferred into WT recipients localise within the spleen at 
comparable levels. This suggests a differential effect of CD31 signals between naïve and activated 
T cells. 
To test this hypothesis, we set up transwell based migration assays to observe the chemokinesis 
of both naïve and memory T cells from CD31-/- and WT mice. The chemokine ligands for CCR7 and 
CXCR3, characteristically expressed by naïve and activated T cells respectively were used to asses 
chemokinetic responses by both CD31-/- and WT T cells (Figure 62). While chemokine responses 
of naïve T cells from both WT and CD31-/- mice to the CCR7 ligands CCL19 and CCL21, were 
comparable, activated or memory T cells (HY specific T cell lines) from CD31-/- mice showed 
enhanced chemokine migration to the CXCR3 ligand CXCL10 compared to their WT counterpart. 
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Figure 62    CD31-deficient activated T cells display enhanced responses to CXCL10 
chemokine in vitro. 
Naïve and activated WT and CD31−/− T cell migration to the chemokines CCL19/21 and CXCL10, 
was assessed over 6 hours using transwell-based chemokinesis assays. The number of migrated 
cells in the bottom chamber was determined through hemocytometric counting of samples from 
each of the triplicate wells. Results are expressed as a percentage of migrated cells. The average 
percentage migration from four independent experiments is shown (n=3, N=4). Error bars indicate 
standard deviation. Statistical significance was calculated with unpaired Student’s t-test.*p<0.01 
 
Additionally, flow cytometric analysis of Chemokine receptors CXCR3 and CCR7 revealed no 
significant difference in surface receptor expression between T cells from CD31-/- and WT mice 
(Figure 63).  
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Figure 63    Phenotype of WT and CD31-deficient naïve and activated T cells. 
 (a) These representative dot plots here show WT and CD31−/− CCR7high and CXCR3high T cells 
within the naïve and activated (anti-CD3 plus anti-CD28, 7 days) T cell pools respectively. (b) Bar 
graphs represent cumulative data from lymph nodes and spleen of 3 mice (n=3) indicating the 
absolute number of CCR7high and CXCR3high T cells within a given CD3 T cell population from both 
WT and CD31−/− mice. Cells analysed were first gated on CD3+ T cells.  
 
Finally, enhanced chemokine recruitment of CD31-/-activated T cells was not restricted to the 
CXCR3 ligand CXCL10 as similar enhanced chemokinesis effect was also seen with the CXCR4 
ligand CXCL12 (Figure 64). 
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Figure 64    CD31-deficient activated T cells display enhanced responses to CXCL12 in 
vitro. 
Activated WT and CD31−/− T cell migration in response to the chemokine CXCL12 (100 ng/ml) was 
assessed over 6 hours using a transwell-based chemokinesis assays. The numbers of migrated cells 
in the bottom chambers were determined through hemocytometric counting of samples from each 
of the triplicate wells. Results are expressed as a percentage of migrated T cells . (n=3, N=3). Error 
bars indicate standard deviation. Statistical significance was calculated with unpaired Student’s t-
test. *p<0.01  
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4.3.3.2 CD31 regulates Chemokine –Induced T cell Migration in vivo 
 
To validate if CD31 negatively regulated chemokinesis in vivo, HY-specific WT or CD31-/- effector 
memory T cells were labelled with PKH26 and injected intravenously into WT recipients that had 
previously been injected with 1200ng of CXCL10 chemokine intra-peritoneally. To rule out any 
interference by antigen-induced migration of the adoptively transferred T cells, recipient mice of 
syngeneic specificity (H2-B) were used in these in vivo migration experiments. Localisation of 
labelled T cells within the peritoneal lavage was assessed after 16 hours by performing flow 
cytometric analysis. Analysis of PHK26 positively labelled T cells within the antibody labelled CD3+ 
positive population revealed a marked increase in CD31-/- T cell recruitment to the peritoneal 
cavity as compared to WT T cells (Figure 65). The proportion of CD4 and CD8 T cells within the 
migrated lymphocyte pool remained comparable between WT and CD31-/- donor T cells 
suggesting that both subsets were equally affected by CD31 signalling. 
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Figure 65    CD31-deficient activated T cells display enhanced responses to CXCL10 
chemokine in vivo. 
Effector memory HY-specific WT or CD31−/− T cells were labelled with PKH26 and injected 
intravenously into syngeneic female mice that had received an intraperitoneal injection of 1.2 µg 
CXCL10 30 minutes earlier. Mice were sacrificed 16 hours later, and the presence of PKH26-labeled 
T cells in the peritoneal lavage was analysed by flow cytometry. Donor populations within a CD3 
staining gate were analysed. Representative dot plots from 3 different experiments are depicted in 
panel (a). The average fold-increase (T cells in chemokine-treated animals/T cells in PBS-treated 
animals of PKH26 (FL-2)-labeled T cells gated in the CD3+ T cell population retrieved from at least 
five animals/group in 3 independent experiments of similar design is shown in panel (b). (n=5, 
N=3).Error bars represent standard deviations. Statistical significance was calculated with 
unpaired Student’s t-test. *p<0.04. 
  
A phenotypic analysis of receptor surface expression between HY specific T cells generated from 
both CD31-/- and WT mice via flow cytometric analysis revealed no significant differences (Figure 
66). Collectively, these data suggest that CD31 induced signals negatively regulate extravasation 
of memory T cells in response to chemokine in non-lymphoid tissue.  
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Figure 66    Phenotype of HY-specific WT and CD31−/− T cells. 
Histograms represent the expression of the molecules indicated above by WT and CD31−/− HY-
specific T cells was assessed at the time of injection (i.e., 7–10 days following re-stimulation in 
vitro) by flow cytometry. Staining with an isotype-matched control antibody is indicated by the 
dashed lines profiles.(N=3) 
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4.3.3.3 CD31-mediated signals interfere with chemokine induced PI3K-Akt signalling 
pathways 
 
PI3K kinase activation and subsequent downstream phosphorylation of Akt/PKB has been shown 
to play a pivotal role in both chemotaxis and cell polarisation mediated via numerous chemokine 
receptors (Ward and Marelli-Berg 2009). As CD31 receptor signalling has been shown to recruit 
phosphatases via the ITIM domains in the cytoplasmic tail of the receptor, we sought to 
investigate whether the increased chemotactic ability observed selectively by the memory T cells 
from CD31-/- mice could be correlated to enhanced Akt/PKB phosphorylation. Both naïve and 
antibody-activated T cells were exposed to 200ng/ml CCL19/21 and 300ng/ml CXCL10 
chemokines, respectively, for 2 minutes. Using an antibody that exclusively recognises 
phosphorylation of Akt/PKB at the serine residue 473 (p-Akt473), activation of Akt following 
chemokine stimulation was measured in T cells from WT and CD31-/- mice by flow cytometric 
analysis (Figure 67).  
 
 
 
 
 
 
 
 
    Results 
218 
 
 
 
Figure 67    CD31 inhibits chemokine-induced Akt phosphorylation in activated T cells. 
Naïve and activated T cells were exposed to CCL19/21 and CXCL10, respectively, for 2 minutes. 
Phosphorylation of Akt at serine 473 was assessed by antibody staining and flow cytometry. In 
panels a and c, representative histograms of the experimental conditions indicated beside each 
profile are shown. Panel b and d indicate cumulative data of the mean fluorescence intensity (MFI) 
indicative of Akt phosphorylation obtained in the various conditions indicated in at least 4 
independent experiments of identical design.(n=3,N=4). Statistical significance was calculated with 
unpaired Student’s t-test.  *p<0.05 **p<0.02. 
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Phospho-Akt (S473) levels in naïve T cells stimulated with CCL19/21 chemokines from WT and 
CD31-/- were comparable. In contrast, phospho-Akt (S473) levels were significantly higher in 
activated CD31-/- T cells exposed to CXCL10 chemokine as compared to their WT counterparts. In 
addition, phospho-Akt (S473) levels in activated CD31-/- T cells exposed to CXCL10 chemokine 
remained significantly higher than in the activated WT T cells following pre-treatment with a 
suboptimal dose of the PI3K inhibitor Wortmannin. The data was further supported by the 
observation that the same suboptimal dose of Wortmannin significantly inhibited the migration of 
activated WT T cells to CXCL10 in in vitro chemokinesis assays, while CD31-/- T cells were inhibited 
significantly less. Phospho-Akt (S473) levels in naïve T cells from both CD31-/- and WT mice 
exposed to CCL19/21 were inhibited by Wortmannin equally. Similarly, chemokinesis of naïve T 
cells to CCL19/21 following Wortmannin treatment was slightly and comparably inhibited in WT 
and CD31-/- T cells (Figure 68). These results are consistent with previous findings, which indicate 
naïve T cell homing and migration to secondary lymphoid tissue to be relatively independent of 
PI3K signalling and largely mediated by activation of DOCK2 (dedicator of cytokinesis 2) (C. 
Nombela-Arrieta et al. 2004). Overall, these data show that CD31 signals attenuate chemokine-
induced signalling by interfering with Akt phosphorylation in activated T cells. 
 
Figure 68    CD31-deficient activated T cell chemokinesis is partially resistant to PI3K 
inhibition. 
Naïve (a) and activated (b) WT and CD31−/−T cell migration in response to either CCL19/21 (naïve) 
or CXCL10 (activated) was assessed using a transwell-based chemokinesis assays. Some T cells 
were pre-incubated with the PI3K inhibitor Wortmannin (10 µM) for 30 minutes at RT. The number 
of migrated cells in the bottom chamber was determined through hemocytometric counting of 
each of the triplicate wells after 6Hrs. Results are expressed as a percentage. (n=3, N=3) Error bars 
represent standard deviations. Statistical significance was calculated with unpaired Student’s t-
test.**p<0.01, *p<0.05 
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4.3.3.4 Differential cellular segregation of CD31 molecules in naïve and activated T 
cells. 
 
To further investigate the molecular basis of the different effects of CD31-mediated regulation of 
chemokine-induced signals in naïve and memory T cells, we analysed the segregation of the CD31 
molecules within these cell types using confocal microscopy. In these experiments, naïve and 
antibody activated T cells from WT mice were stained for CD31 along with LFA-1, a surface 
integrin known to be expressed at low levels and homogenously dispersed on the membrane in 
naïve T cells and upregulated and clustered in activated T cells. Using confocal microscopy, naïve T 
cells exhibited uniform distribution of CD31 on the membrane surface (Figure 69). In contrast, in 
activated T cells the CD31 molecules, albeit downregulated, appeared to be present 
predominantly in large clusters. 
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Figure 69    CD31 molecules segregate differently in naïve and activated T lymphocytes. 
Confocal images of naive WT T cells stained with rabbit-anti-mouse CD31 (green fluorescence) and 
rat anti- mouse LFA-1 (red fluorescence) followed by incubation with secondary antibodies Alexa 
Fluor 488-conjugated donkey anti-rabbit IgG and Alexa Fluor 647-conjugated goat anti-rat IgG, 
respectively, are shown in panel a. Added scale bar = 6 µm. Panel b: WT activated T cells 
generated via anti-CD3 and anti-CD28 treatment over 7 days were allowed to rest for 24 hours in 
low serum and then fixed. LFA-1 and CD31 expression was visualized as described above. Scale bar 
= 6 µm. The average CD31 distribution/expression from at least four 63× magnified fields obtained 
in three independent experiments of identical design is shown in panel c (n=4, N=3) Error bars 
represent standard deviations. Statistical significance was calculated with unpaired Student’s t-
test. *p<0.001 
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Confocal microscopy analysis of CD31 molecules on activated T cells migrating in response to 
CXCL10 chemokine revealed CD31 aggregation towards the polarised leading edge 
(lamellipodium) of the activated T cell (Figure 70). Chemokine receptors have previously been 
shown to segregate towards the lamellipodia of the migrating T cells. Thus, confocal microscopic 
analysis suggests that CD31 molecules in activated T cells are ideally segregated for interfering 
with chemokine receptor signalling. In this context, co-localisation of CD31 molecules and 
phosphatases to the leading edge in migrating granulocytes has been previously reported (Y. Wu 
et al. 2005).  
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Figure 70    Polarization of CD31 molecules in activated T cells following exposure to 
chemokines. 
Activated WT T cells were allowed to migrate through transwells in response to the chemokine 
CXCL-10 (a) or incubated in medium alone (b) and then fixed for analysis. Cells were not 
permeabilised to allow surface staining only. Confocal images of T cells stained with rabbit-anti-
mouse CD31 followed by incubation with Alexa Fluor 488-conjugated donkey anti-rabbit IgG are 
shown in panels a and b. A higher magnification of a migrating lymphocyte further depicting CD31 
molecule polarization is shown in panel c. Confocal z stacks series were acquired using a step size 
of 0.5 µm. Added scale bar = 6 µm. The average CD31 distribution/expression from at least four 
63× magnified fields obtained in three independent experiments of identical design is shown in 
panel d (n=4, N=3). Error bars represent standard deviations.Statistical significance was calculated 
with unpaired Student’s t-test. *p<0.001 
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4.3.3.5 Mechanisms of CD31 Triggering During Chemokinesis 
 
During trans-endothelial migration homophilic interactions most likely occur between CD31 
molecules expressed on EC and T cells. However such cell:cell contact is unlikely to take place 
during migration through a transwell. Thus the observations described above do not explain the 
mechanism of CD31 triggering during chemokinesis.  Previously, dynamic CD31 cis-membrane 
interactions (i.e. clustering within the same cell membrane, homophilic) have been described to 
induce signalling events in CD31-transfected human embryonic kidney and erythroleukemia cells 
(T. Zhao and Newman 2001). We hypothesised that CD31 molecules segregating in compact 
clusters on the memory T cell surface might elicit similar effects. 
 
We therefore sought to investigate whether interfering with this molecular segregation could 
enhance T cells response to chemokines in the absence of intercellular CD31 engagement. As the 
CD31 domain responsible for cis-interactions has not been identified, we decided to disrupt CD31 
oligomerization by steric interference. WT naïve and activated T cells were ‘rested’ in serum-free 
medium overnight and then treated with an anti-CD31 antibody known to inhibit CD31 
homophilic interactions without inducing signalling, in order to prevent cis-membrane re-
clustering. An isotype-matched antibody was used as a control. Naïve and activated T cells were 
then exposed to CCL19/21 and CXCL10, respectively, in a transwell-based chemokinesis assay. 
Anti-CD31-treated activated T cells displayed significantly enhanced chemokinesis, while antibody 
pre-treatment did not affect migration of naïve T cells. Together with the earlier observation that 
CD31 molecules segregate in compact clusters on activated T cell surface these data are 
consistent with the hypothesis that CD31 interactions on the same cell membrane are required to 
inhibit chemokinesis (Figure 71). 
    Results 
225 
 
 
Figure 71    Antibody-mediated CD31 ‘immobilization’ enhances activated T cell 
chemokinesis. 
Naïve (a) and activated (b) WT T cells were incubated overnight in RPMI 0.5% FCS. Some T cells 
were pre-incubated with an anti-CD31 mAb at saturating concentrations (5 µg/ml) for 30 minutes 
at RT. Migration in response to CXCL10 or medium through a transwell was assessed over 6 hours. 
Percentage migration was calculated by dividing the number of cells harvested from the bottom 
chamber following 6 hours incubation at 37°C by the original number of cells plated onto the 
transwell. The average percentage migration from three independent experiments is shown. Error 
bars represent standard deviations. Statistical significance was calculated with unpaired 
Student’s t-test. *p<0.05, n=4, N=3 
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4.3.4 Discussion 
 
In this part of the study, we show that the Ig like CD31 receptor expressed on T cells attenuates T 
cell chemokinesis, a previously unknown function for this receptor. Furthermore, we show that 
CD31-mediated regulation of T cell chemokinesis is restricted to primed T cells where this 
molecule segregates in membrane clusters rather than in naïve (unprimed) T cells where CD31 is 
distributed homogenously on the membrane surface.  
In the previous chapter, we showed that the CD28 and CTLA-4 co-receptor mediated regulation of 
migration occurs in activated Teffs and Tregs. Here we show that another inhibitory co-receptor 
which targets TCR signalling can also modulate T cell migration. 
The results here indicate that in naïve T cells, despite having higher expression of CD31, the 
homogenously distribution of this receptor prevents its ability to interfere with chemokine-
induced Akt phosphorylation and thus, does not affect T cell responses to the chemokines CCL19 
and CCL21 that are expressed in the secondary lymphoid organs. Consistently, naïve T cell 
migration to secondary lymphoid tissue is known to be largely PI3K-Akt independent and largely 
mediated via DOCK2 activation (C. Nombela-Arrieta et al. 2004). In line with this observation, 
naïve T cell numbers and distribution remain unaffected by deletion of CD31. 
Following activation, the spatial distribution of the CD31 molecules on primed T cells favours 
molecular interactions on the same cell membrane. This mechanism induces CD31 signalling in 
polarised migrating T cells. These observations were supported by the observation that blockade 
of CD31 interactions in the same membrane prevented modulation of T cell chemokinesis to 
inflammatory chemokine CXCL10. Previously, such dynamic homophilic cis CD31 interactions have 
been described to occur in human embryonic kidney and erythroleukemia cells transfected with 
CD31 encoding vector. However our results do not exclude the possibility of CD31 interaction with 
other known or unknown ligands on the T cells that could initiate signalling. For example, putative 
heterotypic ligands for CD31 previously described include the neutrophil specific antigen CD177 
(NB1) and the ADP-ribosyl cyclase CD38 (Privratsky et al. 2010). Nonetheless, these results 
indicate that segregation of CD31 molecules in membrane clustering allows for signalling that 
modulates primed T cell chemokinesis. 
A key feature observed in these results was the increased phosphorylation of the PI3K-Akt 
pathway and partial resistance to PI3K inhibition in the CD31-deficient primed T cells. As 
mentioned previously, the CD31 receptor is known to recruit phosphatases via the ITIM domains 
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located in its cytoplasmic tail (D. K. Newman et al. 2001; Newton-Nash and Newman 1999). 
Indeed, another phosphatase SHIP-1 was also shown to be recruited through these motifs 
(Pumphrey et al. 1999). Given that silencing of SHIP-1 has been shown to increase basal 
phosphorylation of protein kinase B (PKB)/Akt and its substrate GSK3β, as well as an increase in 
basal levels of polymerized actin following chemokine stimulation of primary activated human T 
cells (Stephanie J. Harris et al. 2011), it is likely that CD31 mediated recruitment of phosphatases 
following its engagement is essential for its ability to modulate chemokinesis.  
In a physiological context, the distinct effects of CD31 signalling on naïve and activated T cell 
responsiveness to chemokines are likely to be related to the differences in their trafficking and 
proliferative potential. In naïve T cells, trafficking to the chemokines CCL19 and CCL21 expressed 
constitutively in the SLO facilitates their continuous circulation through the secondary lymphoid 
tissue (Marelli-Berg et al. 2008). Here, the trafficking is uncoupled with any inflammation and thus 
remains unregulated by means of CD31 signalling. Once naïve T cells encounter antigen 
presenting DCs, CD31- mediated interactions induce signalling that prevents excessive expansion 
of T cells following activation. Antigen stimulation then initiates reprogramming towards memory 
T cells that respond towards inflammation induced chemokines such as CXCL10 enabling them to 
access non lymphoid tissue where they engage in the immune response (Marelli-Berg et al. 2008). 
CD31 signalling here may prevent excessive infiltration of the memory T cells through modulation 
of their chemotactic responses thereby reducing tissue damage associated with excessive T cell 
infiltration.  
Together with previous findings indicating its role as a regulator of T cell activation and survival 
following priming, CD31-mediated regulation of memory T cell chemokinesis defines this 
molecule as a unique multifunctional immunoregulatory receptor.  
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Chapter 5 Discussion 
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To establish an effective immune response to an invading pathogen, the immune system must be 
able to specifically recognize and mount a response to it, while simultaneously limiting or 
preventing any non-specific responses that may be directed towards self-antigens. To achieve 
this, the adaptive immune system employs a series of carefully regulated processes that enable 
the selective development and maturation of only those lymphocytes that can recognize foreign 
antigens in the thymus (central tolerance). However, some lymphocytes with self-antigen 
specificity escape these selective processes and other measures to limit responses to self-antigens 
are required (peripheral tolerance). Naturally occurring regulatory T cells (referred to hereafter as 
Tregs), provide a key contribution in the maintenance of peripheral tolerance. Removal of 
deletion of this subset from the T cell pool results in autoimmune and inflammatory conditions 
occurring through unchecked self-reactivity thus highlighting their pivotal role in maintaining a 
state of tolerance to self-antigens (Sakaguchi 2005). Treg function involves their localization to 
both the site of T cell priming (draining LNs) (Ding et al. 2012) and the antigen-rich non-lymphoid 
tissue, site of the effector T cell response (Nguyen et al. 2007; Rudensky and Campbell 2006). 
Treg trafficking to these sites is a key event that has only partially been investigated.  
In my project, I have shown that the TCR-mediated regulation of Treg migration is similar to that 
of conventional T cells. This suggests that both T cell subsets are susceptible to this mechanism. 
However, constitutive expression of CTLA-4 by Tregs allows for CTLA-4-mediated inhibition of 
CD28 signalling against CD28 to impact their migratory ability differently than that of conventional 
T cells. Therefore, the differential expression of CD28 and CTLA-4 receptors might be partially 
responsible for endowing Tregs with their distinctive migratory patterns.   
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5.1 Recognition of antigen-presenting endothelium 
promotes Treg cell recruitment and circulation 
 
In order for the immune system to engage a specific response to antigen, antigen specific T cell 
populations must be able to effectively migrate and locate to the tissues where the antigen is 
localised. Previously, reports have highlighted that although CD4+ T cells recruitment is largely 
regulated by Ag-nonspecific mechanisms, such as via the action of homing and chemokine 
receptors, Ag display by EC can facilitate this process (Marelli-Berg et al. 1999b; Marelli-Berg et al. 
2001a; Marelli-Berg et al. 2004b). Additionally, the display of antigenic peptides from the 
underlying tissue promotes the selective recruitment of antigen-specific T cells (Marelli-Berg and 
Jarmin 2004a). In Part 1 of Chapter 4 we tested whether cognate recognition of the endothelium 
could also enable recruitment of naturally occurring regulatory CD4 T cell populations. Our results 
show that, due to their weak affinities towards self-antigens, regulatory T cells are endowed with 
the ability to be recruited to non-lymphoid inflammatory tissues upon upregulation of MHC class 
II molecules by the endothelium and through the cognate recognition of self-derived peptides. 
This effect underpins their timely and efficient recruitment to establish an optimal Treg:Teff ratio 
required for an effective immune response while preventing any non-specific tissue damage. 
Thus, these results highlight the role of the endothelium as an important element in immune 
homeostasis.  
It is important here to point out that, even in the absence of any inflammation, Tregs are still 
recruited to the non-lymphoid tissue (Sather et al. 2007). However their numbers are significantly 
increased upon challenges such as autoimmunity, infection or even injury.  
The study by (Sather et al. 2007) previously shown that Tregs can be found distributed throughout 
non-lymphoid tissues even during steady state (i.e absence of any overt inflammatory response). 
Furthermore, the study by (Rosenblum et al. 2011) and (Malchow et al. 2013) indicated that Tregs 
in these tissues are primed to attenuate subsequent autoimmune reactions in response to self-
antigens. These ‘tissue resident’ Tregs may be derived partly from nTregs that are constantly 
circulating between lymphoid and non-lymphoid tissue, a process carefully regulated in part by 
the endothelium lining the microvasculature of both sites. However, it is also important to 
remember that ‘tissue residents’ Tregs are likely to include iTregs, the migration of which may be 
distinct from that of nTregs and similar to that of Teffs. Furthermore, iTregs may also have 
variable CTLA-4 expression, the impact of which may reflect differences in their migration.  
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Together with previous findings, the results presented in my thesis also highlight a mechanism 
whereby the endothelium at the lymphoid tissue sites facilitates the redistribution of the 
recirculating Tregs towards the non-lymphoid tissue.  
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5.2 CTLA-4 signalling inhibits CD28-induced migration of 
Tregs 
 
How Tregs switch from their constant recirculation to become permanent tissue-resident Tregs 
remains an unexplored aspect of Treg biology. It is known that, upon activation, Tregs upregulate 
tissue selective integrins enabling them to be retained in peripheral tissues. For example, 
activated Tregs upregulate αEβ7 which interacts with E-cadherin expressed on tissue epithelial 
cells facilitating their localisation within peripheral tissue sites (Lehmann et al. 2002). Our results 
are consistent with an additional antigen-specific mechanism for Treg tissue retention involving 
the interaction of Treg CTLA-4 molecules with B7 ligands expressed by tissue-resident APCs. 
Although, the levels of CTLA-4 expression on Tregs in tissues have never been assessed, it is well 
know that Tregs need to be activated to enter non-lymphoid tissue (Corthay 2009). Thus, we 
hypothesize that Treg CTLA-4 upregulation following activation facilitates their retention within 
the peripheral non-lymphoid tissue. 
In Chapter 5, we also show that CD28-induced antigen-independent migration in Tregs could be 
inhibited through signalling via the constitutively expressed CTLA-4 receptor in this subset. In light 
of these results, it is important to envisage where such inhibitory signalling would occur in 
physiological settings. Although constitutively expressed, CTLA-4 is rapidly upregulated on Treg 
surface following TCR induced activation, just as it happens in conventional T cells (Mead 2005). 
Thus, Tregs can receive two distinct levels of CTLA-4 signalling; one high and one low depending 
upon the level of expression of the receptor on the surface. These differential levels of expression 
could also result in the differences that are observed between ‘tissue resident’ and ‘actively 
circulating’ Tregs.  
While actively circulating back and forth between lymphoid and non-lymphoid tissue, CD28-
induced pro migratory signals would enable and enhance Treg migration. As such, lower levels of 
CTLA-4 would allow CD28-induced signalling to remain uninhibited thus favouring motility. 
Following activation and proliferation, Tregs display higher levels of CTLA-4. Here, the strong 
CTLA-4 signals induced by its ligands through tissue APCs would prevent CD28 induced motility. 
This would prevent Tregs from re-entering the circulation ensuring that the cells are retained 
within the local microenvironment. Retention through this mechanism could also explain the 
maintenance of continuous tolerance that is achieved by permanently residing Tregs in the non-
lymphoid tissue. 
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It has recently been argued that CTLA-4 signalling is relatively modest and therefore unlikely to be 
the main mechanism of its inhibitory function (Walker and Sansom). As mentioned previously, the 
mechanism through which CTLA-4 brings forth its inhibitory signalling continues to be a 
controversial topic and therefore highlights the conflicting nature of the literature. Recently, the 
study by (Wakamatsu et al. 2013) noticed very little change in gene expression of Tregs following 
CTLA-4 stimulation, lasting for only a few hours. Similarly, comparative analysis of gene expression 
profiling of CTLA-4 deficient and WT T cells were described as ‘minimal’ in the study by (Friedline 
2009) 2009. Another independent study by (Corse and Allison 2012) noted  two-fold level of 
difference in only 10 independent genes when comparing CTLA-4 expressing cells with CTLA-4 
deficient T cells leading the authors to claim ‘no obvious signature of active negative regulation’ in 
CTLA-4-bearing T cells (Walker and Sansom 2015).  
In our opinion, the studies showing little change in gene expression did not clearly discriminate 
between Tregs that display high and low CTLA-4 surface levels. It is likely that these observations 
were affected by the presence of CTLA-4low Tregs, which are the largest Treg population in steady 
state conditions. Furthermore, these studies do not totally account for the inherent differences of 
CTLA-4 signalling between Tcon and Tregs. Recently, the study from (Stumpf et al. 2014) has 
shown that the onset of EAE is similar in mice bearing a point mutation in the cytoplasmic YVKM 
motif of CTLA-4, where the tyrosine residue at position 201 was replaced with valine (Y201V) to 
prevent phosphorylation, and wild type littermates. However, these mice developed more severe 
EAE as a direct result of impaired Treg suppressive activity in these mice. This observation 
supports the notion that Tregs are distinct from Tcon in their ability to be susceptible to inhibitory 
CTLA-4 signalling and is in support of our findings which show that CTLA-4 inhibitory signalling is 
indeed operational in Tregs.  
Of note, to ensure CTLA-4-induced signalling in our study, we have utilized the same anti-CTLA-4 
antibody that has been extensively studied and also reported in the studies by (Schneider et al. 
2005) and (Wells et al. 2001) to initiate signalling upon crosslinking.  
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5.3 Treg metabolism and migration 
 
One of the hallmark metabolic feature of Tregs, that sets them apart from Teffs, is their 
predominant utilization of the energy efficient metabolic pathways such as the fatty acid 
oxidation (FAO) and the AMPK pathways rather than aerobic glycolysis (Michalek et al. 2011c). 
Classically, studies have identified this T cell subset to metabolically resemble CD8 memory T cells 
more than Teffs (K. Araki et al. 2010; Chi 2012; Peter et al. 2010; van der Windt et al. 2012). 
However, our results suggest that Tregs meet their energy requirements for migration through 
glycolysis rather than FAO. This aspect of Treg motility has been previously overlooked and is 
therefore a novel finding. 
Interestingly, while observing regulation of migration of Tregs via the TCR and all of the co-
stimulatory receptors in this study, we have consistently identified a non-redundant role for the 
PI3K-Akt signalling pathway, which is crucial for both migration and metabolism. In terms of CD28 
induced migration, recruitment of PI3 Kinase via the cytoplasmic tail is a crucial component in the 
regulation of migration of Tregs by this co-receptor. In addition, our results also indicate that 
CD28 induced PI3K-Akt signalling is necessary for glycolysis. In light of these novel findings, we can 
review earlier studies that have investigated PI3K kinase signalling initiated by CD28 from a 
different perspective.  
For example, the study by (Okkenhaug et al. 2001) showed that the CD28Y170F mutant T cells that 
are unable to recruit PI3K were still capable of maintaining IL-2 production and proliferated to 
levels comparable to WT T cells. However, these T cells were prone to survival defects that 
correlated with reduced upregulation of pro-survival protein BCL-xl from the BCL-2 family of 
proteins. Recently, (Vander Heiden et al. 2002), et al have identified BCL-xl to facilitate the switch 
from glycolytic to oxidative mitochondrial metabolism in mammalian cells. Thus, it is possible that 
the defective survival observed in CD28y170F T cells may have been associated with disengagement 
or dysregulation of mitochondrial metabolism. Indeed, PI3K induced activation of both BCL- xl and 
Akt are described to maintain survival through independent mechanisms (Plas et al. 2001). While 
Akt-mediated survival is dependent on promoting glycolysis and maintaining a physiologic 
mitochondrial potential, BCL- xl maintains mitochondrial integrity in the face of reduced 
mitochondrial potential that develops as the cells exhibit low glycolytic rates under conditions of 
growth factor deprivation (Plas et al. 2001). Together, these results suggest that poor survival of 
CD28y170F T cells may be due to inability to maintain mitochondrial metabolism, on account of 
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their failure to upregulate BCL-xl. In contrast, their proliferation, which is glycolysis-dependent, 
remains unaffected as TCR- induced PI3K-akt signalling would be sufficient for glycolysis induction. 
An interesting observation in our results was the utilization of the Hexokinase IV (Glucokinase or 
GCK) isoenzyme of the hexokinase family, rather than the more conventional hexokinase I, in 
pathways that regulate Treg motility. CD28-induced Treg motility and CTLA-4 mediated inhibition 
of CD28 signals in Treg migration directly correlated with the upregulation and downregulation of 
the GCK enzyme respectively. This selective utilization of GCK in Tregs is an interesting finding that 
could potentially reflect their metabolic signature and distribution. Very little is known with 
regard to GCK and T cell metabolism. Unlike other hexokinases, GCK is less susceptible to 
inhibition by the end products of glycolysis (Bell et al. 2002; Matschinsky 1996). Thus, the 
utilization of this enzyme may give Tregs an advantage over Tconv cells to maintain glycolysis and 
motility in environments where excessive proliferation and recruitment of Tconv has produced 
higher quantities of glycolytic end products, which are known to inhibit Tconv (R. Haas et al. 
2015). In such environments, migration of Tconv - which utilize other hexokinase isoenzymes - 
would be inhibited while Tregs would continue to migrate. This may act as a safeguard to prevent 
excessive accumulation of Tregs in the tissue thus avoiding unchecked immunosuppression. The 
fewer number of Tregs could then continue to recirculate within the non-lymphoid tissue reaching 
several different sites that require suppression. This is supported by the observations by (R. Haas 
et al. 2015) who have demonstrated that conventional T cells are actively inhibited in migration 
by glycolysis products such as lactate while Treg migration remains unaffected. Furthermore, it is 
likely that within these environments, the suppressive function and proliferation of Tregs would 
remain intact as these are fuelled primarily through fatty acid oxidation.   
Interestingly, in a recent study by (Hagiwara et al. 2012), the mTORC2 complex has been shown to 
activate GCK and Akt phosphorylation at Ser473 thereby inducing glycolysis in hepatocytes. Given 
that our results indicated CD28-induced Treg migration to be relatively independent of the 
mTORC1 and largely dependent on GCK, perhaps Tregs might be actively utilizing mTORC2 
signalling for migration while restricting mTORC1 signalling for proliferative and functional fitness. 
This aspect needs further exploration.  
Our results also open up the possibility that the GCK enzyme in Tregs may regulate Treg migration 
through actively integrating with cytoskeletal components. In cancer cells, higher glycolytic 
activity has been shown to increase cell motility and cytoskeletal remodelling (Shiraishi et al. 
2015). In addition, in MSV-MDCK-INV tumor cells, the formation of targeted membrane 
extensions or protrusions has been shown to involve the translocation of glycolytic enzymes to 
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the Pseudopod (Jia et al. 2005). In endothelial cells, glycolysis has been observed to be the central 
metabolic pathway that assists in the coordinated motility associated with vascular vessel 
sprouting and angiogenesis (De Bock et al. 2013). It is possible that translocation of active 
glycolytic enzymes, such as GCK in Tregs, to membrane protrusion sites is necessary to facilitate 
cytoskeletal reorganisation for Treg motility (Murata et al. 1997; Toyoda et al. 1994). 
The actin binding protein cofilin has been previously shown to associate with the glycolysis 
enzyme Triose-phosphate Isomerase (TPI) to increase activity of the Na,K-ATPase in HeLa and rat 
skeletal muscle cells through the action of Rho signalling pathways (J. Jung et al. 2002). Cofilin is a 
key regulator of actin dynamics that is important for T cell migration. A similar kind of association 
between potential actin regulators and GCK in T cells could provide the direct link between GCK 
activity and actin reorganisation that facilitates Treg migration (Samstag et al. 2013). 
Translocation of the GCK enzyme to membrane sites has not been described in T cells. However, 
hexokinase translocation from cytosol to periphery for migration has been described in 
neutrophils following activation. In rat hepatocytes, rapid translocation of GCK from the nucleus 
to cytosol actin filaments in the cytoplasm has been described previously to provide a source for 
localised glycolysis-derived energy thought necessary for cytoskeletal affiliated cellular functions.        
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5.4 Clinical implications of this study 
 
5.4.1 Manipulation of co-stimulatory molecules 
 
Similar to conventional T cells, Tregs also require TCR and co-stimulatory signalling to become 
fully active. Although some co-stimulatory pathways are known to differentially regulate Treg and 
Tconv cells, no single pathway is known to regulate one cell type exclusively (Riley et al. 2009). 
Thus, administration of agents that can selectively increase Treg function without affecting Tconv 
activity has proven to be difficult. A typical example is the CD28 superagonist, TGN1412, which 
was hypothesized to increase Treg activity thus restoring tolerance and improving transplant 
success (Attarwala 2010). However, healthy volunteers who were administered the TGN1412 in a 
phase I clinical trial suffered from near fatal multi organ failure associated with massive cytokine 
storm (Suntharalingam et al. 2006). Although the exact pathogenic mechanism of this event 
remains unclear, it is possible that Tconv cells here were also activated resulting in abnormally 
high cytokine production. Thus, a major challenge to the field of immunotherapy is the 
identification of pathways that are selectively utilised by Tregs and Tconv.    
Furthermore, current therapies that provide immunosuppression rely on the administration of 
relatively non-specific molecular mediators that may broadly affect a variety of cell types (J. I. 
Duncan 1994; Eynott et al. 2003; Javier et al. 1997). In our study, we have identified metabolic 
pathways that may be selectively targeted to restrict the function of either Tconv or that of Tregs. 
In particular, the identification of GCK pathway for Treg migration opens the possibility of 
pharmacological exploitation that enables selectively targeting of Treg migration and, ultimately, 
their function.  
Additionally, both CTLA-4 and CD28 co-stimulatory pathways are being investigated in clinical 
trials for the development of several immunotherapies. Fusion proteins of CTLA4 and antibodies 
(CTLA4-Ig) have recently undergone testing in Phase 2 clinical trials for rheumatoid arthritis 
(Westhovens et al. 2004). The CTLA-4-Ig drug Belatacept is currently being investigated as an 
alternative to conventional immunosuppression and has undergone extensive testing in clinical 
trials of renal transplantation (Kirk et al. 2014). CTLA-4 antagonists such as Ipilimumab are being 
devised as an effective treatment to increase immune activity to combat a variety of cancers 
including prostate, lung and skin cancer (Prieto et al. 2012; Singh et al. 2013; Tomasini et al. 
2012). However, the effect of targeting these pathways on Treg migration has not been 
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investigated previously. Our results suggest that these pathways may indeed affect Treg re-
circulation and localisation. Therefore, development of new therapies through these pathways 
should also take into account their effect on Tregs.  
Finally, there are broader implications of my observations on the biology of other members of the 
B7 family of co-stimulatory receptors, such as ICOS and PD1. Targeting additional B7 co-receptor 
members such as PD-1 may prove to be valuable in improving the efficacy of immunotherapy-
based therapeutic strategies. For example, the combined blockade of CTLA-4 and PD-1 was 
thought to provide more potent anti-tumor activity than by blocking a single co-receptor alone 
and has revealed promising results in clinical trials for a variety of cancers including melanoma 
(Callahan et al. 2015). However, the effect of other co-stimulatory receptors and the effect of 
combining the action of several co-stimulatory receptors on the migration of Tregs has not been 
studied previously. Further studies are required to address this. 
 
5.4.2 Treg metabolism in transplantation and disease 
 
In our experiments, we have highlighted metabolic pathways in Tregs that are likely to regulate 
their migration in a manner not previously observed in conventional T cells. The GCK induced 
activity correlated with pro –migratory signals associated with CD28 signalling. Inhibition with 
CTLA-4 reduced the overall pro-migratory CD28 signalling as well as GCK activity. These results 
suggest a potential link between regulation of Treg migration and GCK activity. Experimental 
results from other members of our research team have not identified the involvement of this 
hexokinase isoenzyme in migration of conventional T cells (Haas and Marelli-Berg, unpublished 
observations) data not shown). Thus, inhibition of GCK may serve as a valuable tool that could 
potentially and exclusively disengage Tregs from establishing pro-migratory signals. This might be 
useful in preventing Treg exit from graft sites while ensuring their retention within the grafts to 
achieve long-term immune tolerance. 
Previously, T cell energy metabolism has been described as a crucial regulator of T cell fate 
differentiation in transplantation (Chi 2012; Priyadharshini and Turka 2015). For several years, the 
mTOR inhibitor rapamycin has been utilized to provide immunosuppression to favour graft 
survival in several transplantation settings. Inhibition of mTOR by rapamycin has been shown to 
induce the development of regulatory T cells while preventing Teff activation. Presently, the 
modulation of T cell metabolism is currently being investigated as an attractive alternative to 
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conventional immunosuppression in transplantation (H. Liu et al. 2014). Furthermore, PI-103, a 
dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR is being proposed as the next 
step in development of novel immunosuppressant strategies for transplantation (Y.-J. Zhang et al. 
2011). Interestingly, these strategies target the mTORC1 pathway of the mTOR complex. Our data 
suggest that Treg migration is independent of mTORC1 activity. It is possible that the mTORC2 
pathway may be the crucial pathway involved in regulating Treg migration. Previously, (Hagiwara 
et al. 2012) have demonstrated that mTORC2 activates glycolysis partly through GCK. Thus, we 
hypothesize that inhibiting hexokinases such as GCK would prove to be a valuable addition to 
these immunosuppressive treatments. Administering a regimen of conventional 
immunosuppressant such as rapamycin followed with GCK hexokinase inhibitors may be a novel 
and efficient strategy that may not only promote Treg development but also favour Treg retention 
within the graft sites to rapidly achieve tolerance. The use of selective GCK or mTORC2 inhibitors 
in transplantation is an unexplored area that needs further investigation.   Unfortunately such 
inhibitors have not yet been developed.  
In contrast, the administration of GCK activating agents may promote Treg migration that may 
have therapeutic potential in the treatment of cancer. Here, facilitation of Treg exit and 
withdrawal from tumour sites would allow for uninhibited Tcon cell activity favouring stronger 
tumour clearing responses. In hepatocytes, GCK activity is regulated by the endogenous inhibitor 
GK regulatory protein (GKRP). Recently, two potent small-molecule GK–GKRP disruptors (AMG-
1694 and AMG-3969) have been described as GCK activators for the treatment of type II diabetes 
mellitus (Lloyd et al. 2013). Thus, these may also be utilized to develop stronger anti-cancer 
treatments. 
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5.4.3 CD31 as potent inhibitory receptor for T cell migration    
 
Together with previous findings indicating its role as a regulator of T cell activation and survival 
following priming, CD31 mediated regulation of memory T cell chemokinesis defines this molecule 
as a unique multifunctional immunoregulatory receptor. In terms of a therapeutic context, the 
activity of CD31 is open to possibility of pharmacological exploitation for several therapeutic 
purposes. Earlier, the CD31 derived peptide (residues 551-554) which can bind to truncated CD31 
on memory T cells and activate signalling, was shown to inhibit activation of T cells and 
macrophages and not only delay the onset of atherosclerosis but also reduce its complications 
such as abdominal aortic aneurysms in mice (Fornasa et al. 2012). In another study, this treatment 
was effective in preventing lethal GVHD (Y. Chen et al. 1997). Given that in humans CD31low T cells 
accumulate with age, display enhanced proliferative capacity and are linked with enhanced 
susceptibility to autoimmune diseases (Gomez et al. 2003; Kilpatrick et al. 2008; Kimmig et al. 
2002), the CD31 peptide may serve as an effective therapy in this context. 
 
 
 
 
 
 
 
 
 
 
 
 
    Discussion 
241 
 
5.5 Future Work 
 
In this section, I briefly discuss potential ideas for the continuation of this study. 
First, studies are required to verify the involvement of the GCK hexokinase in the functional 
fitness of both Treg and Teff subset of T cells. Additionally, these studies need to carefully 
establish the impact of selective disruption of GCK on the migratory patterns of these T cell 
subsets. Given the absence of any selective Hexokinase IV (GCK) inhibitor, shRNA knockdown 
methodology could be employed to selectively disrupt GCK activity. Based on our data, one would 
predict that Treg migration would be significantly inhibited following GCK knockdown. In contrast, 
Teffs, which rely heavily on other hexokinases for their migration and function, would not be 
affected.  By carrying out in vitro and in vivo migration assay experiments of GCK knockdown 
Tregs and Teffs, we would then be able to specifically address the relative contribution of this 
hexokinase in the motility of each subset. Conventional suppression assays could be used to 
identify any significant impairment of function of GCK-knockdown Tregs. Given that Tregs 
primarily utilize FAO and the AMPK pathway for functional fitness and glycolysis for migration, the 
effect of GCK knockdown on the Treg suppression is likely to be minimal.  
Additionally, selectively disrupting GCK without inhibiting the activity of other hexokinases could 
minimizing impact of inhibiting other glycolysis activity which might be required for functions 
other than migration. This possibility could be tested by comparing suppression of GCK 
knockdown Tregs with that of Tregs treated with a pan-hexokinase inhibitor such as 
mannoheptulose (Sweet et al. 1996). Very little is known regarding GCK activity in T cells let alone 
Tregs. Thus, parallel studies observing the knockdown of GCK in Teffs would also be carried out to 
fully characterise the activity of this hexokinase in Teff function. 
Second, our results suggest that Treg migration is largely independent of mTORC1 activity. As 
mentioned previously, GCK activity is induced by mTORC2 and Akt activity in hepatocytes 
(Hagiwara et al. 2012). As a consequence, Treg migration could be likely regulated by mTORC2- 
rather than mTORC1-dependent pathways. This can be addressed by selective genetic deletion 
(either by shRNA knockdown or Treg-specific knockout mice) of the Rictor or Raptor component 
proteins (from the mTORC2 and mTORC1 complexes respectively) in Tregs and compare their 
function and migration.  
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Lastly, a direct association between GCK activity and migration of Tregs needs to be addressed. 
For this, confocal microscope analysis and immunoprecipitation experiments may indicate the 
localisation of GCK with components of the cytoskeleton such as actin in Tregs following 
migration-inducing signals such as those provided by CD28. These experiments would further the 
evidence of the involvement of this hexokinase in the regulation of Treg motility.   
Our results have described CTLA-4 as a crucial inhibitor of Treg migratory responses that 
facilitates their retention in tissue sites. To verify this hypothesis and to confirm the presence of 
active inhibitory signalling from the CTLA-4 receptor, we would employ the use of Tregs bearing 
the point mutation at position 201 in the intracellular YVKM motif that has been described 
previously (Stumpf et al. 2014). The YVKM motif is believed to be the key motif involved in the 
recruitment of phosphatases and other signalling proteins. The point mutation (replacing tyrosine 
with valine) in this motif renders it unable to undergo phosphorylation thus disengaging 
recruitment of the signalling proteins (Stumpf et al. 2014). Thus, we hypothesize that Tregs 
bearing this point mutation in the cytoplasmic domain would be less efficient at promoting Treg 
tissue localisation and, as a consequence, their function.  
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